

Stock Code: 4167



松瑞製藥股份有限公司
Savior Lifetec Corporation

2024 Annual Report

Printed on May 7, 2025

Annual report is available on the following websites:

Information filing website as specified by the Financial Supervisory

Commission: <http://mops.twse.com.tw>

Official website: <http://www.saviorlifetec.com.tw>

I. Name, title, phone number, and e-mail address of the spokesperson and the deputy spokesperson:

Spokesperson: Lin Kuo-Wei
Title: Assistant Vice President
Tel: (06)505-1200
E-mail: stock@saviorlifetec.com.tw
Deputy
spokesperson: Lin Yen-Lan
Title: Vice President
Tel: (06)505-1200
E-mail: stock@saviorlifetec.com.tw

II. Address and phone number of the headquarters, branch and factory

1. Headquarters

Address: No. 1, Nanke 6th Rd., Sinshih Dist., Tainan City, Taiwan
Tel: (06)505-1200

2. Branch

Address: No. 11, Dashun 9th Rd., Sinshih Dist., Tainan City, Taiwan
Tel: (06)505-1200

3. Factory

Address: No. 11, Dashun 9th Rd., Sinshih Dist., Tainan City, Taiwan
Address: No. 1, Nanke 6th Rd., Sinshih Dist., Tainan City, Taiwan
Address: 4F. and 5F., No. 12; 4F., No. 16; 4F., No.8, Chuangye Rd., Sinshih Dist., Tainan City, Taiwan

III. Name, address, website and phone number of the stock transfer agency:

Title: Stock Administration, Horizon Securities Corp.
Address: 3F., No. 236, Sec. 4, Sinyi Rd., Da'an Dist., Taipei City, Taiwan
Website: <http://www.honsec.com.tw>
Tel: (02)2326-8818

IV. Name of the CPA and name, address, website and phone number of the accounting firm for the financial report in the most recent year:

Name of CPA: Accountant Cheng Hsu-Jan, Accountant Hsieh Tung-Ju
Name of accounting firm: Deloitte & Touche
Address: 20F, No. 100, Songren Road, Xinyi

District, Taipei City

Website: <http://www.deloitte.com.tw>

Tel: (02)2725-9988

V. Name of overseas exchange where securities are listed and method of inquiry: None.

VI. Official website: <http://www.saviorlifetec.com.tw>

Savior Lifetec Corporation

Table of Contents

One. Letter to Shareholders.....	1
Two. Corporate Governance Report	5
1. Information concerning the directors, supervisors, general managers, assistant general managers, deputy assistant general managers and the supervisors of all the divisions and branch units.....	5
2. Remuneration paid to directors, supervisors, the presidents and vice- presidents in the most recent year	16
3. Corporate Governance	23
4. Information on Independent Auditors' Fee	70
5. Information on the Replacement of Independent Auditors.....	70
6. The Company's Chairman, President, or managers in charge of finance or accounting affairs being employed by the accounting firm of its certified public accountant or affiliated enterprise of such accounting firm in the most recent year ..	71
7. In the Most Recent Year and as of the Publication Date of the Annual Report, Transfer & Pledge of Stock Equity by Directors, Supervisors Managers and Shareholders Holding over 10% of the Company's Shares.....	71
8. Relationship information, if among the 10 largest shareholders any one is a related party, or is the spouse or a relative within the second degree of kinship with another	72
9. The total number of shares and total equity stake held in any single enterprise by the Company, its directors, supervisors managerial officers, and any companies controlled either directly or indirectly by the Company	73
Three. Fundraising Status	75
1. Capital and Shares	75
2. Issuance of Corporate bonds	78
3. Preferred Stock.....	78
4. Overseas Depository Receipts.....	78
5. Employee Stock Options	79
6. New Restricted Employee Shares	80
7. Issuance of new shares in connection with mergers or acquisitions of, or succession to shares of other companies	80
8. Implementation of Capital Utilization Plan	80
Four. Business Overview	81
1. Business Activities	81
2. Market and Production/Sales Overview.....	91
3. Number of workers, average length of service, average age and educational profile of the employees in service for the last two years and up to the date of printing of the annual report.....	98
4. Information on Environmental Protection Expense	98
5. Labor-management relationship.....	98
6. Information and communication security management	100
7. Important Contracts.....	101
Five. Review and Analysis of Financial Position and Financial Performance and Risk Matters	102
1. Financial Status	102
2. Financial performance.....	102

3. Cash flow.....	103
4. Significant capital expenditures in recent years	104
5. The investment policy, main reasons for profit or loss, improvement plans, and investment plans for the next year in the recent year in the recent year	104
6. Risks factors	105
7. Other Important Matters	108
Six. Special Items	109
1. Information on Affiliates	109
2. Any Private Placement of Securities within the Latest Fiscal Year and as of the Date of the Annual Report.....	109
3. Additional Information required to be disclosed.....	109
4. Any situations listed in Article 36, paragraph 3, subparagraph 2 of the Securities and Exchange Act, which might materially affect shareholders' equity or the price of the company's securities, has occurred during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report	109

One. Letter to Shareholders

Dear Shareholders,

I. Operating Results for 2024

(1) Implementation of business plan

In 2024, the Company's consolidated operating revenue reached NT\$1,217,327 thousand, representing a 15.91% increase compared to 2023. This growth was primarily due to the Company's strategic adjustments and proactive expansion into high-margin product markets, which led to increased revenue and an overall improvement in gross profit. Non-operating income also increased, mainly due to the net effects of USD exchange rates and the valuation of financial instruments in 2024. The Company's net profit after tax for 2024 was NT\$182,380 thousand. Detailed information is as follows:

Unit: NTD thousand

Item \ Year	2024	2023	Increase (Decrease) Amount	Increase (Decrease) %
Net operating revenue	1,217,327	1,050,277	167,050	15.91
Operating Gross Profit	346,756	220,949	125,806	56.94
Net operating profit (loss)	118,900	(2,420)	121,320	(5,013.22)
Non-operation income (expense)	60,501	29,959	30,542	101.95
Income tax expense	(991)	(42)	(950)	2,261.90
Current comprehensive income	178,410	27,497	150,912	548.83
Less: Net gains (losses) on non-controlling interests	(3,970)	(2,533)	(1,437)	56.73
The Group's current income	182,380	30,030	152,350	507.33

(2) Consolidated revenue, expense and profitability analysis

Item/Year		2024	2023
Financial structure	Debt to assets ratio (%)	19.65	11.98
	Long-term fund to fixed assets ratio (%)	505.14	419.56
Debt servicing capability	Current ratio (%)	470.60	1,267.29
	Quick ratio (%)	365.36	812.65
Profitability	Return on asset (%)	4.59	0.92
	Shareholder's return on equity (%)	5.32	0.90
	Net profit margin (%)	14.98	2.86
	Earnings per share (NTD)	0.57	0.09

(3) Budget implementation status

The Company did not publish any 2024 financial forecast. Therefore, this is not applicable.

(4) Performance in research and development

Unit: NTD thousand		
Item/Year	2024	2023
R&D expense (A)	75,112	110,955
Operating revenue (B)	1,217,327	1,050,277
(A)/(B)	6.17%	10.56%

In 2024, the Company reallocated its resources to enhance overall operational performance. In addition to optimizing existing processes for carbapenem antibiotics, efforts were directed toward CDMO contract manufacturing for new carbapenem antibiotics and technology transfer for peptide drug products, while effectively controlling R&D expenditures.

II. 2025 business plan overview

(1) Operating guidelines

1. Strengthen the deployment of Ertapenem to increase global market share.
2. Develop a process of new generation to lower product cost.
3. Enhance market expansion for the new operational model of Meropenem.
4. Collaborate with multinational pharmaceutical corporations continuously to develop the CDMO of new antibiotics for international developers of new drugs.
5. Diversify investments to create corporate profits.

(2) Expected sales volume and Basis

Based on business order information, estimated sales growth trends, the progress of drug approval reviews in various countries and market demand conditions, the company anticipates a slight increase in sales volume for 2025 compared to 2024. However, the proportion of niche product sales is expected to grow in order to enhance overall operational performance.

(3) Important production and marketing strategies

1. Retain existing customer groups and develop new customers to increase market share.
2. Strengthen business communication with clients to fully grasp market trends.
3. Continue improving existing equipment and processes to achieve maximum capacity utilization, thereby reducing costs and increasing market competitiveness.
4. Pay more attention to product quality and persist in high standards and customer satisfaction.

5. Leverage aseptic technology to develop high value-added products and enhance the company's overall competitiveness.
6. Strive for collaboration with multinational pharmaceutical corporations and enhance deployments in markets in different regions. Train internationalized talents and extend operation scale and territory stably to march toward the goal of becoming an international leading company.
7. Closely monitor the establishment of new production lines and inspection progress to expand production capacity and increase market share.

III. Impact of external competitive environment, legal environment and macro economic environment

To enhance the quality control of medicines, supervisory authorities of drugs around the world have enhanced their supervision of API manufacturers and conducted inspections more intensively in recent years. Savior Lifetec Corporation (SLC) has long been recognized by the US FDA, EU EMA, and Taiwan FDA for our drug quality monitoring and compliance. Furthermore, countries have gradually announced and implemented stricter regulatory standards to ensure drug quality and safety. In response, the company has been actively promoting various initiatives to enhance its internal quality control capabilities and strengthen its competitive edge.

IV. Future Company Development Strategy

Currently, Savior Lifetec Corporation (SLC) operates as a vertically integrated pharmaceutical manufacturer with full-scale commercial production, covering the entire process from active pharmaceutical ingredients (API) to finished dosage forms (FDF). The company also holds its own U.S. drug approval (ANDA). In the U.S. market for carbapenem antibiotics, the company ranks among the top three suppliers.

Looking ahead to the 2025 operational plan, Ertapenem remains the company's core product. In the Taiwan market, due to the original manufacturer's production capacity allocation and increased National Health Insurance pricing, the company will continue to expand its business to maintain its position as a major supplier. For the U.S. market, aligned with the schedules of American clients and tender shipment plans, market share in the U.S. is expected to increase further.

Beyond the U.S., the company's global market strategy is also bearing fruit, with products now available in over 20 countries. It plans to expand into approximately 10 more new markets in the future. Additionally, if the Ertapenem registration in China proceeds smoothly, drug approval could be obtained as early as Q1 2025, further boosting the product's global market share.

Beyond the carbapenem antibiotic business, the company's subsidiary has entered the health supplement industry, launching its own branded products such as Triplecal Capsules, Kinetest Tablets, Upcular Veggie Capsules, Argipump Essence Drink, Redugar Powder, and Vitapop, as

well as oral hyaluronic acid (RZ Collection). These products are already stocked in pharmacies, clinics, and beauty retail outlets across Taiwan, with online sales channels also being developed. This is expected to further enhance the group's revenue momentum.

In the future, we will continue to improve our product advantages, improve the Company's operational efficiency, and accelerate the expansion to the global market, with the aim of making SLC become the top pharmaceutical manufacturer of penem in the world. With the efforts from all our employees and your support, Savior Lifetec Corporation will certainly maintain its growth momentum on revenue and profits. We are grateful for your continuous support and wish you good health and all the best.

Chairman:

President:

Accounting Officer:

Two. Corporate Governance Report

1. Information concerning the directors, supervisors, general managers, assistant general managers, deputy assistant general managers and the supervisors of all the divisions and branch units

(1) Directors and Supervisors

1. Background information of directors (I)

April 15, 2025; Unit: share, %

Title	Nationality or place of registration	Name	Gender and Age	Date of election (accession)	Term of contract	Commencement date of the first term	Shareholding when elected		Current shareholding		Spouse & Minor Shareholding		Shareholding through nominee		Principal work experience and education	Position(s) held concurrently in the Company and/or in any other company	Executives, Directors or Supervisors who are spouses or relatives within two degrees of kinship with another			Remarks
							Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)			Title	Name	Relationship	
Chairman	R.O.C.	Concord Consulting Inc.		June 15, 2023	3 years	2014/6/10	3,667,555	1.16	3,667,555	1.16	-	-	-	-	None	<ul style="list-style-type: none"> ● Director, Han Yu Venture Capital Corporation ● Director, Key Ware Electronics Co., Ltd. ● Director, Qbic Technology Co., Ltd. 	None	None	None	

Title	Nationality or place of registration	Name	Gender and Age	Date of election (accession)	Term of contract	Commencement date of the first term	Shareholding when elected		Current shareholding		Spouse & Minor Shareholding		Shareholding through nominee		Principal work experience and education	Position(s) held concurrently in the Company and/or in any other company	Executives, Directors or Supervisors who are spouses or relatives within two degrees of kinship with another			Remarks
							Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)			Title	Name	Relationship	
	ROC	Representative: Rebecca Lee	Female 51-60 years old				-	-	299,099	0.09	580	-	-	-	<u>Education</u> <ul style="list-style-type: none"> ● Master's in Accounting, University of Houston, USA <u>Work Experience</u> <ul style="list-style-type: none"> ● Concord Consulting Inc. Vice President 	<ul style="list-style-type: none"> ● Vice President, Concord Consulting Inc. ● Director, Walkgame Corp. ● Director, Qbic Technology Co., Ltd. ● Director, Key Ware Electronics Co., Ltd. (Juristic Person Representative) ● Chairman, Sheng Ding Enterprises Limited (Juristic Person Representative) ● Director (Juristic Person Representative), Concord Consulting Inc. ● Chairman, Ruize Biotechnology Co., Ltd. ● Supervisor, SLC BioPharm Co., Ltd. (Juristic Person Representative) ● Independent Director of Dynapack International Technology Corporation ● Chairman, Peng Rui Construction Co., Ltd. (Juristic Person Representative) 	None	None	None	
Director	Cayman Islands	SFS Venture Ltd.		June 15, 2023	3 years	2020/6/5	7,393,448	2.33	7,393,448	2.33	-	-	-	-	None	None	None	None	None	
	ROC	Representative: Chung Hsing-Yung	Male 71-80 years old				-	-	-	-	224,341	0.07	-	-	<u>Education</u> <ul style="list-style-type: none"> ● Chemistry, Tamkang University <u>Work Experience</u> <ul style="list-style-type: none"> ● Chairman, DSM Coating Resins Ltd. 	<ul style="list-style-type: none"> ● Director, SLC BioPharm Co., Ltd. (Juristic Person Representative) 	None	None	None	
Director	Cayman Islands	SFS Venture Ltd.		June 15, 2023	3 years	2020/6/5	7,393,448	2.33	7,393,448	2.33	-	-	-	-	None	None	None	None	None	
	ROC	Representative: Chen Zheng	Male 61-70 years old				-	-	-	-	-	-	-	-	<u>Education</u> <ul style="list-style-type: none"> ● Ph.D. in Chemistry, University of Rochester, USA 	<ul style="list-style-type: none"> ● Chairman and Chief Strategy Officer, Genovate Biotechnology Co., 	None	None	None	

Title	Nationality or place of registration	Name	Gender and Age	Date of election (accession)	Term of contract	Commencement date of the first term	Shareholding when elected		Current shareholding		Spouse & Minor Shareholding		Shareholding through nominee		Principal work experience and education	Position(s) held concurrently in the Company and/or in any other company	Executives, Directors or Supervisors who are spouses or relatives within two degrees of kinship with another			Remarks
							Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)			Title	Name	Relationship	
															<u>Work Experience</u> <ul style="list-style-type: none"> ● Moderator, Project Novartis ● Vice President of Asia Business, Genelabs ● Chairman, QPS-Qualitix Clinical Research Co., Ltd. ● Bio Taiwan Committee Member(BTC) 	Ltd. <ul style="list-style-type: none"> ● Director, QPS Taiwan (Juristic Person Representative) ● Directo (Juristic Person Representative), Genovate Biotechnology (Cayman) Co., Ltd. ● Chairman and Chief Strategy Officer, UniPharma Co., Ltd. ● Director, Reber Genetics Co. Ltd (Juristic Person Representative) ● Chairman, NaviFUS Corporation (Legal Person Representative) and Chief Strategy Officer ● Genovate NaviFus (Australia) Director of Pty. Ltd. (Representative) 				
Director	ROC	Min-Ju Investment Co., Ltd.		June 15, 2023	3 years	2020/6/5	6,221,975	1.96	6,241,975	1.97	-	-	-	-	None	None	None	None	None	
	ROC	Representative: Chen Yung-Fa	Male 61-70 years old				-	-	641,598	0.2	-	-	-	-	<u>Education</u> <ul style="list-style-type: none"> ● Ph.D. in Chemistry, Wayne State University, USA ● Master's in Chemistry, National Taiwan University ● Chemistry, Tunghai University <u>Work Experience</u> <ul style="list-style-type: none"> ● Part-time Associate Professor in Chemistry, Tunghai University ● Project Manager, Refining & Manufacturing Research Institute, CPC Corporation ● President and Chief R&D Officer, ScinoPharm Taiwan Limited ● Director (Juristic Person Representative), 	<ul style="list-style-type: none"> ● Chairman, SLC BioPharm Co., Ltd. (Juristic Person Representative) 	None	None	None	

Title	Nationality or place of registration	Name	Gender and Age	Date of election (accession)	Term of contract	Commencement date of the first term	Shareholding when elected		Current shareholding		Spouse & Minor Shareholding		Shareholding through nominee		Principal work experience and education	Position(s) held concurrently in the Company and/or in any other company	Executives, Directors or Supervisors who are spouses or relatives within two degrees of kinship with another			Remarks
							Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)			Title	Name	Relationship	
															ScinoPharm Taiwan Limited ● Director, SPT International, Ltd. ● Director, Scinopharm Singapore Pte Ltd. ● Director and President, ScinoPharm Pharmaceuticals Co., Ltd. (Kunshan) ● Director and President, Scino Pharm Pharmaceuticals (Changshu) Ltd. ● Director, SciAnda Shanghai Biochemical Technology, Ltd. ● President, Savior Lifetec Corporation					
	ROC	Representative: Hsieh Jung-Cheng	Male 71-80 years old				-	-	-	-	10,000	-	-	-	Education ● Master of Law, National Chengchi University Work Experience ● Chief Prosecutor, Supreme Prosecutors Office	● Director, Qbic Technology Co., Ltd. (Juristic Person Representative) ● Independent Director, Shine-On Biomedical Co., Ltd.	None	None	None	
Director	ROC	Fine Horse Investment Co., Ltd.					4,387,349	1.38	4,387,349	1.38	-	-	-	-	None	● Director, Key Ware Electronics Co., Ltd.	None	None	None	
	ROC	Representative: Chou Chia-Chu	Male 41-50 years old	June 15, 2023	3 years	June 10, 2014	-	-	62,444	0.02	-	-	-	-	Education ● MBA, National Taiwan University ● Bachelor, School of Business, New York University Work Experience ● Vice President of investment department, Concord Consulting Inc.	● Concord Consulting Inc. Vice-President of the Investment Department ● Director, Key Ware Electronics Co., Ltd. (Juristic Person Representative) ● Director, Kai Da Precise Industries Co., Ltd. (Juristic Person Representative) ● Director, Qbic Technology Co., Ltd. ● Director, Ruize Biotechnology Co., Ltd. ● Director (representative of legal person) of Laserwings Technology Co., Ltd.	None	None	None	

Title	Nationality or place of registration	Name	Gender and Age	Date of election (accession)	Term of contract	Commencement date of the first term	Shareholding when elected		Current shareholding		Spouse & Minor Shareholding		Shareholding through nominee		Principal work experience and education	Position(s) held concurrently in the Company and/or in any other company	Executives, Directors or Supervisors who are spouses or relatives within two degrees of kinship with another			Remarks
							Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)			Title	Name	Relationship	
																<ul style="list-style-type: none"> Chairman of Huan Qing Construction Co., Ltd. Director, Huanyu Construction Co., Ltd. (Juristic Person Representative) 				
Independent Director	ROC	Chang Ryh-Yan	Male 71-80 years old	June 15, 2023	3 years	June 10, 2014	283,458	0.09	283,458	0.09	-	-	-	-	<u>Education</u> <ul style="list-style-type: none"> Master's in Finance, College of Management, National Taiwan University Accounting, National Taipei University (previously known as College of law and business, National Chung Hsin University) <u>Work Experience</u> <ul style="list-style-type: none"> CEO and Director, Deloitte & Touche Member of Discipline Committee and Business Service Committee, Taipei CPA Association Director, The National Federation of CPA Associations of the R.O.C.; Chairman, Professional Ethics Committee 	<ul style="list-style-type: none"> Chairman, Qin Zheng Financial Management Consulting Corporation Independent Director, Panion & BF Biotech Inc. Independent Director, E.SUN Financial Holding Company Independent Director, E.SUN Bank Independent Director, Qbic Technology Co., Ltd. Remuneration Committee, Super Dragon Technology Co., Ltd 	None	None	None	
Independent Director	ROC	Lin Chih-Ming	Male 71-80 years old	June 15, 2023	3 years	2020/6/5	-	-	-	-	-	-	-	-	<u>Education</u> <ul style="list-style-type: none"> M.D., National Taiwan University College of Medicine <u>Work Experience</u> <ul style="list-style-type: none"> Dean and medical consultant, Cathay General Hospital Associate Professor, Ministry of Education 	<ul style="list-style-type: none"> Medical consultant, Cathay General Hospital Supervisor, Cathay Life Insurance Company, Ltd. Director, Cathay General Hospital 	None	None	None	

Title	Nationality or place of registration	Name	Gender and Age	Date of election (accession)	Term of contract	Commencement date of the first term	Shareholding when elected		Current shareholding		Spouse & Minor Shareholding		Shareholding through nominee		Principal work experience and education	Position(s) held concurrently in the Company and/or in any other company	Executives, Directors or Supervisors who are spouses or relatives within two degrees of kinship with another			Remarks
							Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)			Title	Name	Relationship	
Independent Director	ROC	Cheng Chin-Hua	Female 61-70 years old	June 15, 2023	3 years	2022/6/01	-	-	-	-	-	-	-	-	<u>Education</u> ● Doctor of Pharmacy, Taipei Medical University ● Master's in Veterinary Medicine, Kaohsiung Medical University ● Master of Pharmacy, University of Arizona, the USA <u>Work Experience</u> ● Senior Research Fellow, Medical and Pharmaceutical Industry Technology and Development Center; Director-General, Industry Development Center Division; Director-General, Industry Service Division; Vice Director-General, Preparations R&D Division, Senior Specialist, President's Office; Vice Director-General Industry Service Division; Assistant Manager, Planning Division; Chief, Service Promotion Group of Planning Division; Associate Research Fellow, Planning Division. ● TBS labs, Inc. New Jersey, USA ● Department of Research & Development Group leader & Researcher, Research Associate II ● University of Arizona College of Pharmacy Research Assistant and Teaching Assistant ● Lecturer and teaching assistant, College of Pharmacy, Kaohsiung Medical University	● Independent Director, ChongDah Health Co., Ltd. ● Independent Director, Prince Pharmaceutical Co., Ltd.	None	None	None	

(1) Major shareholders of juristic person shareholders

April 15, 2025

Juristic person shareholder	Major shareholders of juristic person shareholders
Concord Consulting Inc.	NORWICH FINANCE CORP. (100%)
SFS Venture Ltd.	Chung Hsing-Yung (100%)
Min-Ju Investment Co., Ltd.	D.J. AMC INC. (94.34%)
Fine Horse Investment Co., Ltd.	D.J. AMC INC. (95.24%)

(2) Major owners of juristic person shareholder's major owner who is a juristic person

April 15, 2025

Name of Institutional shareholder	Major shareholders of the institution
NORWICH FINANCE CORP.	WALPAC INC. (30%) FIRST TROPHY INTERNATIONAL LIMITED (10%) Chow Pong-Chi (30%) Liu Lien-Chun (10%) Lee Shu-Juan (8%) Chiao Tzu-Yi (7%)
D.J. AMC INC.	BLISSMORE HOLDINGS LIMITED (100%)
D.J. AMC INC.	BLISSMORE HOLDINGS LIMITED (100%)

2. Background information of directors (II)

(1) Disclosure of information on the professional qualifications of directors and the independence of independent directors:

Name \ Criteria	Professional qualifications and experience (Note)	State of Independence	Concurrent Positions in Other Public Companies Number of Independent Directors
Concord Consulting Inc. Representative: Rebecca Lee	Master's in Accounting, University of Houston, USA Vice President, Concord Consulting Inc.	N/A	1
SFS Venture Ltd. Representative: Chung Hsing-Yung	Chemistry, Tamkang University Chairman, DSM Coating Resins Ltd.	N/A	0
SFS Venture Ltd. Representative: Chen Zheng	Ph.D. in Chemistry, University of Rochester, USA Chairman and Chief Strategy Officer, Genovate Biotechnology Co., Ltd.	N/A	0

Min-Ju Investment Co., Ltd. Representative: Chen Yung-Fa	Ph.D. in Chemistry, Wayne State University, USA President and Chief R&D Officer, ScinoPharm Taiwan Limited	N/A	0
Min-Ju Investment Co., Ltd. Representative: Hsieh Jung-Cheng	Master of Law, National Chengchi University Chief Prosecutor of the Supreme People's Court	N/A	1
Fine Horse Investment Co., Ltd. Representative: Chou Chia-Chu	MBA, National Taiwan University Vice President of investment department, Concord Consulting Inc.	N/A	0
Chang Ryh-Yan (Independent Director)	Master's in Finance, College of Management, National Taiwan University CPA, Chang Ryh-Yan CPA Firm Members of the Audit Committee with Accounting or Financial Expertise CPA Not a person of the conditions specified in the sub-paragraphs of Article 30 of the Company Act.	<ul style="list-style-type: none"> ● All of Independent Director of the Company, meeting the independence criteria. ● Whether is a director, supervisor, or employee of the Company or its affiliated companies (nor are the spouse or relatives within the second degree of kinship thereof): None. ● The number and percentage of the Company's shares held or by spouse, relatives within the second degree of kinship (or by nominee arrangement): , Independent Director Chang Ryh-Yan held 283 thousand shares, i.e. 0.09%, while the other independent directors didn't hold any shares. 	4
Lin Chih-Ming (Independent Director)	M.D., National Taiwan University College of Medicine Director, Cathay General Hospital Qualified physician Not a person of the conditions specified in the sub-paragraphs of Article 30 of the Company Act.	<ul style="list-style-type: none"> ● Whether serves as a director, supervisor or employee of a company with specific relations with the Company (see Article 3, paragraph 1, subparagraphs 5 to 8 of the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies): None. ● Provides commercial, legal, financial, or accounting services to the Company and the amount of remuneration received accordingly in the most recent two years: None. 	0
Cheng Chin-Hua (Independent Director)	Doctor of Pharmacy, Taipei Medical University Senior researcher, Medical and Pharmaceutical Industry Technology and Development Center Qualified pharmacist Not a person of the conditions specified in the sub-paragraphs of Article 30 of the Company Act.	<ul style="list-style-type: none"> ● Whether serves as a director, supervisor or employee of a company with specific relations with the Company (see Article 3, paragraph 1, subparagraphs 5 to 8 of the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies): None. ● Provides commercial, legal, financial, or accounting services to the Company and the amount of remuneration received accordingly in the most recent two years: None. 	2

Note: This is a summary list of professional qualifications and experience. For details, please refer to the "Background information of directors (I)" on pages 5~10 herein.

(2) Board diversity and independence:

(1) Board diversity:

(1) The company has established the "Corporate Governance Best Practice Principles," which stipulate that the composition of the board of directors should consider diversity and appropriate diversity policies should be formulated based on the company's operations, business model and development needs. Board diversity is categorized into three main aspects: basic composition, industry experience and professional expertise. In terms of basic composition, 22% of the board members are women; one independent director has served for 10 years or more; four directors are aged 71–80, three are aged 61–70 and two are aged 51–60. For diversity in industry experience and professional expertise, please refer to Appendix 3 and the company's website.

(2) Specific management objectives and achievements of the board diversity policy:

Management Objectives	Status
Female representation on the board is more than 33%	Not achieved
At least one third of the board of directors has experience in the medical, pharmaceutical and chemical industry	Achieved

(2) Independence of the Board:

The board consists of 9 members, including 3 independent directors, accounting for approximately 33% of the board. None of the board members are related by marriage or within the second degree of kinship. Two board members also serve as employees of the company, accounting for about 22%.

The board provides strategic guidance, supervises the management team, and is accountable to both the company and its shareholders. In all governance practices and arrangements, the board exercises its powers in accordance with laws, the company's articles of incorporation or resolutions of shareholders' meetings. The board emphasizes independent operation and transparency. All directors, including independent directors, act independently in the execution of their duties. For the declaration of board independence, please refer to page 12 for a disclosure of directors' professional qualifications and independent status.

(2) Background Information of the President, Vice-Presidents, Assistant Vice-Presidents and department and branch managers

April 15, 2025; Unit: share, %

April 13, 2023, Unit: Share, %																	
Title	Nationality	Name	Gender	Date of election (accession) Date	Shareholding		Shareholdings of Spouse & Minor		Shareholding through nominee		Principal work experience and academic qualifications	Position(s) held concurrently in any other company	Managers who are spouses or relatives within the second degree of kinship			Remarks	
					Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)			Title	Name	Relationship		
President	R.O.C.	Chen Chih-Fang	Male	2020/7/20	85,851	0.03	3,159	-	-	-	<u>Education</u> <ul style="list-style-type: none">● Master's in Chemical Engineering, National Cheng Kung University● Chemical Engineering, National Cheng Kung University <u>Work Experience</u> <ul style="list-style-type: none">● Vice President of Production Center and President of Changshu Factory, ScinoPharm Taiwan, Ltd.● Senior Department Head of Manufacturing, SOC member, Department Head of manufacturing, and Manager of Manufacturing, ScinoPharm Taiwan, Ltd.● Manager of Methods Engineering, Tuntex Petrochemical Inc.	None	None	None	None		
Vice President	ROC 民國	Chen I-Hsiu	Male	2022/8/6	10,000	-	-	-	-	-	<u>Education</u> <ul style="list-style-type: none">● Master's in Microbiology, National Taiwan University● Department of Biological Science and Technology, National Chiao Tung University <u>Work Experience</u> <ul style="list-style-type: none">● Nang Kuang Pharmaceutical Co., Ltd.: R&D Team Leader, R&D and QC Section Chief, R&D and QC Manager, Vice Director-General of Quality Division.	None	None	None	None		
Vice President	ROC 民國	Lin Yen-Lan	Male	2014/7/30	75,708	0.02	-	-	-	-	<u>Education</u> <ul style="list-style-type: none">● Master's in Veterinary Medicine, National Taiwan University● IMBA, National Chengchi University● Veterinary medicine, National Chung Hsing University <u>Work Experience</u> <ul style="list-style-type: none">● Senior Product Sales and Marketing Manager, Roche Products Ltd.● Product Sales and Marketing Manager, GlaxoSmithKline Far East B.V., Taiwan Branch (Netherlands)	None	None	None	None		
Vice president/ Representative of director	ROC 民國	Chou Chia-Chu	Male	2018/5/3	62,444	0.02	-	-	-	-	<u>Education</u> <ul style="list-style-type: none">● MBA, National Taiwan University● Bachelor, School of Business, New York University <u>Work Experience</u> <ul style="list-style-type: none">● Vice President of investment department, Concord Consulting Inc.	<ul style="list-style-type: none">● Vice President of investment department, Concord Consulting Inc.● Director (Juristic Person Representative), Key Ware Electronics Co., Ltd.● Director (Juristic Person Representative), Kai Da Precise Industries Co., Ltd.● Director, Qbic Technology Co., Ltd.● Director, Ruize Biotechnology Co., Ltd.● Director (representative of legal	None	None	None	None	

												person) of Laserwings Technology Co., Ltd. ● Chairman of Huan Qing Construction Co., Ltd. ● Director (corporate representative) of Huanyu Construction Co., Ltd.				
Vice President	ROC 民國	Chen Ming-Hui	Male	2023/8/4	8,000	-	-	-	-	-	Education ● Master of Engineering Management, National Cheng Kung University Work Experience ● Production manager of Shenlong Co., Ltd., Taiwan ● Divisional Engineer, Evergreen Materials Corporation	None	None	None	None	None
Associate Vice-President/ Chief of Finance and Accounting/ Corporate Governance Officer	ROC 民國	Lin Kuo-Wei	Male	2023/8/4	8,000	-	-	-	-	-	Education ● Accounting, National Cheng Kung University Work Experience ● Head of Finance and Spokesperson, Kakoel Electronics Co., Ltd. ● Chief of Accounting Section, Radiant Opto-Electronics Corporation	None	None	None	None	None

II. Remuneration paid to directors, supervisors, presidents and vice- presidents in the most recent year
(1) Remuneration of Directors and Independent Directors

For the year ended December 31, 2024; Unit: %, NTD thousand

Title	Name	Remuneration to directors								Sum of A, B, C, and D and the sum as a percentage of net income		Compensation as company employee								Sum of A, B, C, D, E, F and G and the sum as a percentage of net income		Remuneration from investees other than subsidiaries, or parent company
		Remuneration (A)		Pension (B)		Remuneration to directors (C)		For professional practice (D)				Salary, bonuses and special allowances (E)		Pension (F)		Employee Compensation (G)						
		The Company	All companies included in the financial statements	The Company	All companies included in the financial statements	The Company	All companies included in the financial statements	The Company	All companies included in the financial statements	The Company	All companies included in the financial statements	The Company	All companies included in the financial statements	The Company		All companies included in the financial statements		The Company	All companies included in the financial statements			
Cash Amount	Amount paid in shares	Amount paid in cash	Amount paid in shares																			
Chairman	Concord Consulting Inc. Representative: Rebecca Lee	3,068	4,521	-	-	2,400	2,400	117	117	5,585 3.06%	7,038 3.86%	5,637	5,637	-	-	951	-	951	-	12,173 6.67%	13,626 7.47%	-
Director	SFS Venture Ltd. Representative: Chung Hsing-Yung SFS Venture Ltd. Representative: Chen Zheng																					
Director	Min-Ju Investment Co., Ltd. Representative: Chen Yung-Fa Representative: Hsieh Jung-Cheng																					
Director	Fine Horse Investment Co., Ltd. Representative: Chou Chia-Chu																					
Independent Director	Chang Ryh-Yan	1,800	1,800	-	-	600	600	57	57	2,457 1.35%	2,457 1.35%	-	-	-	-	-	-	-	-	2,457 1.35%	2,457 1.35%	-
Independent Director	Lin Chih-Ming																					
Independent Director	Cheng Chin-Hua																					
1. Please describe the remuneration policy, system, standards, and structure for independent directors, and explain the correlation between the remuneration amount and factors such as responsibilities, risks and time commitment: The remuneration is proposed by the company's Remuneration Committee based on an overall performance evaluation of the board, the company's operational results, and the level of participation and value contributed by the independent directors. 2. Compensation received by director for providing service to all companies included in the financial statements (e.g., consultancy service to the parent company, any entity included in the financial reports or invested businesses without the title of an employee) in the last year, except those disclosed in the above table: None.																						

Remuneration brackets table

Remuneration ranges paid to each director of the company:	Name of Directors			
	Total amount of the first four types of remuneration (A + B + C + D)		Total amount of the first seven types of remuneration (A + B + C + D + E + F + G)	
	The Company	All companies included in the financial statements	The Company	All companies included in the financial statements
Less than NT\$1,000,000	Chang Ryh-Yan, Lin Chih-Ming, Cheng Chin-Hua Fine Horse Investment Co., Ltd. (Representative: Chou Chia-Chu)	Chang Ryh-Yan, Lin Chih-Ming, Cheng Chin-Hua Fine Horse Investment Co., Ltd. (Representative: Chou Chia-Chu)	Chang Ryh-Yan, Lin Chih-Ming, Cheng Chin-Hua	Chang Ryh-Yan, Lin Chih-Ming, Cheng Chin-Hua
NT\$1,000,000 (inclusive) – NT\$2,000,000 (not inclusive)	Management Consultant, Concord Venture Capital Group (Representative: Rebecca Lee) SFS Venture Ltd. (Juristic Person Representative: Chung Hsing-Yung/ Chen Zheng) Min-Ju Investment Co., Ltd. (Representative: Chen Yung-Fa/ Hsieh Jung-Cheng)	Concord Consulting Inc. (Representative: Rebecca Lee) SFS Venture Ltd. (Juristic Person Representative: Chung Hsing-Yung/ Chen Zheng)	SFS Venture Ltd. (Juristic Person Representative: Chung Hsing-Yung/ Chen Zheng), Min-Ju Investment Co., Ltd. (Representative: Chen Yung-Fa/ Hsieh Jung-Cheng)	SFS Venture Ltd. (Juristic Person Representative: Chung Hsing-Yung/ Chen Zheng)
NT\$2,000,000 (inclusive) – NT\$3,500,000 (not inclusive)		Min-Ju Investment Co., Ltd. (Representative: Chen Yung-Fa/	Fine Horse Investment Co., Ltd. (Representative: Chou Chia-Chu)	Min-Ju Investment Co., Ltd. (Representative: Chen Yung-Fa/ Hsieh Jung-Cheng)

		Hsieh Jung-Cheng)		Fine Horse Investment Co., Ltd. (Representative: Chou Chia-Chu)
NT\$3,500,000 (inclusive) – NT\$5,000,000 (not inclusive)			Concord Consulting Inc. (Representative: Rebecca Lee)	Concord Consulting Inc. (Representative: Rebecca Lee)
NT\$5,000,000 (inclusive) – NT\$10,000,000 (not inclusive)				
NT\$10,000,000 (inclusive) – NT\$15,000,000 (not inclusive)				
NT\$15,000,000 (inclusive) – NT\$30,000,000 (not inclusive)				
NT\$30,000,000 (inclusive) – NT\$50,000,000 (not inclusive)				
NT\$50,000,000 (inclusive) – NT\$100,000,000 (not inclusive)				
NT\$100,000,000 and above				
Total	9	9	9	9

(2) Remuneration to President and vice- presidents

For the year ended December 31, 2024; Unit: %, NTD thousand

Title	Name	Salary (A)		Pension (B)		Bonus and Special Disbursement, etc. (C)		Employee Compensation (D)				Sum of A, B, C, and D and the sum as a percentage of net income		Remuneration from investees other than subsidiaries, or parent company
		The Company	All companies included in the financial statements	The Company	All companies included in the financial statements	The Company	All companies included in the financial statements	The Company		All companies included in the financial statements		The Company	All companies included in the financial statements	
								Amount paid in cash	Amount paid in shares	Amount paid in cash	Amount paid in shares			
President	Chen Chih-Fang	13,992	13,992	-	-	2,584	2,584	3,083	-	3,083	-	19,659 10.78%	19,659 10.78%	-
Vice-President of Business	Lin Yen-Lan													
Vice-President of Quality	Chen I-Hsiu													
Vice President of Production	Chen Ming-Hui													
Vice-President of Administration	Chou Chia-Chu													

Remuneration brackets table

Range of remunerations to the President and vice presidents	Name of President and vice presidents	
	The Company	All companies included in the financial statements
Less than NT\$1,000,000	-	-
NT\$1,000,000 (inclusive) – NT\$2,000,000 (not inclusive)	-	-
NT\$2,000,000 (inclusive) – NT\$3,500,000 (not inclusive)	Lin Yan-Lan, Chen I-Hsiu, Chou Chia-Chu	Lin Yan-Lan, Chen I-Hsiu, Chou Chia-Chu

NT\$3,500,000 (inclusive) – NT\$5,000,000 (not inclusive)	Chen Ming-Hui	Chen Ming-Hui
NT\$5,000,000 (inclusive) – NT\$10,000,000 (not inclusive)	Chen Chih-Fang	Chen Chih-Fang
NT\$10,000,000 (inclusive) – NT\$15,000,000 (not inclusive)	-	-
NT\$15,000,000 (inclusive) – NT\$30,000,000 (not inclusive)	-	-
NT\$30,000,000 (inclusive) – NT\$50,000,000 (not inclusive)	-	-
NT\$50,000,000 (inclusive) – NT\$100,000,000 (not inclusive)	-	-
NT\$100,000,000 and above	-	-
Total	5	5

- (3) Name of the managerial officers whom the employee remuneration was allocated to and status of the allocation:

Ended December 31, 2024; Unit: NTD thousands

	Title	Name	Amount paid in shares	Amount paid in cash	Total	Ratio of total amount to profit after tax (%)
Managerial officer	Chairman	Rebecca Lee	0	3,902	3,902	2.14%
	President	Chen Chih-Fang				
	Vice-President of Business	Lin Yen-Lan				
	Vice-President of Quality	Chen I-Hsiu				
	Vice President of Production	Chen Ming-Hui				
	Vice-President of Administration	Chou Chia-Chu				
	Chief of Finance and Accounting/ Corporate Governance Officer	Lin Kuo-Wei				

- (4) Separately compare and describe total remuneration, as a percentage of net income stated in the parent company only financial reports or individual financial reports, as paid by the Company and by each other company included in the consolidated financial statements during the past two fiscal years to directors, supervisors, president and vice presidents, and analyze and describe remuneration policies, standards, and packages, the procedure for determining remuneration and its linkage to operating performance and future risk exposure:

1. Directors', Supervisors', President's and Vice Presidents' remuneration paid in the last two fiscal years as a percentage to net income stated in the parent company only financial reports or individual financial reports.

Unit: %

Title	2023		2024	
	The Company	All companies included in the financial statements	The Company	All companies included in the financial statements
Director	30.79	35.46	4.41	5.21
President and vice presidents	51.98	51.98	10.78	10.78

Explanation: (1) The Company's net (loss) income on standalone financial reports for the year ended December 31, 2023 and 2024 were NT\$30,030 thousand and NT\$182,380 thousand, respectively.

(2) The decrease in the proportion of the total remuneration of the Company's directors, presidents and vice-presidents in 2024 from 2023 was mainly due to the increase in 2024 net income from 2023.

2. Remuneration policies, standards, and packages, the procedure for determining remuneration and its link to operating performance and future risk exposure:
 - (1) Policies, standards and packages for payment of remuneration:
 - (1) Regarding the remuneration of the Company's directors, in accordance

with Article 19-1 of the Company's Articles of Incorporation, it shall be determined by the Board of Directors based on the degree of their participation in the Company's operations and the value of their contributions, with reference to the standards of the industry domestically and internationally. Additionally, if the Company makes a profit in the current year, no more than 3% shall be allocated as remuneration for directors. The Company regularly evaluates the performance of directors in accordance with the "Procedures for Performance Evaluation of the Board of Directors" and the relevant performance evaluation and the reasonableness of the remuneration are reviewed by the Remuneration Committee and the Board of Directors.

(2) The compensation levels of managerial officers are assessed by considering the general pay levels in the industry, the time spent by the individual and their responsibilities, the extent of goal achievement, their performance in other positions and the compensation paid to employees holding equivalent positions in recent years. Additionally, the reasonableness of the correlation between the individual's performance and the Company's operational performance and future risk exposure, with respect to the achievement of short-term and long-term business goals and the financial position of the Company, is evaluated. Compensation is determined by the Remuneration Committee and submitted for the Board of Directors' approval.

(3) The combination of remuneration paid by the Company shall be determined in accordance with the organizational charter of the Remuneration Committee, and include cash remuneration, stock options, bonus shares, retirement benefits or severance pay, various allowances and other measures with substantial incentives.

(2) Procedures for Determining Remuneration:

The Company regularly evaluates the salaries and remunerations to directors and managers, based on the evaluation results of the Company's "Regulations Governing Performance Evaluation of the Board of Directors" and the "Employee Performance Evaluation Regulations" applicable to managers and employees. The actual amount of remuneration to directors and managers is reviewed by the Remuneration Committee and submitted to the Board of Directors for approval.

(3) Correlation between business performance and future risks:

The payment standards and system review related to the Company's remuneration policy take the Company's overall operation as the main consideration, and determine the payment standard based on the performance achievement rate and contribution, in order to improve the overall organizational efficiency. The important policies of the Company's management are based on balanced consideration of various risk factors. The performance of the relevant decisions is reflected in the Company's profitability, and the remuneration to the management is related to the performance of risk control.

III. Corporate Governance

(1) Information concerning the Board of Directors

In 2024, the Company's Board of Directors convened six meetings. The attendance of directors is detailed as follows:

Title	Name	Attendance in person B	Attendance by proxy	Rate of attendance in person (%) [B/A]	Remarks
Chairman	Concord Consulting Inc. Juristic Person Representative: Rebecca Lee	6	0	100	Re-elected
Director	SFS Venture Ltd. Representative: Chung Hsing-Yung	6	0	100	Re-elected
Director	SFS Venture Ltd. Representative: Chen Zheng	6	0	100	Re-elected
Director	Min-Ju Investment Co., Ltd. Representative: Chen Yung-Fa	6	0	100	Re-elected
Director	Min-Ju Investment Co., Ltd. Representative: Hsieh Jung-Cheng	6	0	100	Re-elected
Director	Fine Horse Investment Co., Ltd. Representative: Chou Chia-Chu	6	0	100	Re-elected
Independent Director	Chang Ryh-Yan	6	0	100	Re-elected
Independent Director	Lin Chih-Ming	6	0	100	Re-elected
Independent Director	Cheng Chin-Hua	6	0	100	Re-elected

Other items to be stated:

- I. If the Board of Directors meets any of the following circumstances, the minutes concerned shall clearly state the meeting date, term, contents of proposals, opinions of all independent directors, and the Company's resolution of said opinions:
- (1) Regarding the matters listed under Article 14-3 of the Securities and Exchange Act: Since the Company has established an Audit Committee, the provisions of Article 14-3 are not applicable.
For explanations regarding the matters listed under Article 14-5 of the Securities and Exchange Act, please refer to the section on the Audit Committee's operations in this annual report.
- (2) Other than those described above, any other resolution(s) passed but with independent directors voicing opposing or qualified opinions on the record or in writing: None.
- II. Regarding the situation of directors' conflict of interested recusal, the name of the director with potential conflict of interest, subject matter, reason for conflict of interest recusal and deliberation participation shall be recorded:

Name of recusing director	Subject Matter	Reason for recusal	Participation in voting
Rebecca Lee, Chung Hsing-Yung, Chen Zheng, Chen Yung-Fa, Hsieh Jung-Cheng Chou Chia-Chu	The motion for the Company's 2023 remuneration to employees and directors.	Interests related to the case	Abstained from discussion and voting by voluntarily leaving the meeting
Rebecca Lee, Chung Hsing-Yung, Chen Yung-Fa, Hsieh Jung-Cheng Chou Chia-Chu	Adjustment on the remuneration to the Chairman of the Company.	Interests related to the case	Abstained from discussion and voting by voluntarily leaving the meeting
Rebecca Lee, Chou Chia-Chu	The Company's 2024 Distribution of year-end bonuses for the Company's managerial officers.	Interests related to the case	Abstained from discussion and voting by voluntarily leaving the meeting
Rebecca Lee, Chou Chia-Chu	The Company's 2023 Distribution of remuneration to managers	Interests related to the case	Abstained from discussion and voting by voluntarily leaving the meeting

III. The company listed on the TWSE or the TPEx shall disclose the evaluation cycle and period, scope of evaluation, method

and contents of evaluation about the Board of Directors' self-performance evaluation (or peer evaluation): please refer to Table 1

IV. The objectives of strengthening the competency of the Board of Directors for the present year and the most recent year, such as establishment of the Audit Committee and improvement of information transparency and the assessment on implementation:

- (1) The Company regularly discloses various operational, financial, corporate governance, and corporate social responsibility information through the Market Observation Post System, the Company's website and the annual report to enhance information transparency.
- (2) To strengthen directors' corporate governance competencies, the Company regularly arranges training courses in line with the "Guidelines for the Continuing Education of Directors and Supervisors." In 2024, all directors completed at least 6 hours of training.
- (3) The Audit Committee and the Remuneration Committee are composed entirely of independent directors, who assist the Board of Directors in performing its duties.
- (4) To implement sound corporate governance and enhance the effectiveness of the Board, the Company has established a "Board Performance Evaluation Policy" to regularly assess the performance of the Board each year. The scope of board performance evaluation includes the overall board, individual directors and functional committees.
- (5) To ensure that the risks undertaken by directors and managers in the course of their duties are covered, the Company annually purchases "Directors and Officers Liability Insurance" and reports the coverage to the Board.

(2) Operation of the Audit Committee or Supervisors' Participation in the Operation of the Board of Directors.

The Audit Committee is composed of all independent directors and its major duties and tasks for 2024 are as follows:

1. Regularly communicate with the head of internal audit regarding audit report results in accordance with the annual audit plan
2. Review financial statements
3. Examination of effectiveness of internal control system
4. Review and approve the business report and the proposal for earnings distribution
5. Evaluate the appointment, dismissal or remuneration of the CPA, as well as their independence

A total of six meetings (A) were held in 2024; below are the attendance records of independent directors:

Title	Name	Actual attendance (B)	Attendance by proxy	Rate of attendance in person (%) (B/A)	Remarks
Independent Director	Chang Ryh-Yan	6	0	100	Re-elected
Independent Director	Lin Chih-Ming	6	0	100	Re-elected
Independent Director	Cheng Chin-Hua	6	0	100	Re-elected

Other items to be stated:

- I. For Audit Committee meetings that meet any of the following descriptions, state the date and session of the Audit Committee meeting held, the discussed topics, the content of the objections, reservations, or material recommendations of independent directors, the Audit Committee's resolution and how the company responded to Audit Committee's opinions:
 - (1) Conditions described in Article 14-5 of the Securities and Exchange Act: Please refer to Table 2.
 - (2) Other than the conditions described above, any resolutions unapproved by the Audit Committee but passed by more than two-thirds of directors: None.
- II. Regarding the situation of independent directors' conflict of interested recusal, the name of the independent director with potential conflict of interest, subject matter, reason for conflict of interest recusal and participation in voting shall be recorded: None.
- III. Communication between Independent Directors and internal/external auditors (e.g. discussions concerning the Company's financial and business position, the method of communication used and the outcome):
 1. In addition to submitting internal audit reports and follow-up reports to independent directors at the end

of each month and attending Audit Committee meetings, the internal audit department manager is available for discussion with independent directors.

2. Independent directors hold at least one private meeting per year with the certified public accountant. During the meeting, the accountant reports on the audit or review results of the current financial statements and communicates matters required by relevant regulations. They also provide assessments on significant adjustment entries or the impact of regulatory changes.
3. In 2024, the communication matters between the Company's independent directors, the internal audit supervisor and the certified public accountant are as follows:

Date	Meeting	Communication Party	Key Discussion Topics	Recommendations and Actions Taken Implementation status
2024.03.08	Audit Committee	Internal Audit Officer	1. Summary report of audit operations from December 2023 to Jan 2024 2. Statement of Internal Control for 2023	No objections
	Seminar (separate communication)	CPA	1. Audit results of the 2023 consolidated financial statements 2. Updates on key accounting standards or interpretations, securities regulations and tax laws	No objections
2024.05.03	Audit Committee	Internal Audit Officer	1. Summary report of audit operations from February 2024 to March 2024	No objections
	Seminar	CPA	1. Review results of Q1 2024 consolidated financial statements 2. Updates on key accounting standards or interpretations, securities regulations and tax laws	No objections
2024.08.08	Audit Committee	Internal Audit Officer	1. Summary report of audit operations from April 2024 to June 2024	No objections
	Seminar	CPA	1. Review results of Q2 2024 consolidated financial statements 2. Updates on key accounting standards or interpretations, securities regulations and tax laws	No objections
2024.11.07	Audit Committee	Internal Audit Officer	1. Summary report of audit operations from July 2024 to September 2024	No objections
	Seminar	CPA	1. Review results of Q3 2024 consolidated financial statements 2. Updates on key accounting standards or interpretations, securities regulations and tax laws	No objections
2024.12.26	Audit Committee	Internal Audit Officer	1. Summary report of audit operations from October 2024 to November 2024 2. 2024 Audit Plan Report	No objections

Table 1: Board performance evaluation implementation:

The 2024 performance evaluations of the Board of Directors and functional committees were submitted to the Board on March 6, 2025

Evaluation frequency	Evaluation period	Evaluation scope	Evaluation method	Evaluation content	Result
Conducted annually Once a year	2024/01/01 ~ 2024/12/31	Board of Directors' Meeting	Internal self-evaluation by the Board	1. Participation in the Operations of the Company 2. Improvement of decision quality by the board 3. Composition and Structure of the Board of Directors	Overall average 4.88 (Total Score 5)

				4. Election and continuing education of directors 5. Internal Control	
		Individual Board Member	Self-evaluation of directors	1. Understanding of the Goals and Mission of the Company 2. Awareness of the Duties of a Director 3. Participation in the Operations of the Company 4. Management of Internal Relationships and Communication 5. Director's Professionalism and Continuing Education 6. Internal Control	Overall average 4.96 (Total Score 5)
		Functional Committees (Audit and remuneration)	Internal self-evaluation by functional committees	1. Participation in the Operations of the Company 2. Awareness of Functional Committees' Responsibilities 3. Improvement of functional committee's decision quality. 4. Composition of functional committee and election. 5. Internal Control	Overall average 5 (Total Score 5)

Table 2: Conditions described in Article 14-5 of the Securities and Exchange Act:

Audit Committee Date/Period	Subject Matter	Independent directors' objection, reservations, or major suggestions	Audit Committee's resolution	The Company's subsequent handling to Audit Committee's opinion
2024/2/23 6th meeting of the 5th term	Approved the company's increased investment in U.S. stock SANA Biotechnology, Inc. (Stock Symbol: SANA) to USD 2 million.	None	All attending committee members approved.	N/A
2024/3/8 7th meeting of the 5th term	Approved the 2023 Assessment of the Effectiveness of the Internal Control System and the "Internal Control System Statement" of the Company.	None	All attending committee members approved.	N/A
	Approved the Company's 2023 business report and financial report.	None	All attending committee members approved.	N/A
	Approved the proposal for the appointment and remuneration of the Company's 2024 financial report CPAs and their independence and suitability assessment.	None	All attending committee members approved.	N/A
	Approved the proposal for removal of the non-competition restrictions against the Company's directors.	None	All attending committee members approved.	N/A
	Approved the setting of a record date for the issuance of new shares for subscription by employee stock warrant holders.	None	All attending committee members approved.	N/A
	Approved the motion for the Company to loan funds to	None	All attending committee members approved.	N/A

Audit Committee Date/Period	Subject Matter	Independent directors' objection, reservations, or major suggestions	Audit Committee's resolution	The Company's subsequent handling to Audit Committee's opinion
	subsidiaries.			
	Approval of the proposal for adjustments of the Company's financial and accounting managers.	None	All attending committee members approved.	N/A
2024/5/3 8th meeting of the 5th term	Approved the Company's 2023 distribution of earnings.	None	All attending committee members approved.	N/A
	Approved the company's registered address change and shutdown of the Chunan plant.	None	All attending committee members approved.	N/A
	Approved the disposal of the Company's Chunan Plant buildings and ancillary equipment.	None	All attending committee members approved.	N/A
	Approved the Company's Articles of Incorporation amendment.	None	All attending committee members approved	N/A
	Approved the motion for adjustment of the Company's Internal Audit Officer.	None	All attending committee members approved	N/A
2024/8/8 9th meeting of the 5th term	Approved the consolidated financial statements of the Company for the 2nd quarter of 2024.	None	All attending committee members approved	N/A
2024/11/7 10th meeting of the 5th term	Approved the cash capital increase of the subsidiary, SLC BioPharm Co., Ltd..	None	All attending committee members approved	N/A
	Approved the revision of the company's "Rules of Procedure for Meetings of its Board of Directors" and "Audit Committee Charter"	None	All attending committee members approved	N/A
	Approved the establishment of the company's "Sustainable Information Management Procedures" and "Procedures for Preparation and Verification of the Sustainability Report"	None	All attending committee members approved	N/A

(3) The status of the Company's implementation of corporate governance, any variance from the Corporate Governance Best-Practice Principles for TWSE/TPEX-Listed Companies and the reason for any such variance

Item of evaluation	Status			Deviations from "Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies" and reasons
	Yes	No	Summary	
I. Has the Company established and disclosed the corporate governance practice principles according to the Corporate Governance Best-Practice Principles for TWSE/TPEX-Listed Companies?	✓		The Company has established the "Corporate Governance Practice Principles" and disclosed on the Company's website and the Market Observation Post System.	No major difference
II. Equity structure and shareholders' rights of the Company				
(1) Has the Company implemented a set of internal procedures to handle shareholders' suggestions, queries, disputes and litigations?	✓		(1) The Company has the spokesperson, deputy spokesperson and stock administration unit available to handle shareholders' suggestions and disputes.	No major difference
(2) Has the Company possessed the list of the major shareholders and the list of the ultimate controllers of the major shareholders?	✓		(2) The Company has delegated the professional stock administration agency and assigned a specialist for its stock affairs, so it has possessed the list of the major shareholders.	No major difference
(3) Has the Company established and implemented risk management and firewalls on companies it is affiliated with?	✓		(3) The Company has adopted the "Operating Procedure for Transactions with Related Parties, Specific Companies and Group Companies" and "Regulations Governing Supervision of Subsidiaries" to expressly distinguish the assets, finance and business between the Company and its affiliates. Meanwhile, the Company did implement the risk assessment strictly and established adequate firewalls.	No major difference
(4) Has the Company established internal rules against insiders trading with undisclosed information?	✓		(4) The Company has established the internal control policy of "Operation governing prevention of insider trading."	No major difference
III. Composition and responsibilities of Board of Directors:	✓		(1) The Company has established a "Corporate Governance Best Practice Principles" that outlines and implements a board diversity policy. For details, refer to Page 12.	No major difference
(1) Has the Board of Directors formulated a diversity policy, set specific management goals and implemented them accordingly?				
(2) Has the Company voluntarily established other functional committees in addition to the Remuneration Committee and the Audit Committee?		✓	(2) The Company has only formed the Remuneration Committee and the Audit Committee as required; no other functional committees have been established.	Additional committees may be formed as needed.
(3) Has the Company established a standard to measure the performance of the Board, and implement it annually? Has the Company submitted results of	✓		(3) The Company has established the "Policy for Performance Evaluation on the Board of Directors" and evaluation method, and distributed the self-evaluation questionnaire to the board members each year to evaluate the performance of the	No major difference

Item of evaluation	Status			Deviations from “Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary	
<p>performance evaluation to the board of directors as reference in determining the compensation of individual directors and nomination for successive term?</p> <p>(4) Does the Company conduct regular assessments regarding the independence of its independent external auditors?</p>	✓		<p>board of directors. In addition to the assessment of performance of the board of directors, the Company also conducts self-evaluations on board member and functional committee members.</p> <p>The evaluation of board performance includes the following five indicators:</p> <p>(1) The extend of participation in the Company’s operation.</p> <p>(2) Improvement of decision quality by the board.</p> <p>(3) Composition and structure of the board.</p> <p>(4) Election and continuing education of directors.</p> <p>(5) Internal control.</p> <p>The evaluation on performance of an individual board member includes the following six indicators:</p> <p>(1) Comprehension of the Company’s targets and missions.</p> <p>(2) Directors’ duty awareness.</p> <p>(3) The extend of participation in the Company’s operation.</p> <p>(4) Management and communication of internal relations.</p> <p>(5) Professionalism and continuing education of directors.</p> <p>(6) Internal control.</p> <p>The evaluation on performance of an individual functional committee member includes the following 5 indicators:</p> <p>(1) The extend of participation in the Company’s operation.</p> <p>(2) Comprehension of the functional committee’s duty.</p> <p>(3) Improvement of functional committee’s decision quality.</p> <p>(4) Composition of functional committee and election.</p> <p>(5) Internal control.</p> <p>The Company completed the 2024 performance evaluation of the entire board, individual directors, and functional committees in January 2025. Details of the evaluation methods and results are on page 22.</p> <p>The 2024 Board of Directors’ performance result was good, and the evaluation functioned effectively. The implementation unit has submitted the evaluation result to the Board of Directors’ meeting on March 6, 2025.</p> <p>(4) The Audit Committee annually assesses the independence and suitability of the company’s appointed CPA, requiring an “Independence Declaration” and evaluation based on 13 Audit Quality Indicators (AQIs). The latest assessment results were approved by the Audit Committee and the Board on March 6, 2025. The CPA was found to meet the company’s standards for both independence and suitability. For</p>	No major difference

Item of evaluation	Status			Deviations from “Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary	
			the evaluation criteria, please refer to Table 4.	
IV. Whether the TWSE/GTSM Listed Company assigns the adequate number of competent corporate governance officers, and appoints the chief corporate governance officer responsible for the corporate governance affairs (including but not limited to, providing directors/supervisors with the information needed to perform their duties, helping directors/supervisors with compliance, organization of the Board of Directors meetings and shareholders’ meetings, and preparation of board meeting and shareholders’ meeting minutes)?	✓		The Company’s Finance Department is the delegated unit responsible for the corporate governance affairs, and the board of directors has approved and appointed the Company’s Assistant Vice President of the Finance Department as chief corporate governance officer. Duties of the Chief Corporate Governance Officer: handling of matters related to board meetings and shareholders’ meetings according to laws, production of the minutes of board meetings and shareholders’ meetings, assistance to directors in assumption of the position and continuing education, provision to directors the information needed by them to perform their duties, assistance to directors in compliance, and any other matters required by the Articles of Incorporation or contract. For the continuing education programs attended by the Chief Corporate Governance Officer in the current year, please refer to Table 5.	No major difference
V. Has the Company set up any means to communicate with stakeholders (including but not limited to shareholders, employees, customers and suppliers etc.)? Has a stakeholders’ area available on the Company’s website that properly addresses material corporate social responsibility issues concerned by its stakeholders?	✓		The “Stakeholders” section has been set up on the Company’s website, and relevant contact information is provided for stakeholders’ communication.	No major difference
VI. Has the Company delegated professional stock administration agency to handle affairs regarding the shareholders’ meeting?	✓		The Company has assigned the Stock Administration of Horizon Securities Corp. to handle its shareholders’ meeting affairs.	No major difference
VII. Information Disclosure (1) Has the Company built a website to disclose its financial and corporate governance information?	✓		(1) The Company has built a website to disclose its financial and corporate governance information.	No major difference
(2) Has the Company adopted other means to disclose information (e.g. English website, assignment of specific personnel to collect and disclose corporate information, implementation of a spokesperson system, broadcasting of investor conferences via the Company’s website)?	✓		(2) The Company has established an English website to disclose financial and business information, with designated personnel responsible for collecting relevant data and disclosing significant corporate events. A spokesperson system has also been implemented. Information related to institutional investor conferences can be found under the "Investor Relations" section of the Company’s website.	No major difference
(3) Whether the Company announces and reports the annual financial report within 2 months after the end		✓	(3) Pursuant to Article 36 of the Securities and Exchange Act, the Company announces and reports the annual financial report within 3 months after the end of fiscal year, and the financial report for Q1, Q2 and Q3 and monthly operation overview before the	The item is considered to be improved with the accommodation of the

Item of evaluation	Status			Deviations from “Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary	
of each fiscal year, and the financial report for Q1, Q2 and Q3 and monthly operation overview before the prescribed time limit?			prescribed time limit. No early report was made.	Company’s accounting firm.
VIII. Does the Company have other information that enables a better understanding of the Company’s corporate governance practices (including but not limited to employee rights, employee care, investor relations, supplier relations, stakeholders’ rights, continuing education of directors/supervisors, implementation of risk management policies and risk measurements, implementation of customer policy and insuring against liabilities of the Company’s directors and supervisors)?	✓		<ol style="list-style-type: none"> 1. Employee rights and care: A Welfare Committee has been established and operates through representatives elected by employees to handle various welfare initiatives and administer the pension system. The company also offers group insurance plans and schedules regular health check-ups for employees. The Company’s measures regarding the labor relations are handled in accordance with relevant laws and regulation and effectively implemented. Any addition or revision of labor relations measures shall be made over a thorough mutual communication, with regular labor-management meetings serving as a communication bridge. 2. Investor relations: The Company organizes the shareholders’ meeting annually in accordance with the Company Act and relevant laws and regulations, and furnishes opportunities of inquiry and proposal to its shareholders. The spokesperson system can handle shareholders’ suggestions, queries and disputes. Meanwhile, the Company discloses and reports relevant information as stipulated by authorities to ensure timely delivery of material decision-making information to its investors. 3. Supplier relations: The Company pays attention to the reasonableness of purchase price, so the purchase decision is made after the procurement personnel’s careful price inquiry, comparison, negotiation with various suppliers by taking into consideration of price, specification, payment term, delivery date, product and service quality or other information. The Company has built long-term close relation, collaborated, trusted, benefited and grown together with its suppliers. 4. Stakeholders’ rights: The Company keeps its communication means with banks, employees, customers and suppliers opened, and respects and maintain their legitimate rights. It has set up the spokesperson system to answer questions from investors aiming to provide highly transparent financial information to its investors and stakeholders. 5. Director and Supervisor Training: All directors have completed the required training hours. In 2024, the company’s directors completed a total of 54 course hours and this information has been disclosed on the Market Observation Post System. 6. Implementation of risk management policies and risk measurements: The Company has adopted the “Procedures for the Acquisition and Disposal of Assets,” “Procedures for Making of Endorsements/Guarantees,” “Procedures for Loaning of Funds” and “Procedures for Engaging in Financial Derivatives Trading” as the basis of risk 	No major difference

Item of evaluation	Status			Deviations from “Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary	
			<p>management and standard of risk measurement while engaging in relevant businesses for the execution unit and internal auditors.</p> <p>7. Implementation of customer policy: For a full-dimensional service and protection to its customers, the Company delivers prompt response to customer complaints, communicates to understand customer needs, and increases mutual interaction between company and customers. Improvements are discussed and made in the internal meetings from time to time.</p> <p>8. Insuring against liabilities of the Company’s directors: The Company has insured against liabilities of its directors and Managerial officers and reviewed the policy on an annual basis in order to eliminated risk of liabilities posed to its directors and company as well as reporting to the board, and build a complete corporate governance system.</p>	
<p>IX. Please specify the status of the correction based on the corporate governance assessment report released by the Corporate Governance Center of TWSE in the most recent year and the priority corrective actions and measures against the remaining deficiencies.</p> <p>As per the results of the 2024 (11th) Corporate Governance Evaluation published by the Corporate Governance Center, the Company ranked among the top 36%–50% of the companies listed on Taipei Exchange. The Company will continue to improve and strengthen unqualified areas.</p>				

Table 3: Implementation of diversify policy for the board members

Title	Core diversity criteria	Basics									Professional qualification								
		Nationality	Gender	Employee of the Company	Age			Years of service as an independent director			Operational decision making	Accounting and financial analysis	Operational management	Risk management	Industrial knowledge	Global marketing	Leadership	Decision-making	Medicine, pharmacy and chemistry
	Below 60				60 to 70	Over 70	Less than 3 years	3–9 years	Over 9 years										
Name of Directors																			
Chairman	Concord Consulting Inc. (Juristic Person Representative: Rebecca Lee)	R.O.C.	Female	✓	✓						✓	✓	✓	✓	✓	✓	✓	✓	
Director	SFS Venture Ltd. (Juristic Person Representative: Chung Hsing-Yung)	R.O.C.	Male				✓				✓		✓	✓	✓	✓	✓	✓	✓
Director	SFS Venture Ltd. (Juristic Person	R.O.C.	Male			✓					✓		✓	✓	✓	✓	✓	✓	✓

Title	Core diversity criteria Name of Directors	Basics									Professional qualification								
		Nationality	Gender	Employee of the Company	Age			Years of service as an independent director			Operational decision making	Accounting and financial analysis	Operational management	Risk management	Industrial knowledge	Global marketing	Leadership	Decision-making	Medicine, pharmacy and chemistry
					Below 60	60 to 70	Over 70	Less than 3 years	3–9 years	Over 9 years									
	Representative: Chen Zheng)																		
Director	Min-Ju Investment Co., Ltd. (Juristic Person Representative: Chen Yung-Fa)	R.O.C.	Male			✓					✓		✓	✓	✓	✓	✓	✓	✓
Director	Min-Ju Investment Co., Ltd. (Juristic Person Representative: Hsieh Jung-Cheng)	R.O.C.	Male				✓				✓		✓	✓	✓	✓	✓	✓	
Director	Fine Horse	R.O.C.	Male	✓	✓						✓		✓	✓	✓	✓	✓	✓	

Title	Core diversity criteria Name of Directors	Basics									Professional qualification								
		Nationality	Gender	Employee of the Company	Age			Years of service as an independent director			Operational decision making	Accounting and financial analysis	Operational management	Risk management	Industrial knowledge	Global marketing	Leadership	Decision-making	Medicine, pharmacy and chemistry
					Below 60	60 to 70	Over 70	Less than 3 years	3–9 years	Over 9 years									
	Investment Co., Ltd. (Juristic Person Representative: Chou Chia-Chu)																		
Independent Director	Chang Ryh-Yan	R.O.C.	Male				✓			✓	✓	✓	✓	✓	✓	✓	✓	✓	
Independent Director	Lin Chih-Ming	R.O.C.	Male				✓		✓		✓		✓	✓	✓	✓	✓	✓	✓
Independent Director	Cheng Chin-Hua	R.O.C.	Female			✓		✓			✓		✓	✓	✓	✓	✓	✓	✓

Table 4: Criteria for the independence of independent external auditors

Item	Criteria	Result	Compliance Independent
1.	The independent external auditor has served as the Company's independent external auditor for less than 7 years.	Not applicable	Qualified
2.	Independent external auditors and member of the external audit team have not, in the most recent two years, served as the Company's directors or managers, or any other position that may materially affect the audit service.	Not applicable	Qualified
3.	Independent external auditors and member of the external audit team are not relatives of the Company's directors or managers, or any other position that may materially affect the audit service.	Not applicable	Qualified
4.	Independent external auditors have not, within one year after dismissal, served as the Company's directors or managers, or any other position that may materially affect the audit service.	Not applicable	Qualified
5.	There exists no direct or indirect material financial interest between the auditors and the Company.	Not applicable	Qualified
6.	Auditors does not overly depend on the fees sourced from single client (the Company).	Not applicable	Qualified
7.	There exists no material business relation between auditors and the Company.	Not applicable	Qualified
8.	There exists no employment relation between auditors and the Company	Not applicable	Qualified
9.	Auditors have not had any contingent fees related to the audit cases.	Not applicable	Qualified
10.	Non-audit services provided by auditors to the Company may not directly affect any significant account of the Audit service.	Not applicable	Qualified
11.	Auditors do not represent the Company in a legal case against a third party or in any other dispute.	Not applicable	Qualified
12.	Auditors do not promote or intermediate stocks or securities issued by the Company.	Not applicable	Qualified
13.	Auditors do not receive valuable gifts or preferential treatments from the Company or its directors, manager or major shareholders.	Not applicable	Qualified
14.	Auditors and member of the external audit team are not entrusted by the Company with money.	Not applicable	Qualified

Table 5: Continuing education programs attended by the Chief Corporate Governance Officer in 2024

Course date	Organizer	Name	Course hours	Total course hours in the current year
2024/04/17	Taiwan Academy of	Corporate Governance Forum	3	12

	Banking and Finance			
2024/09/30	Taiwan Academy of Banking and Finance	Corporate Governance Forum	3	
2024/09/25	Taipei Exchange	TPEX/Emerging Market Listed Company Insider Stock Ownership Seminar	3	
2024/10/15	Taipei Exchange	2024WIW: Themed Lecture on "Digital Finance and Sustainable Finance Concerto under the AI Boom"	3	

(4) Composition and Status of the Remuneration Committee

1. Information about remuneration committee members

May 7, 2025

Criteria Identity / Name		Professional qualifications and experience (Note)	State of Independence	Number of positions as a Remuneration Committee Member in other public listed companies
Independent Director (Convener)	Chang Ryh-Yan	Please refer to Page 12 for disclosure related to directors' professional qualifications and the independence of independent directors.		4
Independent Director	Lin Chih-Ming			0
Independent Director	Cheng Chin-Hua			1

2. Responsibilities of Remuneration Committee

The Committee shall faithfully perform the following duties with the care of a good administrator and submit its recommendations to the Board of Directors for discussion:

Discussions at the meeting:

- (1) Periodically reviewing Remuneration Committee's Charter and making recommendations for amendments.
- (2) Establishing and periodically reviewing the performance assessment standards, annual and long-term performance goals, and the policies, systems, standards, and structure for the compensation of the directors and managerial officers of the Company.
- (3) Periodically assessing the degree to which performance goals for the directors and managerial officers of the Company have been achieved, setting the types and amounts of their individual compensation based on the results of the reviews conducted in accordance with the performance assessment standards.

3. Operations of Remuneration Committee

(1) Total of three members on the Remuneration Committee.

(2) Term of Service: from June 15, 2023 to June 14, 2026.

A total of three meetings (A) were held by the Remuneration Committee in 2024

Title	Name	Actual attendance (B)	Attendance by proxy	Rate of attendance in person (%) (B/A)	Remarks
Convener	Chang Ryh-Yan	3	0	100	Re-elected
Member	Lin Chih-Ming	3	0	100	Re-elected
Member	Cheng Chin-Hua	3	0	100	Re-elected

Meeting agenda items, resolutions, and the company's handling of the Remuneration Committee's opinions in 2024:

Remuneration Committee Date/Period	Subject Matter	Resolution Result	The Company's handling of the opinion from the Remuneration Committee
2024/3/8 3rd meeting of the 6th term	The motion for the Company's 2023 remuneration to employees and directors.	All attending committee members approved.	N/A
	Approval of the proposal for adjustments of the Company's financial and accounting managers	All attending committee members approved.	N/A
	Remuneration to the Company's managerial officers.	All attending committee members approved.	N/A
4th meeting of the 6th term	Adjustment on the remuneration to the Chairman of the Company.	All attending committee members approved.	N/A
2024/12/26 5th meeting of the 6th term	Distribution of 2024 year-end bonuses for the Company's managerial officers.	All attending committee members approved.	N/A
	Distribution of 2023 Remuneration to Employees for the Company's managerial officers.	All attending committee members approved.	

Other items to be stated:

I. If the Board of Directors does not adopt or decide to revise the recommendation of

	the Remuneration Committee, the Board shall record the date and term, subject matter, resolution, and measures taken concerning the recommendation of the Remuneration Committee (for example, if the compensation passed by the Board of Directors is higher than the recommendation proposed by the Remuneration Committee, the Board shall explain the differences and reasons): None.
II.	In the resolutions of the Remuneration Committee, if any member expresses objections or has reservations, then the Remuneration Committee shall record the date, term, subject matter, opinions of its members and the measures taken: None.

4. Information on the members and operations of the Nomination Committee: The Company has not established a Nomination Committee.

(5) Discrepancies between the promotion of sustainable development and the Sustainable Development Best Practice Principles for TWSE/TPEX-Listed Companies and reasons

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary	
I. Has the Company established exclusively (or concurrently) dedicated units to promote sustainable development, and has the Board of Directors put personnel at the senior management in charge of the promotion and monitored the promotion?	✓		<p>The Company’s Board of Directors approved the establishment of Corporate Sustainable Development Committee subordinated to the Board of Directors on August 5, 2022. The Committee shall consist of 5 members, and the Chairman serves as the Committee’s chairman, the President as the Committee’s vice chairman, and the Chief Corporate Governance Officer, SHE managers and HR managers as the ex officio members of the Committee. The Corporate Governance and Partner Co-Prosperity Group, Environment and Climate Change Group and Society & Workplace Friendliness Group subordinated to the Committee are responsible for coordinating related departments to identify, evaluate, control and supervise risks, and reporting the implementation status to the Board of Directors regularly.</p> <p>In addition to holding regular meetings to track the progress of achieving the goals, the Corporate Sustainable Development Committee is arranged to report the annual implementation status to the Board of Directors at least once a year.</p> <p>The contents of the motions include (1) identification of sustainability issues requiring attention and formulation of corresponding action plans; (2) goals and policy amendments for sustainability-related issues; (3) supervision of the implementation of sustainability matters and evaluation of implementation.</p> <p>The Company’s Board of Directors regularly listens to reports from the management team (including ESG reports) every year. The management must propose corporate strategies to the Board of Directors. The Board of Directors must evaluate the likelihood of success for these strategies, constantly review the progress of the strategies, and urge the management team to make adjustments when necessary.</p>	No major difference
II. Whether the Company conducts the risk assessment on the environment, society and corporate governance issues related to the Company’s operation and adopts related risk management policies or strategies, pursuant to the materiality principle? (Note 2)	✓		<p>The Company is committed to manufacturing high-quality products to satisfy global needs; meanwhile, it aims to create value for its employees, shareholders and pharmacy industry in Taiwan, furnish a healthier environment and practice corporate social responsibility under materiality principle. It emphasizes stakeholders’ rights, cares for environmental, social and corporate governance issues.</p> <p>The disclosed data cover the sustainable development performance of the Company’s main business locations from January 1, 2024 to December 31, 2024. The risk assessment boundary is primarily based on the Company, including SLC headquarters in Chunan, Tainan Plant, Tainan Injection Plant, Taipei Office, and the subsidiary, SLC BioPharm Co., Ltd..</p>	No major difference

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies” and reasons			
	Yes	No	Summary				
			2024 Risk Management Execution Results				
			Type of risk	Risk factors		Preventive measures	2024 Operating Status
			Operational risk	Risk of corporate governance		Regular promotion to directors and senior executives.	Regular briefings for directors and senior executives. To comply with laws and prevent insider trading, regular training sessions are arranged for directors and senior executives to strengthen awareness.
			Human Resources Risk	1. Employee benefits and compensation. 2. Talent recruitment and retention. 3. Employee development and training.		1. Enhance harmonious labor-management relations and foster a positive corporate culture and employee value. The Employee Welfare Committee holds regular meetings to maximize employee benefits. 2. Provide three major festival bonuses, year-end bonuses, employee profit sharing, birthday gifts, health checkups, labor insurance, national health insurance, labor pensions and group insurance for employees and their dependents. 3. Encourage	

Promoted item	Implementation status (Note 1)						Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies” and reasons
	Yes	No	Summary				
						employees to pursue continued education and participate in domestic and international courses and seminars.	
				Changes in Domestic and International Policies and Laws	Closely monitor important policy and legal changes both domestically and internationally.	1. Evaluate and consolidate developments in relevant regulations and policies from regulatory authorities and draft related plans for internal reference. 2. Seek advice from competent authorities or external experts when necessary to ensure the appropriateness of legal interpretations.	
			Financial risk	Exchange Rate and Interest Rate Risk	1. Strengthen group-level fund control to reduce financial loss risk. 2. Manage foreign currency positions within the group to minimize exchange rate loss risk.	1. Continuously monitor interest rate trends and global economic developments. 2. Enhance market analysis for key materials domestically and internationally to form advantageous procurement strategies and reduce expenses.	

Promoted item	Implementation status (Note 1)						Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary				
				Derivative Product Trading Risk	Executed in accordance with the Regulations Governing the Acquisition and Disposal of Assets by Public Companies.	No derivative transactions have been conducted this year; monthly disclosures are made on the Market Observation Post System, as required.	
				Accounts receivable risk	1. Limit customer transaction amounts. 2. Modify trading terms to LC and T/T in Advance.	1. Adjust credit limits for current customers based on past transaction records. 2. Change trading terms for high-risk clients. 3. Hold regular finance/accounting meetings to monitor accounts receivable and optimize financial planning and fund allocation.	
				Investment risk	Handled in accordance with the company’s investment handling policies and subsidiary supervision guidelines.	Long-term investee companies must provide monthly financial statements to assist parent company management.	
			Operational risk	Legal Compliance Risk	1. All contracts must be reviewed by legal counsel before signing. 2. Regular and ad hoc maintenance and updates are conducted regarding	1. The company has signed a legal counsel agreement. 2. All contract sign-offs must go through legal approval. 3. Legal team replaces in-person training	

Promoted item	Implementation status (Note 1)						Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary				
					amendments to regulations by the competent authorities, along with tracking the impact of such changes on the company and its operations. Additionally, legal consultation, coordination and communication channels are strengthened and legal education and training sessions are conducted.	with legal bulletins.	
				Information Security Risk	1. Implementation of antivirus software and firewall functions. 2. Conducting information security education and training.	1. Deployment of cybersecurity defense tools to prevent threats. 2. Company-wide cybersecurity awareness training to enhance security consciousness.	
				Occupational Safety and Health Management Risks	1. Regular promotion of safety education messages. 2. Conducting fire safety and occupational safety training. 3. Routine self-inspection, testing, maintenance and upkeep of fire	1. Ad hoc safety awareness campaigns 2. Basic fire safety and occupational training for new employees. 3. Regular self-inspections (evacuation equipment, fire extinguishers/mont	

Promoted item	Implementation status (Note 1)						Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary				
					safety equipment. 4. Labor health management and construction safety supervision.	hly) and outsourced maintenance of fire equipment. 4. Implementation of safety and health education (construction hazards, labor safety meetings), reinforced through pre-shift training and inspection management meetings. 5. Enforcing employee health care systems with monthly onsite services by contracted occupational health professionals; legally mandated health checks are provided, promoting a healthy and friendly workplace.	
			Environmental risks	Climate change risk Environmental pollution risk	1. Setting short-, medium- and long-term goals for different environmental indicators. 2. Implementing energy-saving, carbon-reduction and greenhouse gas	1. Identification of climate change risks and opportunities via TCFD and international reports, based on likelihood and impact to determine material	

Promoted item	Implementation status (Note 1)						Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary				
					management plans. 3. Compliance with government air pollution control regulations and execution of reduction measures.	issues. 2. Assessing potential financial impacts of significant risks and opportunities. 3. Continuously monitoring policy and regulatory changes related to energy and carbon reduction, actively participating in public hearings and consultations on new or revised climate-related laws, such as the “Climate Change Response Act,” to evaluate and respond to regulatory impacts.	
III. Environmental topic (1) Has the Company established environmental policies suitable for the Company’s industrial characteristics?	✓		The Group is engaged in R&D and manufacturing of APIs for antibiotics, small molecule drugs and peptide products, and the consistent manufacturing process for vertical integration of sterile APIs to finished injection preparations. The high-standard factory premises & equipment satisfy the cGMP and standards of the government health agencies of Japan, Europe and the United States. The Group’s employees acknowledge that respect for life, care for health, energy conservation and carbon reduction, promotion of environmental harmony, and creation of a safe and healthy working environment are the common goals to be pursued by all of us. In order to ensure the safety and health in the working environment and prevent personnel injuries, diseases, property loss, environmental pollution and damage, all of the Group's employees need to participate in the activities to improve environmental hygiene more proactively. In order to achieve said targets, we commit to keep improving and upgrading the targets for environmental protection and ESG, and also implement the following strategies: Social responsibility: Fulfill social responsibility and care for the environment - maintain the resources on the earth and mitigate the impact posed by carbon emissions.				No major difference

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary	
			<p>Accountability: Responsible for promotion and communication-counseling, communication, and awareness toward personal responsibility.</p> <p>Vocation: Education and training of the sense of mission - the concept about education and safety, and culture of proactivity.</p> <p>Improvement: Continuous improvement-improvement of the safety and health performance to ensure the sustainability.</p> <p>Observation: Care for health-mitigation of the risk over safety and health to promote the workplace health.</p> <p>Regulation compliance: Legal compliance-practicing the full participation and compliance with environmental, health and safety laws.</p> <p>No confirmation or guarantee opinion has been obtained from the verification unit of the third party.</p>	
(2) Does the Company endeavor to upgrade the energy use efficiency and use environmentally-friendly materials?	✓		<p>The "Sustainable Development Committee" established by the Company to integrate and promote the Company's environmental protection, safety and health, energy conservation, water conservation, and GHG management proposes sustainable management plans and reviews the implementation results each year, as the basis for internal inspection.</p> <p>In 2024, SLC's energy consumption totaled 49,607.84 GJ, down from 2023, primarily a result of a decrease in the consumption of power, natural gas, steam and diesel. The energy intensity was 40.76 GJ/million output value in 2024, down from the output value in 2023.</p> <p>The existing practices include recycling of garbages, use of recycled materials posing low impact to the environmental load, recycling the water discharged from RO water purifiers and air-conditioning condensate to the cooling tower, adoption of hand-washing faucets to limit the water consumption, domestic water conservation, and implementation of the eco-friendly and green energy concept into the process and equipment, promotion of green environmental protection, and focus on ecological balance, etc..</p> <p>The goal is to reduce annual energy consumption and energy intensity, and thereby reduce the environmental impact.</p>	No major difference
(3) Has the Company evaluated the climate change on the present and future potential risks and opportunities of the corporation, and has the company adopted responsive actions on climate related issues?	✓		<p>Savior Lifetec Corporation, from the perspective of business operations and future market conditions, has assessed the 17 climate-related risks and 20 climate-related opportunities outlined in the TCFD guidelines. These risks are discussed based on their "likelihood" and "urgency" (short-term and medium-to-long-term). Short-term is defined as 1–3 years, while medium-to-long-term is 3–10 years. Mitigation and adaptation strategies have been formulated accordingly, aligning with SDG 13 climate goals.</p>	No major difference

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons						
	Yes	No	Summary							
			<p>In order to further evaluate the financial impact that might be posed by the climate change risk, the Group determines and prioritizes the most important climate-related risk issues through the matrix of risk, and then perform the related financial evaluation and responsive strategies. It aims to ensure the business continuity free from any interruption, so as to realize the corporate sustainability.</p> <table><tr><th>Category</th><th>Climate-related risks</th><th>Potential financial impact</th></tr><tr><td>Physical risk:</td><td><p>Short term: Extreme changes in precipitation and climate patterns lead to increased operating costs.</p><p>Medium-to-long-term: Rising sea levels affect operations, resulting in reduced income and increased operating costs</p></td><td><p>Short-term: The Tainan plant of the Group’s subsidiary, Savior Lifetec Corporation, is located in a water-scarce area. The region experiences droughts in autumn and winter and heavy rainstorms in spring. In the event of phased water restriction measures, our approach and corresponding financial impacts are as follows: (1) Phase 1: Reduced water pressure during off-peak and specific time periods. ● Impact: Temporarily covered by the plant’s water storage tanks, so operations are not affected. (2) Phase 2: For large water users consuming over 1,000 cubic meters per month—non-industrial users will face a 20% water supply reduction and industrial users will face a 5–20% reduction. However, medical and other specially designated users are exempt. ● Response measures: a. Initiate reduced pressure supply for domestic water use within the plant. b. Increase cooling tower concentration ratio to reduce</p></td></tr></table>	Category	Climate-related risks	Potential financial impact	Physical risk:	<p>Short term: Extreme changes in precipitation and climate patterns lead to increased operating costs.</p> <p>Medium-to-long-term: Rising sea levels affect operations, resulting in reduced income and increased operating costs</p>	<p>Short-term: The Tainan plant of the Group’s subsidiary, Savior Lifetec Corporation, is located in a water-scarce area. The region experiences droughts in autumn and winter and heavy rainstorms in spring. In the event of phased water restriction measures, our approach and corresponding financial impacts are as follows: (1) Phase 1: Reduced water pressure during off-peak and specific time periods. ● Impact: Temporarily covered by the plant’s water storage tanks, so operations are not affected. (2) Phase 2: For large water users consuming over 1,000 cubic meters per month—non-industrial users will face a 20% water supply reduction and industrial users will face a 5–20% reduction. However, medical and other specially designated users are exempt. ● Response measures: a. Initiate reduced pressure supply for domestic water use within the plant. b. Increase cooling tower concentration ratio to reduce</p>	
Category	Climate-related risks	Potential financial impact								
Physical risk:	<p>Short term: Extreme changes in precipitation and climate patterns lead to increased operating costs.</p> <p>Medium-to-long-term: Rising sea levels affect operations, resulting in reduced income and increased operating costs</p>	<p>Short-term: The Tainan plant of the Group’s subsidiary, Savior Lifetec Corporation, is located in a water-scarce area. The region experiences droughts in autumn and winter and heavy rainstorms in spring. In the event of phased water restriction measures, our approach and corresponding financial impacts are as follows: (1) Phase 1: Reduced water pressure during off-peak and specific time periods. ● Impact: Temporarily covered by the plant’s water storage tanks, so operations are not affected. (2) Phase 2: For large water users consuming over 1,000 cubic meters per month—non-industrial users will face a 20% water supply reduction and industrial users will face a 5–20% reduction. However, medical and other specially designated users are exempt. ● Response measures: a. Initiate reduced pressure supply for domestic water use within the plant. b. Increase cooling tower concentration ratio to reduce</p>								

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary	
				<p>discharge (from 1500 to 2000).</p> <p>●Financial impact: Only maintenance costs for equipment are required.</p> <p>(3) Phase 3: cut water supply two days a week</p> <p>●Response measures:</p> <p>a. Recycle effluent from the wastewater plant for use in the sludge dewatering system.</p> <p>b. Install water purifiers on wastewater effluent to supply the cooling tower.</p> <p>c. Enhance existing ROR wastewater recycling by adding ROR recycling equipment.</p> <p>d. Activate backup water storage tanks in the plant.</p> <p>e. Deploy water delivery trucks.</p> <p>Medium-to-long-term:</p> <p>The rising sea level will increase the risk in the factory premises and affect the Company's operations directly.</p>
			<p>Transitional risk:</p>	<p>Medium-to-long-term:</p> <p>Increasing raw materials and supplies costs</p> <p>1. The high GHG emission price results in the increase in the Company's costs.</p> <p>2. Reinforce greenhouse gas emission reporting obligations.</p> <p>3. Mandatory or legislative requirements for existing products and services to disclose</p> <p>Medium-to-long-term:</p> <p>Due to the short supply of raw materials caused by the climate change, the procurement cost was increasing. Finally, the production cost increased too.</p> <p>95% of the Group's products are exported overseas. If the domestic laws and regulations are amended and the international GHG emission cost increase, the operating costs will increase relatively if the average temperature increases.</p> <p>Savior Lifetec Corporation conducts annual greenhouse gas</p>

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies” and reasons												
	Yes	No	Summary													
			<table><tr><td></td><td>carbon emissions. 4. Cost increased</td><td>inventories for each plant and considers carbon reduction strategies from all aspects of operational management. If the average temperature is growing, the costs in the air conditioner and process temperature controls at the Company’s factory premises will increase and thereby cause the operating costs to increase relatively.</td></tr><tr><td rowspan="2">Climate Opportunities</td><td>Short-term: Recycling and re-use to increase resource efficiency</td><td>Short term: Recycling can reduce costs and enhance the company’s reputation.</td></tr><tr><td>Short term: reducing water usage and consumption to increase resource efficiency.</td><td>Short term: Using more efficient production and distribution processes to increase resource efficiency. Recycling can reduce costs and enhance the company’s reputation.</td></tr></table>		carbon emissions. 4. Cost increased	inventories for each plant and considers carbon reduction strategies from all aspects of operational management. If the average temperature is growing, the costs in the air conditioner and process temperature controls at the Company’s factory premises will increase and thereby cause the operating costs to increase relatively.	Climate Opportunities	Short-term: Recycling and re-use to increase resource efficiency	Short term: Recycling can reduce costs and enhance the company’s reputation.	Short term: reducing water usage and consumption to increase resource efficiency.	Short term: Using more efficient production and distribution processes to increase resource efficiency. Recycling can reduce costs and enhance the company’s reputation.					
	carbon emissions. 4. Cost increased	inventories for each plant and considers carbon reduction strategies from all aspects of operational management. If the average temperature is growing, the costs in the air conditioner and process temperature controls at the Company’s factory premises will increase and thereby cause the operating costs to increase relatively.														
Climate Opportunities	Short-term: Recycling and re-use to increase resource efficiency	Short term: Recycling can reduce costs and enhance the company’s reputation.														
	Short term: reducing water usage and consumption to increase resource efficiency.	Short term: Using more efficient production and distribution processes to increase resource efficiency. Recycling can reduce costs and enhance the company’s reputation.														
(4) Has the Company gathered statistics on the greenhouse gas emissions, water usage, and total waste weight over the past two years, and has the Company established policies for carbon reduction, greenhouse gas emission reduction, reduction of water usage, or other waste management?	✓		<div>● GHG emission management</div> <table><tr><th>Item</th><th>2023</th><th>2024</th></tr><tr><td>Total GHG emission</td><td>8,539.15 tons CO2e</td><td>6,430.31 tons CO2e</td></tr><tr><td>Direct emission (Scope 1)</td><td>1,372.59 tons CO2e</td><td>1,192.34 tons CO2e</td></tr><tr><td>Indirect energy emission (Scope 2)</td><td>7,166.56 tons CO2e</td><td>5,237.97 tons CO2e</td></tr></table> <p>The greenhouse gas emissions of the Group in 2024 were estimated to be 1,192.34 metric tons of carbon dioxide equivalent for Scope 1 and 5,237.97 metric tons of carbon dioxide equivalent for Scope 2, totaling 6,430.31 metric tons, an increase from 2023. The greenhouse gas emission intensity was 10.73, an increase from 2023.</p> <p>Note 1: The greenhouse gas emission coefficient required for the inventory of greenhouse gas emissions is mainly based on the “Greenhouse Gas Emission Coefficient Management Table Version 6.0.4.”</p> <p>Note 2: Based on the global warming potential data provided by the United Nations Intergovernmental Panel on Climate Change (IPCC) 6th Assessment Report.</p>	Item	2023	2024	Total GHG emission	8,539.15 tons CO2e	6,430.31 tons CO2e	Direct emission (Scope 1)	1,372.59 tons CO2e	1,192.34 tons CO2e	Indirect energy emission (Scope 2)	7,166.56 tons CO2e	5,237.97 tons CO2e	No major difference
Item	2023	2024														
Total GHG emission	8,539.15 tons CO2e	6,430.31 tons CO2e														
Direct emission (Scope 1)	1,372.59 tons CO2e	1,192.34 tons CO2e														
Indirect energy emission (Scope 2)	7,166.56 tons CO2e	5,237.97 tons CO2e														

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons						
	Yes	No	Summary							
			<p>Note 3: The Company adopts the operational control approach, consolidating the Scope 1 and Scope 2 greenhouse gas emissions from each production area. The greenhouse gases inventoried include carbon dioxide, methane, nitrous oxide, hydrofluorocarbons, perfluorocarbons, sulfur hexafluoride, and nitrogen trifluoride.</p> <p>Note 4: As Scope 3 is not a “self-owned or controlled emission source” and it is more difficult to aggregate and obtain relevant emission information, it is exempted from the scope of inspection in the first place.</p> <p>● Water resource management</p> <table><tr><th>Item</th><th>2023</th><th>2024</th></tr><tr><td>Water consumption</td><td>85.55 million liters</td><td>65.96 million liters</td></tr></table> <p>100% tap water is used by the Group. In 2024, the Nanke production sites with a total water intake of 85.96 million liters. This represented a decrease from 2023.</p> <p>Southern Taiwan Branch has successfully completed process optimization to significantly reduce energy consumption, water consumption, and energy intensity.</p> <p>With respect to the industrial wastewater that needs to be discharged ultimately, the Company plans the wastewater treatment facilities with care, based on the characteristics of its process wastewater source, and implements the reduction in and classification of the process wastewater sources, and combine appropriate treatment equipment and technology, in order to enable the wastewater treatment system to mitigate the pollutants effectively. Meanwhile, the Company will contract external agencies to collect water for testing periodically or conduct the test independently in accordance with the standards announced by the competent authority, in order to ensure the industrial wastewater emission quality.</p> <p>The domestic wastewater and industrial wastewater generated by various factory premises are all included into the sewage sewer systems of the relevant industry parks or the municipal sewage pipe network. The various control indicators about the emission quality all satisfy the inclusion standards adopted by the sewage treatment plants in various areas.</p> <p>In 2024, SLC’s two production bases, Chunan Plant and Tainan Plant, have both passed the water quality test, delivering the 100% wastewater treatment coincidence rate.</p>	Item	2023	2024	Water consumption	85.55 million liters	65.96 million liters	
Item	2023	2024								
Water consumption	85.55 million liters	65.96 million liters								

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons									
	Yes	No	Summary										
			<p>As the company engaged in the pharmaceutical manufacturing industry, SLC is not allowed to use recycled water as its process water, according to GMP. Meanwhile, Hsinchu Science Park Bureau also agrees that SLC does not need to recycle wastewater.</p> <p>No confirmation or guarantee opinion has been obtained from the verification unit of the third party.</p> <p>● Waste Treatment</p> <table><tr><th>Item</th><th>2023</th><th>2024</th></tr><tr><td>Total hazardous waste weight</td><td>305.84 mt</td><td>933.76 mt</td></tr><tr><td>Total non-hazardous waste weight</td><td>310.77 mt</td><td>551.18 mt</td></tr></table> <p>In accordance with government regulations on waste disposal and the company’s established “Waste Management Procedures,” the industrial waste generated is outsourced for recycling and re-use, incineration or landfill disposal, among other primary methods. Some hazardous industrial waste (mainly waste solvents) is self-incinerated, with the steam recovered for internal use and reverse recycling with suppliers. All disposal methods have been fully outsourced to qualified national professional disposal agencies (without any export, import or transit disposal activities) and the waste management process is properly executed. The measures currently adopted include on-site classification, storage, and labeling of waste, evaluation and contracting of disposal companies, weighing of waste and tracking of transportation vehicles, online reporting and confirmation of disposal manifests, regular audits and random inspections of disposal companies (irregular follow-ups to ensure proper disposal of all types of waste by outsourced companies), and emergency response measures. These measures are taken to avoid additional environmental burden and pollution risks caused by waste.</p> <p>No confirmation or guarantee opinion has been obtained from the verification unit of the third party.</p>	Item	2023	2024	Total hazardous waste weight	305.84 mt	933.76 mt	Total non-hazardous waste weight	310.77 mt	551.18 mt	
Item	2023	2024											
Total hazardous waste weight	305.84 mt	933.76 mt											
Total non-hazardous waste weight	310.77 mt	551.18 mt											
IV. Social issues (1) Has the Company developed its policies and procedures in accordance with laws and International Bill of Human Rights?	✓		The Group upholds the management philosophy respecting human values, values human right-related issues and keeps modifying its work rules in line with domestic and foreign laws and regulations. Meanwhile, in response to the latest Labor Standards Act amended by the government, the Group modifies the requirements about working hours, wages and leave in the work rules to enable each employee to work safely and enjoy the protection	No major difference									

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary	
			<p>at work and also to build a friendly and fine-quality workplace.</p> <p>The Group attaches great importance to the rights and interests of employees, and has established a variety of open communication channels, including internal website and platform, Line, email system, etc., to convey important information, policy updates and company news to employees and ensure information transparency. Although no labor union has been established, we have convened quarterly labor-management meetings and employee welfare committee in accordance with the law to provide a platform for management and employee representatives to discuss company operations, major decisions and issues of concern to employees. This platform enables employees to freely express their opinions, raise questions and suggestions, further enhance the coordination and cooperation between the labor and management and promote the harmonious development between the Company and employees.</p> <p>In response to the world trend and corporate governance tendency, the Company prepared its human rights policy based on the four core principles and rights for the workplace upheld by the International Labor Organization (ILO), SLC’s corporate culture core, management philosophy and foundation of a happy enterprise, and the local laws and regulations applicable in the jurisdiction where the Company’s business locations are situated in the world, upon multiple discussions by the decision makers and management meetings, in 2020, expressly stating that SLC:</p> <p>I. Provide a safe and healthy workplace in accordance with related laws and regulations.</p> <p>II. Stop discrimination to ensure equal Job opportunity.</p> <p>III. Respect the human rights at workplace.</p> <p>IV. Diversified communication channels: Set up the employees’ opinion mailbox and grievance channel, as well as the channel via which employees may propose any suggestions, in order to enhance the labor-management cooperation.</p> <p>V. Forbid child labor and forced labor.</p> <p>Engage in the labor-management negotiation, keep the labor-management communication channels uninterrupted and convene the labor-management meetings regularly to ensure the rights and interests of labors and the management.</p> <p>VII. Personal data protection: Establish the “Personal Data Protection Management Act” pursuant to laws, in order to practice the personal data protection and management.</p>	
(2) Whether the Company adopts and implements reasonable employee benefit policy (including remuneration, vacation and other benefits), and reflects the	✓		The Group values the rights and interests of its employees. Its management procedures and work rules are formulated in accordance with the principles of the Labor Standards Act in order to provide our employees with good remuneration and a safe working environment.	No major difference

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary	
operating performance or results to the remuneration to employees adequately?			<p>In addition to national health insurance and labor insurance, the Company provides group insurance for all employees and annual health check-ups in accordance with various laws and regulations. A Employee Welfare Committee has been established and relevant welfare funds have been allocated to increase employee welfare funding for the purpose of implementing the various welfare initiatives and activities that have been planned. In 2023, SLC received the 1111 Happy Workplace Awards-Gold Award from Job Bank.</p> <p>● Composition of the Company's Employees In 2024, SLC had 293 full-time employees, with 65.5% being male employees and 34.5% being female employees. The proportion of male employees is higher than that of female employees. This is due to the fact that most of the production sites provide heavy work that requires physical strength and the employees working at the production units are mostly male. In contrast, administrative paperwork is processed primarily by female employees. The overall average service age of the Company is 36.74 years old and the average tenure is 5.5 years. The structure of manpower is stable. There are 8 non-employees, mainly cleaning, contractors and security personnel.</p> <p>● Salary Policy SLC provides remuneration packages that are competitive in the market. Its remuneration policy is designed in reference to the standards of the pharmaceutical-related industry and the regional salary standards to ensure that the employee's salary level is commensurate to the market trend and is positioned according to the needs of different positions. In addition to regularly assessing the internal and external environments, the Company also regularly reviews the overall compensation and benefit structure, including resource allocation, to ensure that they comply with the principles of identifiability and fairness to ensure that the Company can effectively attract and motivate high-performance talents to achieve the Company's long-term development goals.</p> <p>According to the “Instructions for the Declaration of Salary information for Full-time Non-managerial Employees” promulgated by TWSE, it calculates the average salary of employees hired by various business locations. According to the CPA's review and verification, the number of full-time employees who hold non-managerial positions was 267 persons in 2024, the average salary of full-time employees who hold non-managerial positions was NT\$791 thousand, and the median salary of employees was NT\$701 thousand. Both the average salary and median salary have increased from 2023.</p>	

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary	
			<p>● Performance Appraisal</p> <p>The Group established the "Employee Performance Appraisal Management Regulations" as the reference for employees' cultivation and training, counseling to employees, communication between supervisors and employees, raise, promotion and year-end bonus of employees, employees' subscription for stocks and distribution of stock dividends. For twice per two years, the President is responsible for authorizing the staff throughout the Company. The UR unit is responsible for executing, maintaining and amending regulations. Various unit supervisors are responsible for performance appraisal on, interview with and assessment on their staff. At the end of 113, the performance appraisal on the whole formal employees has been completed 100%.</p>	
(3) Does the Company provide a safe and healthy work environment for its employees? Does the Company regularly provide its employees with health and safety education?	✓		<p>The Company provides employees a safe and healthy work environment and regularly furnishes training courses on safety and health issues, summarized as follows:</p> <ol style="list-style-type: none"> 1.The Company holds employee health check on an annual basis, and, through diverse online health seminars and health education information, it allows employees taking control over their health condition and equipped with self-health management knowledge and method. 2.For work safety, the Company, through continuous training courses and promotion, strengthens employees' knowledge to reduce unsafe acts and prevent accidents. 3.The Company promotes smoke-free environment that allows its employees to work under a comfortable and healthy environment. 4.Maintenance and disinfection have been done to water dispensers regularly. 5.For emergencies caused by nature disasters or human negligence, the Company held fire and earthquake drills from time to time enabling employees to handle these emergencies following the emergency procedure and eliminate impacts on employees. 6.In terms of fire safety management, there was no fire incident in 2024, so there was no casualty. The Company regularly organizes emergency response drills every year, and also educational training at each factory premises. 	No major difference
(4) Does the Company establish an effective career development and training program for employees?	✓		<p>In order to improve the professional skills of our staff and enhance their research and development capabilities, we encourage our staff to attend diverse education and training courses, including new recruit training, on-the-job training courses, as well as various job-related training courses, in order to help employees to develop professional skills.</p> <p>Employee education and training is very important to the Group. In addition to the education and training for new employees and professional training required by laws and regulations, the Company requires employees to complete the education and training corresponding to their duties. PIC/S GMP and GDP quality education and training are crucial for enterprises. This training ensures that employees fully understand and comply</p>	No major difference

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies” and reasons
	Yes	No	Summary	
			<p>with relevant quality management regulations and standards, thereby ensuring the safety, quality, and efficacy of products during the production and distribution processes. This is critical to protecting the health and safety of consumers, and is also an important guarantee for companies to maintain a good reputation and brand image. Secondly, quality education and training help to improve the professional knowledge and skills of employees, so that they are better able to deal with various challenges and problems in the complex manufacturing and distribution process. This not only helps improve production efficiency and product quality, but also helps reduce the occurrence of errors and accidents, reducing business risks and costs. Education and training hours will reach 5,944.6 hours in 2025.</p> <p>●Orientation Training SLC provides new employees with the orientation training, in order to enable them to understand the Company's overview, organization, regulations and systems and operating procedures rapidly. The training includes the basic training and professional training.</p> <p>The training program includes:</p> <ul style="list-style-type: none"> ● Get to know SLC: Company introduction, business philosophy, corporate mission and prospect, industry direction, action standard, behavioral example, group relationship, and career prospects. ● Organizational status: organizational structure, organizational functions, current status, and future development. ● Work rules: employment, transfer, service rules, salary policy, work and rest, talent cultivation, performance evaluation, rewards, punishments and subsidies, insurance benefits. ● Payment requisition: petty cash request, item collection, procurement requisition process, general payment request process. ● Safety and health: safety and health regulations, safety and security work rules, automatic inspections, emergency response, fire and first aid knowledge, etc. ● Plant introduction: manufacturing plants, sales, R&D, quality assurance, management, finance. ● QA required document study. ● Department-specific projects. <p>The basic training program includes:</p> <ul style="list-style-type: none"> ● Introduction to the Company’s history, organization & human resource, regulations & systems, and related benefits. 	

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary	
			<ul style="list-style-type: none"> ● Quality system introduction & training ● Basic principles for integrity of data ● Promotion of labor safety <p>Professional training: The training for job contents and work skills to be executed and exercised by new employees or colleagues who are new to some operation in the future.</p>	
(5) Has the Company complied with laws and international standards with regard to the customer health and safety of products and services, customer privacy, marketing and labeling of products and services, and has the Company established policies and reporting procedure to protect consumers' or customers' rights and interests?	✓		The Company has adopted the rules for handling customer complaints. Customers can enjoy after-sale inquiry service and the complaint channel. There is specialist available to answer customer question hotline. In addition, the Company has insured its products to protect customers' rights; all products of the Company are certified, and product labels are in compliance with relevant regulations. (See Table 6)	No major difference
(6) Has the company established supplier management policy, requested suppliers to comply with relevant regulations with regards to the issues of the environmental protection, occupational safety and health or labor rights etc. and the implementation status thereof?	✓		<p>The Group demands that all suppliers of raw materials and packaging materials should satisfy the GMP, provide the product quality in line with the plant's specifications and execute the “Code of Corporate Responsibility and Conduct for Suppliers.”</p> <p>Before initiating relation with a supplier, the Group would collect related information to conduct the risk assessment and execute the “Code of Corporate Responsibility and Conduct for Suppliers.” Nevertheless, in the current business environment, the Company cannot state such clause in a contract with suppliers, provided that if any supplier materially breaches its corporate social responsibilities, the Company will cease relation with such a supplier and terminate the contract.</p>	No major difference
V. Has the Company stipulated standards or guidelines for the preparation of reports according to internationally accepted reports, and does it prepare sustainability reports and other reports to disclose non-financial information of the Company? Has the aforementioned reports obtained the assurance or guarantee opinions from a third verification unit?	✓		The Company's ESG report was prepared in accordance with the GRI (Global Reporting Initiative) Standards and SAAB (Sustainability Accounting Standards Board) Standards. Said report has not yet been certified by a third-party certification unit.	No major difference
VI. If the Company has established sustainable development best-practice principles based on Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, please describe any discrepancies between the principles and their implementation: None.				

Promoted item	Implementation status (Note 1)			Deviations from “Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies” and reasons
	Yes	No	Summary	
VII. Other important information that facilitates the understanding of the promotion of sustainable development: (1)The Company has established, pursuant to the Regulations Governing Occupational Safety and Health, the occupational safety and health unit and personnel based on the Company’s scale and nature to manage safety and health affairs. (2)The Company is environmentally friendly and requires employees to maintain digital documents instead of paper files and reuse the blank side of used paper. The Company is committed to energy saving and constantly pays attention to other social responsibilities and social welfare wishing to give back to the public.				

Note 1: If you check “Yes” for the implementation status, please specify the important policies, strategies, and measures adopted and the implementation status; if you check “No,” please state the discrepancies and reasons in the column of “Discrepancies between the promotion of sustainable development and the Sustainable Development Best-Practice Principles for TWSE/TPEX Listed Companies and reasons,” and specify relevant policies, strategies, and measures to be adopted in the future. Notwithstanding, with respect to the Items 1 and 2, the TWSE/TPEX listed company shall specify the governance and supervision framework of the sustainable development, including but not limited to, the enactment of management policies, strategies and targets, and review on the measures, etc.. Further, please state the Company’s risk management policies or strategies on the environment, society and corporate governance issues, and the assessment thereon.

Note 2: Materiality principle is the environmental, social and corporate governance issues that may materially impact the Company’s investors and other stakeholders.

Note 3: For the method by which such information shall be disclosed, please refer to the sample annual report disclosed on the website of TWSE Corporate Governance Center.

Table 6: The Company's product certificates.

Year	Description
2006	GMP certificate was issued to Tainan plant by the Department of Health, Executive Yuan.
2007	GMP certificate was issued to Tainan plant by Merck Taiwan.
2008	GMP certificate was issued to Chunan plant by the Department of Health, Executive Yuan. Meropenem production line in Chunan plant was registered in Japan for accreditation. A drug manufacture permit license for Meropenem by Department of Health was issued to SLC. A drug manufacture permit license for Imipenem by Department of Health was issued to SLC.
2009	Meropenem production line in Chunan plant passed the Japan Ministry of Health, Labor and Welfare PMDA inspection, and obtained the GMP certificate.
2010	Registration of Imipenem and Cilastatin was completed in India.
2011	Meropenem production line in Chunan plant passed the French Afssaps inspection and obtained the GMP certificate. Meropenem API and Sterile Buffered production lines in Chunan plant passed the UK MHRA inspection, and obtained the GMP certificate. A license for export product for Ertapenem by Department of Health was issued to SLC. Sterile Buffered production line in Chunan plant passed Korea KFDA inspection and was issued the GMP Certificate. Imipenem/Cilastatin production line in Tainan plant passed Korean KFDA official inspection and was issued the GMP Certificate. Imipenem/Cilastatin API and Sterilem production line in Tainan plant passed UK MHRA inspection, and obtained the GMP certificate.
2012	Meropenem production line in Chunan plant and Imipenem /Cilastatin production line in Tainan plant passed US FDA inspection and officially received the approval. Imipenem/Cilastatin production line in Tainan plant passed the Taiwan TFDA routine inspection. Filling line of Tainan injection plant completed Taiwan TFDA inspection. Filling line of Tainan injection plant completed EU (France/Spain) inspection.
2013	Tainan injection plant passed Taiwan TFDA inspection, and were certified in compliance with PIC/S GMP guideline. An approval was officially received. Tainan injection plant passed EU (France/Spain) AEMPS inspection, and was certified in compliance with PIC/S GMP guideline. A GMP certificate was officially received. Tainan I/C plant and new production line passed UK MHRA inspection and obtained the GMP certificate. Ertapenem (lyophilization) production line in Tainan injection plant passed Taiwan TFDA inspection, and obtained the GMP certificate. Tainan I/C plant and new production line passed Taiwan TFDA inspection, and obtained the GMP certificate. Chunan plant and Tainan I/C plant passed the UK MHRA routine inspection, and was certified in compliance with PIC/S GMP guideline. A GMP certificate was officially received.
2014	Sterile Buffered and Ertapenem production lines in Chunan plant and Imipenem/Cilastatin production line in Tainan plant passed the Taiwan TFDA routine inspection, and was certified in compliance with PIC/S GMP guideline. A GMP certificate was officially received. Ertapenem (lyophilization) production line in Tainan injection plant passed Taiwan TFDA inspection, and was certified in compliance with PIC/S GMP guideline. A GMP certificate was officially received. Chunan plant completed US FDA routine inspection and officially received the approval. An approval was officially received. Imipenem/Cilastatin production line in Tainan plant passed US FDA routine inspection, and an approval was officially received. Injection plant passed US FDA inspection, and an approval was officially received. Meropenem API and Sterile Buffered production lines in Tainan second campus passed Taiwan TFDA inspection, and obtained the GMP certificate. SLC injection plant passed Brazil ANVISA inspection, and obtained the GMP certificate.
2015	Meropenem production line in Chunan plant passed Brazil ANVISA inspection, and an approval was officially received. Tainan injection plant passed the Good Distribution Practice for Medicinal Products (GDP) compliance evaluation conducted by the Ministry of Health and Welfare.
2016	Chunan plant completed Taiwan TFDA routine inspection. Chunan plant completed US FDA routine inspection and officially received the approval. Tainan first and second campuses completed US FDA routine inspection and officially received the approval. Tainan first and second campuses completed MHRA routine inspection; Meropenem API, Sterile Buffered and Ertapenem (lyophilization) production lines passed the inspection, and approvals were received. Tainan first campus completed the Taiwan TFDA routine inspection. Ertapenem (lyophilization) production line in Tainan second campus completed the Taiwan TFDA inspection and received the approval. Injection plant passed AEMPS routine inspection, and an approval was officially received. Injection plant completed US FDA routine inspection and officially received the approval. Drug sale licenses for SLC's Meropenem injection form were issued in Portugal and Germany. SLC's Meropenem injection form was approved for sale by US FDA. SLC's Imipenem /Cilastatin injection form were officially registered in Portugal, Spain, France, the Czech Republic and Poland and the sale license was issued in the Czech Republic. A sale license for SLC's Ertapenem injection form was issued by TFDA.
2017	A drug sale license for SLC's Imipenem/Cilastatin injection form was issued in Portugal.
2018	SLC Ertapenem injection product was permitted for sale by the UK official. SLC's injection plant was certified with the good manufacturing practices for western medicinal products (Chapter 3: Distribution) adopted by the Taiwan Food and Drug Administration.

Year	Description
	SLC's Chunan plant completed the TFDA PIC/S GDP compliance evaluation, and is verified in compliance with the Western Pharmaceuticals Good Distribution Practice Regulations. SLC's Chunan plant completed the TFDA PIC/S GDP routine inspection, and its production permit was extended.
2019	Tainan injection plant passed Taiwan TFDA inspection, and an approval was officially received. Ertapenem API production line in Tainan plant passed Taiwan TFDA inspection, and an approval was officially received. Ertapenem API production line in Tainan plant passed Korea MFDS inspection.
2020	Meropenem API production line in Zhunan Plant passed Taiwan TFDA inspection. Southern Taiwan Science Park Injection Plant passed Taiwan TFDA inspection, and were certified in compliance with PIC/S GMP guideline. An approval was officially received. Southern Taiwan Science Park Ertapenem API production line (B-Line) received the license for export product from TFDA.
2021	Tainan Ertapenem API production line (A-Line) received completed the TFDA PIC/S GMP's routine audit, and its production permit was extended. Tainan Ertapenem API production line (B-Line) received passed the evaluation by TFDA PIC/S GMP for plant expansion. Tainan injection plant completed the TFDA PIC/S GDP's routine audit, and its production permit was extended. Tainan injection plant completed AEMPS's official routine audit and obtained an approval letter.
2022	Meropenem API production line in Chunan plant passed US FDA routine audit. Meropenem API production line in Chunan plant passed Taiwan TFDA routine audit. Ertapenem API production line in Tainan plant passed US FDA routine audit.
2023	Nanke injectables factory passed the U.S. FDA inspection and obtained an EIR. Nanke injectables factory passed the routine inspection by Taiwan TFDA and obtained PIC/S GMP and GDP certificates Savior Lifetec Corporation's Southern Taiwan Science Park Injection Plant obtained ANVISA GMP certification in Brazil.
2024	Nanke's bulk drug Ertapenem passed the routine factory inspection by Taiwan TFDA and obtained PIC/S GMP and GDP certificates Southern Taiwan Science Park API Plant of Savior Lifetec Corporation passed the AEMPS (Spain) inspection and received the EU GMP. Southern Taiwan Science Park Injection Plant of Savior Lifetec Corporation passed the AEMPS (Spain) inspection and received the EU GMP.

(6) Climate-related information

1. Implementation of climate-related information

Item	Implementation status
1. Describe the monitoring and governance of climate-related risks and opportunities by the Board of Directors and the management.	The Corporate Sustainable Development Committee under the Board of Directors serves as the responsible unit, and works with the Audit Office, Corporate Governance and Partner Prosperity Group, Environment Change and Climate Change Group and Social and Friendly Workplace Group to achieve rationalization of risk and remuneration. Many board members have been concerned about climate change for a long time. They have a full understanding of the importance and impact of climate change and have attended related ESG courses.
2. Describe how the identified climate risks and opportunities affect the business, strategy and finance of the Company (short-, medium-, and long-term).	In reference to the TCFD framework, SLC identifies opportunities and risks, and divides risks into short-term (1-3 years) and medium- and long-term (3-10 years) based on the probability of occurrence and possible impact. Based on the functions of each functional unit, various types of risk management organizations are divided. The functional unit is responsible for the identification and assessment of relevant risks and formulates the management plan based on the level and priority of the identified risks and opportunities. Please refer to Page 48 for climate change risk and opportunity impact analysis.
3. Describe the financial impact of extreme climate events and transformation actions.	Regarding the physical risk over response to extreme weather events, such as precipitation and extreme changes in climate patterns, each production site has long been strengthening its water storage and recycling capacity and improving the adaptability of important operational measures, so the financial impact is limited. The rising sea level will increase the risk at the factory premises and might affect the Company's operations directly. For the climate risks, potential financial impacts, and responsive measures, please refer to Page 48.
4. Describe how climate risk identification, assessment and management processes are integrated into the overall risk management system.	The Corporate Sustainable Development Committee serves as the responsible unit, and works with the Audit Office, Corporate Governance and Partner Prosperity Group, Environment Change and Climate Change Group, and Social and Friendly Workplace Group to achieve rationalization of risk and remuneration. Based on the changes in the Company's internal and external environment, relevant units are

	requested to report changes in the external operating environment related to operations and risk management topics related to the Company's internal operations for discussion and resolution and the follow up the same.
5. If a scenario analysis is used to evaluate the resilience in the face of climate change risks, the scenarios, parameters, assumptions and analysis factors applied and main financial impacts shall be explained.	The Company has not used the scenario analysis to evaluate the resilience in the face of climate change risks.
6. If there is a transformation plan in response to the management of climate-related risks, describe the contents of the plan and the indicators and targets used to identify and manage physical risks and transformation risks.	The Company currently has no transformation plan for climate-related risks.
7. If the internal carbon pricing is used as a planning tool, the basis for setting the price shall be stated.	So far, the Company has not yet used the internal carbon pricing as a planning tool.
8. If climate-related goals are set, the activities covered, the scope of greenhouse gas emissions, the planning period and the progress achieved each year shall be explained. If carbon offsets or RECs are used to achieve the relevant goals, the source and volume of carbon offsets or the	<p>The Company issued its first sustainability report in 2023. The climate-related management goal will set 2023 as the base year for the results of greenhouse gas inventory. The determination of the management goal will be explained in the sustainability report.</p> <p>The Company has not yet used carbon offset or RECs to achieve related goals.</p>

number of RECs shall be explained.	
9. Greenhouse gas inventory and assurance status, as well as reduction goals, strategies and concrete action plans.	<p>The Company's paid-in capital is less than NT\$5 billion. The Company's greenhouse gas inventory and assurance status, as well as information on reduction goals, strategies and concrete action plans shall be handled in accordance with the following schedule:</p> <p>1. The parent company shall complete the disclosure of inventory information starting from 2026, and the disclosure of assurance information starting from 2028.</p> <p>2. The subsidiaries included in the consolidated financial statements shall complete the disclosure of inventory information starting from 2027 and the disclosure of assurance information starting from 2029.</p> <p>3. The Company's (including subsidiaries in the consolidated financial statements) carbon reduction goals, strategies and concrete action plans shall be disclosed in 2027.</p>

2. The Company's GHG inventory and assurance in the last 2 years

(1) Greenhouse gas inventory information

Describe the greenhouse gas emission volume (metric tons CO₂ e), intensity (metric tons CO₂ e/NTD million), and data coverage for the most recent two years.

N/A

(2) Greenhouse gas assurance information

Describe the status of assurance in the last 2 years up to the date of publication of the annual report, including the scope of assurance, assurance organization, assurance criteria and assurance opinions.

N/A

(3) Greenhouse gas reduction goals, strategies and concrete action plans.

Describe the greenhouse gas reduction base year and data, reduction goals, strategies and concrete action plans and achievement of the reduction goals.

N/A

(7) Implementation of ethical management and deviation from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX-Listed Companies and the reasons thereof

Item of evaluation	Status			Deviations from “Ethical Corporate Management Best-Practice Principles for TWSE/GTSM Listed Companies” and reasons
	Yes	No	Summary	
I. Enactment of ethical management policy and program				
(1) Has the company established ethical operation policies approved by the board of directors’ meeting and stated in its memorandum or external correspondence about the policies and practices it has to maintain business integrity? Are the board of directors and the management committed in fulfilling this commitment?	✓		(1) The Company has formulated the " Procedures for Ethical Management and Guidelines for Conduct ," which have been approved by the Board of Directors, as the policies and operating principles of the Company's ethical management. Members of the board of directors and senior management have signed the Declaration of Good Faith while on-board.	No major difference
(2) Does the Company establish a risk assessment mechanism against unethical conduct, analyze and assess on a regular basis business activities within their business scope which are at a higher risk of being involved in unethical conduct, and establish a prevention program accordingly with the inclusion of the preventive measures against each behavior specified in Article 7 Paragraph 2 of the “Ethical Corporate Management Best-Practice Principles for TWSE/GTSM Listed Companies”?	✓		(2) In the " Procedures for Ethical Management and Guidelines for Conduct ". the Company has established relevant operating rules to identify the business activities that might involve the risk over unethical management. It also specifies the ethical standards that employees shall abide by when engaging in any business activities.	No major difference
(3) Does the Company specify the operating procedures, behavior guidelines, disciplinary actions for violation, and complaint system in the prevention program for unethical conduct, and implement the program accordingly? Does the Company review and modify the program mentioned above regularly?	✓		(3) The “Procedures for Ethical Management and Guidelines for Conduct” formulated by the Company have expressly stated the operating procedures, punishment for violations and complaint system. So far, no violation of the ethical management policy has occurred in the Company.	No major difference
II. Implementation of ethical operations				

Item of evaluation	Status			Deviations from “Ethical Corporate Management Best-Practice Principles for TWSE/GTSM Listed Companies” and reasons
	Yes	No	Summary	
(1) Has the Company assessed a trading counterpart’s ethical operation record, and expressly states the ethical operation clause in the contract to be signed with the trading counterpart?	✓		(1) Before doing business with a trading counterpart, the Company has assessed its legality, and record of unethical conduct to ensure it trades fairly and transparently, and does not request, provide or accept any bribery.	No major difference
(2) Has the Company established a dedicated unit for promoting the corporate ethical operation under the board of directors and reporting its ethical management policy and plan for preventing unethical conducts as well as the supervision of implementation status to the board of directors periodically (at least once annually)?	✓		(2) The Administration Department of the Company is the dedicated unit for corporate ethical management, responsible for the assessment and inspection of relevant violations of ethical management. Report to the Board of Directors, in case of any violation of ethical corporate management found.	No major difference
(3) Does the Company have any policy that prevents conflict of interest and channels that facilitate the report of conflicting interests?	✓		(3) The Company has provided the regulations governing recusal for conflict of interest in the “Procedures for Ethical Management and Guidelines for Conduct.” Meanwhile, in any business practice, if any employee has a conflict of interest, he or she shall report such conflicting interest to his/her direct manager and the Company’s dedicated unit.	No major difference
(4) Has the company implemented effective accounting system and internal control system for the purpose of maintaining ethical operation? Has the internal audit unit established relevant audit plan according to the assessment result of unethical conduct risk and audit the status of compliance with the prevention against unethical conduct plan or entrust the CPA to perform audit?	✓		(4) In order to implement ethical operation, the Company has adopted effective accounting system and internal control system. The Audit Department shall audit the compliance of the system referred to in the preceding paragraph.	No major difference
(5) Has the Company organized internal/external education training program for ethical operation periodically?	✓		(5) Through the management meetings and education and training, the Company promotes to employees to make them clearly understand the ethical corporate management philosophy and regulations and arranges the Company's ethical culture promotion courses during the orientation training for new employees.	No major difference
III. Status of the Company’s complaint system				
(1) Has the Company provided incentives and easy access for employees to report misconducts? Does the Company assign dedicated personnel to investigate the reported misconducts?	✓		The Company has established the Employee Appraisal and Rewards Policy. In circumstance of violation of ethical operation by employees, the competent supervisors jointly	No major difference No major difference

Item of evaluation	Status			Deviations from “Ethical Corporate Management Best-Practice Principles for TWSE/GTSM Listed Companies” and reasons
	Yes	No	Summary	
(2) Has the Company established any investigation standard operation procedures for accepting reported misconducts, subsequent measures and relevant confidentiality measures required to be performed after the completion of the investigation?	✓		discuss and decide the punishment and notify that employee about the punishment through a personnel order. The handling process is highly confidential in order to protect whistleblower against any misconduct.	No major difference
(3) Has the Company provided proper whistleblower protection against any misconduct?	✓			
IV. Enhancing Information Disclosure Has the Company disclosed its ethical operation policy and progress thereof on its website and the Market Observation Post System?	✓		The "Procedures for Ethical Management and Guidelines for Conduct" formulated by the Company have been fully disclosed on the Company's website and the Market Observation Post System. The Company adheres to the ethical management best practice principles and implements the corporate governance to ensure the rights and interests of shareholders.	No major difference
V. If the Company has established “Ethical Corporate Management Best-Practice Principles” in accordance with “Ethical Corporate Management Best-Practice Principles for TWSE/TPEX-Listed Companies,” please describe the current practices and any deviation from the principles. The Company has established the procedures for ethical operation and behavioral guidelines and has remained disciplined with the aforementioned procedures. There is no major difference between current practices and the procedures.				
VI. Other information material to the understanding of ethical business operation (e.g., the discussion and amendment to the ethical business best-practice principles defined by the Company) (1) The Company complies with the Company Act, the Securities and Exchange Act, the regulations of TWSE/TPEX listed companies or other business practices, as the basis for the implementation of ethical corporate management. (2) The Company regularly arranges for directors and department heads to participate in corporate governance courses to enhance their ability to supervise and govern the Company, hoping to improve the effectiveness of corporate governance and the implementation of ethical management.				

(8) Other significant information that will provide a better understanding of the state of the Company’s implementation of corporate governance may also be disclosed:

The Company has set up the “Corporate Governance Section” on the Company’s website to disclose relevant corporate governance policies and information.

- (9) The section on the status of implementation of the company's internal control system shall furnish the following:

1. Internal Control System Statement

Savior Lifetec Corporation
Internal Control System Statement

Date: March 6, 2025

We make the following statement based on the results of the self-inspection of the internal control system in 2024:

- I. We acknowledge that the Board of Directors and managers are responsible for the establishment, operation and maintenance of the internal control system. We have established such a system. to provide reasonable assurance for achievement of the objectives concerning the effectiveness and efficiency of operations (including profits, performance and protection of asset security), reliability, timeliness, transparency, and regulatory compliance of reporting, and compliance with applicable laws, regulations, and bylaws.
- II. Any internal control system has its inherent limitations. No matter how well an internal control system is designed, it can only provide reasonable assurance for the achievement of the above three objectives. Moreover, the effectiveness of an internal control system may vary as a result of changes in the environment and circumstances. However, our internal control system has a self-monitoring mechanism, and we take corrective actions immediately once a nonconformity is identified.
- III. We judge the design and operations of the internal control system for their effectiveness with reference to the items to be judged for the effectiveness of the internal control system specified in the "Regulations Governing Establishment of Internal Control Systems by Public Companies" (hereinafter referred to as the "Regulations"). The judgment items of the internal control system adopted in the Regulations are divided into the following five constituent elements according to the management control process: 1. control environment; 2. risk assessment; 3. control operations; 4. information and communications; and 5. monitoring operations. Each constituent element contains a number of items. Refer to the provisions of the above-mentioned "Regulations."
- IV. We have adopted the judgment items of the internal control system to assess the effectiveness of the design and implementation of the internal control system.
- V. Based on the results of the above-mentioned assessment, we confirm that our internal control system on December 31, 2024 (including monitoring and management of subsidiaries) was effective in terms of its design and operations with respect to understanding the effectiveness and efficiency of operations, the reliability, timeliness, transparency and regulatory compliance of reporting, and the compliance with applicable laws, regulations and bylaws in order to reasonably ensure that these objectives are achieved.
- VI. The Statement will be a major part of our annual reports and prospectuses, and will be open to the public. If there is any misrepresentation, nondisclosure or other illegality in the contents open to the public referred to in the previous sentence, legal responsibility specified in Articles 20, 32, 171 and 174 of the Securities and Exchange Act shall apply.
- VII. We hereby declare that the Statement was approved by the Board of Directors at the meeting held on March 6, 2025, and none of the nine directors present expressed any dissent and all of them agree on the Statement.

Savior Lifetec Corporation

Chairman: Concord Consulting Inc. (Signed)

Representative: Rebecca Lee (Signed)

President: Chen Chih-Fang (Signed)

2. If review of the internal control system has been conducted by entrusted CPAs, the CPAs' review report shall be disclosed: None.

(10) Shareholder meeting(s) and significant board resolutions during the most recent year and up to the date of publication of this annual report

1. Important resolutions made by the general shareholders' meeting in 2024, and execution thereof.

Date	Important resolution		Implementation status
2024/06/14	Ratification	1. Ratification of 2023 business report and financial statement.	The resolution was passed. Therefore, the relevant financial statements have been filed with the competent authority for future reference and announcement and filing in accordance with the Company Act and other relevant laws and regulations.
		2. Ratification of 2023 earnings distribution proposal.	The resolution was passed. The Company planned to distribute cash dividends, NT\$27,027,002. July 20, 2024 was set as the ex-dividend date, and the distribution was completed on August 5, 2024. The distribution amounted to NT\$0.0851 per share.
	Discussions	1. Approved the proposal for removal of the non-competition restrictions against the Company's directors.	The resolution was passed and announced in accordance with the regulations.
		2. Approved the amendment to the "Articles of Incorporation" of Company.	The resolution was passed and executed according to the motion.

2. Major resolutions of Board of Directors' meetings

Date	Important resolution
2024/03/08	(1) Approved the 2023 Assessment of the Effectiveness of the Internal Control System and the "Internal Control System Statement" of the Company. (2) Passed the motion for the Company's 2023 remuneration to employees and directors (3) Approved the Company's 2023 business report and financial report. (4) Approved the proposal for the appointment and remuneration of the Company's 2024 financial report CPAs and their independence and suitability assessment. (5) Approved the proposal for removal of the non-competition restrictions against the Company's directors. (6) Approved the convening of the Company's 2024 annual general meeting. (7) Approved the setting of a record date for the issuance of new shares for subscription by employee stock warrant holders. (8) Approved the proposal for the Company to loan funds to subsidiaries. (9) Approved the proposal for adjustments of the Company's accounting managers.
2024/05/03	(1) Approved the consolidated financial statements of the Company for the year ended March 31, 2024. (2) Approved the Company's 2023 distribution of earnings. (3) Approved the Company's registered address change and shutdown of the Zhunan Plant. (4) Approved the disposal of the Company's buildings and ancillary equipment in Zhunan. (5) Approved the amendment to the Articles of Incorporation of Company. (6) Approved the addition of the cause or subject for convening the 2024 Annual General Meeting of the Company. (7) Approved the proposal for the Company to apply for a credit line renewal with the bank. (8) Approved the adjustment on the remuneration to the Chairman of the Company. (9) Approved the proposal for adjustment of the Company's Internal Audit Officer.
2024/08/08	(1) Approved the consolidated financial statements of the Company for the year ended June 30, 2024. (2) Approved the proposal for the Company to apply for a credit line renewal with the bank. (3) Approved the proposal for additional budgetary investment on the Company's production equipment.
2024/11/07	(1) Approved the consolidated financial statements of the Company for the year ended September

Date	Important resolution
	<p>30, 2024.</p> <p>(2) Approved the application for credit facilities between the Company and banks.</p> <p>(3) Approved the cash capital increase of the subsidiary, SLC BioPharm Co., Ltd..</p> <p>(4) Approved the revision of the Company's formation of and amendments to certain provisions of the "Rules of Procedure for the Board of Directors Meetings" and "Audit Committee Charter."</p> <p>(5) Approved the Company's formulation of the Company's "Sustainable Information Management Procedures" and "Procedures for Preparation and Verification of the Sustainability Report."</p>
2024/12/26	<p>(1) Approved the Company's 2025 Audit Plan.</p> <p>(2) Approved the Company's 2025 Business Plan.</p> <p>(3) Approved the proposal for the Company to apply for a credit line renewal with the bank.</p> <p>(4) Approved the distribution of 2024 year-end bonuses for the Company's managerial officers.</p> <p>(5) Approved the distribution of 2023 employee remuneration for the Company's managerial officers.</p>
2024/03/06	<p>Approved the 2024 Assessment of the Effectiveness of the Internal Control System and the "Internal Control System Statement" of the Company.</p> <p>(2) Approved the proposal to amend the Company's "Regulations Governing the Remuneration of Directors and Managers" and "Rules Governing the Scope of Powers of Independent Directors."</p> <p>(3) Passed the motion for the Company's 2024 remuneration to employees and directors</p> <p>(4) Approved the Company's 2024 business report and financial report.</p> <p>Approved the proposal for the appointment and remuneration of the Company's 2025 financial report CPAs and their independence and suitability assessment.</p> <p>(6) Approved the proposal to define the scope of "entry-level employees."</p> <p>(7) Approved the amendment to the "Articles of Incorporation" of Company.</p> <p>(8) Approved the convening of the Company's 2025 annual general meeting.</p> <p>(9) Approved the proposal for the Company to apply for a credit line renewal with the bank.</p>
2025/04/09	<p>(1) Approved the resolution to repurchase treasury shares.</p>
2025/05/02	<p>(1) Approved the consolidated financial statements of the Company for the year ended March 31, 2025.</p> <p>(2) Approved the Company's 2024 distribution of earnings.</p> <p>(3) Approved the addition of the cause or subject for convening the 2025 Annual General Meeting of the Company.</p> <p>(4) Approved the proposal for the Company to apply for a credit line renewal with the bank.</p>

- (11) Recorded or written statements made by any director or supervisor which specified dissent to important resolutions passed by the Board of Directors meetings during the most recent year and up to the date of publication of the annual report, the main content: None.

IV. Information on Independent Auditors' Fee

Information on Independent Auditors' Fee

Unit: NTD thousand

Accounting firm name	Name of accountant	Audit period	Audit Fee	Non-Audit Fees	Total	Remarks
Deloitte & Touche	Cheng Hsu-Jan Hsieh Tung-Ju	January 1, 2024 – December 31, 2024	2,090	538	2,628	(Note)

Note: Non-audit services include tax certification , review on salary information checklist for full-time employees not holding the managerial positions , bonded certification services, legal consulting services, industrial and commercial registration of cash capital increase for issuance of new shares and inventory supervision, destruction and scrapping, etc. .

- (1) When the Company changes its CPA firm and audit fees paid for the financial year in which the change took place are lower than those paid for the financial year immediately preceding the change, the amount of audit fees before and after the change and the reason shall be disclosed: Not applicable.
- (2) When audit fees paid for the current financial year are lower than those paid for the immediately preceding financial year by 10 percent or more, the amount and percentage of and reason for the reduction in audit fees shall be disclosed: Not applicable.

V. Information on the Replacement of Independent Auditors:

If the Company changed its CPAs in the most recent two years and subsequently, please disclose the following:

(I) About the former independent auditor

Date of Change	March 29, 2023		
Cause of change, and explanation	To satisfy the internal management needs.		
To specify whether the client or CPA terminates or rejects the appointment	Related parties		CPA
	Status		Client
	Voluntary termination of the appointment		V
	No longer accept (continue) the appointment		
Issuance of the audit report other than the audit report containing unqualified opinions in the most recent two years, and cause thereof	None		
Any disagreement with the issuer	Yes		Accounting principles or practices
			Disclosure of financial report
			Audit scope or steps
			Others
	None	V	
	Description		

Other disclosures (To be disclosed under the subparagraphs 6.1(4)–(7) of Article 10 of the Regulations.)	None
---	------

(2) About the successor CPAs

Name of accounting firm	Deloitte & Touche
Name of accountant	Cheng Hsu-Jan, Hsieh Tung-Ju
Date of appointment	Appointed by the Board of Directors on March 29, 2023, to be the Company's independent directors from Q1 of 2023.
Matters and results of consultation on the accounting treatment or accounting principles for specific transactions and on the possible issuance of financial statements prior to the appointment	None
Written disagreements from the successor CPA against opinions of the predecessor CPA	None

- (3) The former independent auditor's response to the items referred to in the subparagraphs 6(1) and (2)3 of Article 10 of the Regulations: Not applicable.

VI. The Company's Chairman, President, or managers in charge of finance or accounting affairs being employed by the accounting firm of its certified public accountant or affiliated enterprise of such accounting firm in the most recent year: None

VII. In the Most Recent Year and as of the Publication Date of the Annual Report, Transfer & Pledge of Stock Equity by Directors, Supervisors Managers and Shareholders Holding over 10% of the Company's Shares:

(1) Changes in shareholdings of directors, supervisors, managers and major shareholders

Title	Name	2024		2025 Up to May 7	
		Increase (decrease) in shares held	Increase (decrease) in shares pledged	Increase (decrease) in shares held	Increase (decrease) in shares pledged
Chairman	Concord Consulting Inc.	-	-	-	-
	Representative: Rebecca Lee	-	-	100,000	-
Director	SFS Venture Ltd.	-	-	-	-
	Representative: Chung Hsing-Yung	-	-	-	-
	Representative: Chen Zheng	-	-	-	-
Director	Min-Ju Investment Co., Ltd.	20,000	-	-	-
	Representative: Chen Yung-Fa	-	-	-	-
	Representative: Hsieh Jung-Cheng	-	-	-	-
Director	Fine Horse Investment Co., Ltd.	-	-	-	-
	Representative: Chou Chia-Chu	-	-	-	-
Independent Director	Chang Ryh-Yan	-	-	-	-

Title	Name	2024		2025 Up to May 7	
		Increase (decrease) in shares held	Increase (decrease) in shares pledged	Increase (decrease) in shares held	Increase (decrease) in shares pledged
Independent Director	Lin Chih-Ming	-	-	-	-
Independent Director	Cheng Chin-Hua	-	-	-	-
President	Chen Chih-Fang	-	-	-	-
Vice President	Chou Chia-Chu	-	-	-	-
Vice President	Chen I-Hsiu	8,000	-	2,000	-
Vice President	Chen Ming-Hui	-	-	8,000	-
Vice President	Lin Yen-Lan	-	-	-	-
Financial Supervisor Accounting Manager	Lin Kuo-Wei (Note 1)	6,000	-	2,000	-
Accounting Manager	Huang Chu-Yuan (Note 2)	-	-	-	-

Note 1: Due to the job transfer, Lin Kuo-Wei became the new accounting officer on March 8, 2024.

Note 2: Huan Shu-Yuan Huang resigned on March 8, 2024 due to job transfer. The information on the change in equity in 2024 is available until the date of termination of the employment.

(2) The counterparty in the equity transfer is a related party: None.

(3) The counterparty in the equity pledge is a related party: None.

VIII. Relationship information, if among the 10 largest shareholders any one is a related party, or is the spouse or a relative within the second degree of kinship with another

April 15, 2025; Unit: share, %

Name	Own Shareholding		Shareholdings of Spouse & Minor		Shareholding using other's name		Relationship characterized as spouse or relative of second degree or closer among the top 10 shareholders.		Remarks
	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Name (or individual name)	Relationship	
Key Ware Electronics Co., Ltd. (Key Ware) Responsible person: Chou Pang-Chi	15,943,035	5.02	0	0	0	0	Fine Horse	Responsible by the same person	None
							Min-Ju	The person-in-charge are spouses	
							Ji Shan	Relatives within second degree of kinship	
Yizheng Investment Management Limited, under the custody of CTBC Bank	7,393,448	2.33	0	0	0	0	None	None	None

Name	Own Shareholding		Shareholdings of Spouse & Minor		Shareholding using other's name		Relationship characterized as spouse or relative of second degree or closer among the top 10 shareholders.		Remarks
	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Shares	Shareholding ratio (%)	Name (or individual name)	Relationship	
Min-Ju Investment Co., Ltd. (Min-Ju) Representative: Wang, Shan-Shan	6,241,975	1.97	0	0	0	0	Key Ware, Fine Horse	The person-in-charge are spouses	None
Han Yu Venture Capital Co. Responsible person: Huang Hui-Ling	5,624,290	1.77	0	0	0	0	None	None	None
Sheng Ding Enterprise Co., Ltd. Representative: Rebecca Lee	4,909,451	1.55	0	0	0	0	None	None	None
	299,099	0.09	580	0	0	0	None	None	
Fine Horse Investment Co., Ltd.(Fine Horse) Representative: Chou Pang-Chi	4,387,349	1.38	0	0	0	0	Key Ware	Responsible by the same person	None
							Min-Ju	The person-in-charge are spouses	
							Ji Shan	Relatives within second degree of kinship	
Qing Yu Investment Co., Ltd. Representative: Lin Kao, Hui-I	3,883,947	1.22	0	0	0	0	None	None	None
	504,786	0.16	0	0	0	0	None	None	
Business Department of Standard Chartered Bank entrusted for custody	3,838,851	1.21	0	0	0	0	None	None	None
Ji Shan Investment Co., Ltd. (Ji Shan) Representative: Chow, Pong-Wei	3,792,989	1.20	0	0	0	0	Key Ware, Fine Horse	Relatives within second degree of kinship	None
	35,534	0.01	0	0	0	0			
Shen Kun	3,699,223	1.17	0	0	0	0	None	None	None

IX. The total number of shares and total equity stake held in any single enterprise by the Company, its directors, supervisors managerial officers, and any companies controlled either directly or indirectly by the Company

Unit: shares; %

Invested business (Note)	Invested by the Company		Held by directors, supervisors, managers, and businesses directly or indirectly controlled		Consolidated investment	
	Shares	Shareholding percentage	Shares	Shareholding percentage	Shares	Shareholding percentage
SLC BioPharm Co., Ltd.	11,000,000	100%	0	0%	11,000,000	100%
Ruize Biotechnology Co., Ltd.	1,000,000	33.33%	530,000	17.67%	1,530,000	51%

Peng Rui Construction Co., Ltd.	24,100,000	100%	0	0%	24,100,000	100%
Huanyu Construction Co., Ltd.	0	0%	14,700,000	35%	14,700,000	35%

Note: It is the investment using equity method.

Three. Fundraising Status

I. Capital and Shares

(1) Source of share capital

1. Capital formation

May 7, 2025; Unit: NTD thousand, thousand shares

Date	Issue price (NTD)	Authorized capital stock		Paid-in capital		Remarks		
		Shares	Amount	Shares	Amount	Equity Capital sources	Offset against equity capital by property other than cash	Others (Note 1)
March 2023	16.5	350,000	3,500,000	317,217	3,172,166	NT\$1,860 thousand for employee stock options exercised.	None	Note 2
May 2023	16.5	350,000	3,500,000	317,232	3,172,316	NT\$150 thousand for employee stock options exercised.	None	Note 3
November 2023	16.5	350,000	3,500,000	317,389	3,173,891	NT\$1,575 thousand for employee stock options exercised.	None	Note 4
March 2024	16.5	350,000	3,500,000	317,399	3,173,991	NT\$100 thousand for employee stock options exercised.	None	Note 5

Note 1: Represents the information for the most recent fiscal year as well as the current fiscal year up to the date of publication of the annual report.

Note 2: Zhu-Shang-Zi No. 1120008101 dated on 2023/03/16.

Note 3: Zhu-Shang-Zi No. 1120016354 dated on 2023/05/22.

Note 4: Zhu-Shang-Zi No. 1120038932 dated on 2023/11/28.

Note 5: Zhu-Shang-Zi No. 1130008062 dated on 2024/03/21.

2. Types of shares

May 7, 2025; Unit: share

Types of shares	Authorized capital stock			Remarks
	TWSE (TPEX)-listed	Unissued shares	Total	
Nominal common shares	317,399,107	32,600,893	350,000,000	The Company has an authorized capital of NT\$3.5 billion in 350 million shares. Each share has a par value of NT\$10. The Board of Directors is authorized to issue the shares at different phases. 18 million shares of these shall be reserved for issuance of employee stock warrants.

3. Information related to the shelf registration: Not applicable.

(2) Major Shareholder List

Name, number and percentage of shareholdings for shareholders with more than 5% of shareholdings or for the top 10 shareholders

April 15, 2025; Unit: share

Major Shareholders	Shares	Shares held	Shareholding percentage
Key Ware Electronics Co., Ltd.		15,943,035	5.02%
Yizheng Investment Management Limited, under the custody of CTBC Bank		7,393,448	2.33%
Min-Ju Investment Co., Ltd.		6,241,975	1.97%
Han Yu Venture Capital Co.		5,624,290	1.77%
Sheng Ding Enterprise Co., Ltd.		4,909,451	1.55%
Fine Horse Investment Co., Ltd.		4,387,349	1.38%
Qing Yu Investment Co., Ltd.		3,883,947	1.22%
Business Department of Standard Chartered Bank entrusted for custody		3,838,851	1.21%
Ji Shan Investment Co., Ltd.		3,792,989	1.20%
Shen Kun		3,699,223	1.17%

(3) Stock dividend policy and execution thereof

1. Stock dividend policy

According to Article 21 and Article 22 of the Articles of Incorporation, if there is profit for the year, the Company shall set aside no less than 3% thereof as remuneration to employees (no less than 20% thereof shall be distributed as the remuneration to the entry-level employees) and no more than 3% as remuneration to directors. However, the profit must first be used to cover the Company's cumulative loss, if any. Employee remuneration, as mentioned above, shall be paid in shares or cash to employees of affiliated companies that satisfy certain criteria in level and performance. The criteria shall be defined by the Board of Directors. The report on remuneration to employees and directors shall be submitted to the shareholders' meeting.

If the Company has a net profit at the year's final accounting, it shall first be used to pay the income tax and then a 10% contribution of the balance shall be made to the legal reserve, unless the legal reserve reaches the amount of the Company's paid-in capital, and provision/reversal of special reserves shall also be made pursuant to laws and regulations. The residual balance shall be added to undistributed earnings. The Board of Directors shall draft a motion for allocation of the residual balance and submit the same to a shareholders' meeting to resolve whether shareholder bonus shall be allocated.

According to the dividend policy, the Company shall set aside no less than 50% of the distributable earnings for allocation of shareholder bonus. However, shareholder bonus may not be distributed if the accumulated distributable earnings are less than 3% of the paid-in capital. The payment may be made in cash or shares and the dividend in cash shall not be less than 5% of the total dividend. If the earnings referred to in the preceding paragraph are distributed in the form of cash dividends, the Board of Directors shall be authorized to make a resolution and report to the shareholders' meeting.

2. The allocation of stock dividends proposed by the shareholders' meeting:

The Company's 2024 earnings distribution proposal has not yet been resolved by the shareholders' meeting. At the Board of Directors' meeting held on May 2, 2025, the Company resolved to appropriate the legal surplus reserve from the net profit after tax for the year 2024 in accordance with the law, and to distribute a cash dividend of NT\$126,959,643 from the remaining distributable surplus after the appropriation, which is approximately NT\$0.4 per share. For the aforementioned cash dividend distribution,

where the distribution rate must be changed and modification must be conducted due to amendments of regulations, instructions of the competent authority, or changes in the number of outstanding shares, the Chairman is fully authorized to handle the matters. The same is applicable to any other matters that are not addressed appropriately.

3. If there is a significant change in the expected dividend policy, an explanation should be provided: None.
- (4) Effect of the allocation of bonus shares proposed at the shareholders' meeting to the Company's business performance and Earnings per share: Not applicable.
- (5) Remuneration to employees, directors and supervisors
 1. Please refer to the above-mentioned paragraph (III) 1. Description of the Company's dividend policy, for the percentage or scope of the remuneration of employees, directors and supervisors as provided in the Articles of Incorporation.
 2. The accounting treatment for any differences between the estimated amount, the basis for calculating the remuneration of employees, directors and supervisors, the number of shares for employee remuneration distributed in shares and the actual amount distributed during the period:

If there is any discrepancy between the amount of payment resolved by the Board of Directors and the estimated figure after the end of the year, it shall be adjusted and recorded in the next year in accordance with changes in accounting estimates.
 3. Information on distribution of bonuses resolved by the Board of Directors:
 - (1) The amount of any employee remuneration distributed in cash or stocks and remuneration for directors and supervisors. If there is any discrepancy between the amount and the estimated amount of the expense recognized, the discrepancy, cause and treatment status shall be disclosed:

For the Company's proposal for the distribution of remuneration to employees and directors for 2024, the Board of Directors resolved on March 6, 2025 to distribute NT\$14,000 thousand as the remuneration to employees and NT\$3,000 thousand as the remuneration to directors. There is no discrepancy between said distribute amount and the amount distributed in 2024. The remuneration to directors is distributed by dividing by half of the recognized amount based on the actual operating conditions. The discrepancy shall be adjusted and recorded in the next year in accordance with changes in accounting estimates.
 - (2) The amount of any employee remuneration distributed in stocks and the size of that amount as a percentage of the sum of the after-tax net income stated in the parent company only financial reports or individual financial reports for the current period and total employee remuneration: None.
 4. Any differences between the actual distribution of employees' and directors/supervisors' remuneration (including the number, amount and price of shares distributed) and recognition of employees' and directors'/supervisors' remuneration in the previous year, the difference in amount, the reasons and the treatment should be disclosed: There is no difference between the amount distributed by the Company and the estimated remuneration to employees and directors.

(6) Shares repurchased by the Company:

May 7, 2025

Frequency	1st time
Purpose of repurchase	To protect the Company's credit and shareholder equity
Scheduled repurchased stock type	Ordinary shares
Ceiling on total monetary amount of share repurchase	NT\$325,143 thousand
Scheduled repurchase period	2025/04/10~2025/06/09
Scheduled repurchased quantity	8,000 thousand shares
Scheduled repurchase price range	NT\$13~22 per share
Repurchased quantity	2,982 thousand shares
Total amount of repurchased shares	NT\$ 54,531 thousand
The number of the shares repurchased as a percentage of the number scheduled to be repurchased	37.28%

II. Issuance of Corporate bonds: None.

III. Preferred Stock: None.

IV. Overseas Depository Receipts: None.

V. Employee Stock Options

I. Employee Stock Options

- (1) The annual report shall disclose unexpired employee subscription warrants issued by the company in existence as of the date of publication of the annual report, and shall explain the effect of such warrants upon shareholders' equity.

May 7, 2025

Types of Employee Stock Warrants	6th (issue) Employee Stock Warrants 2018	
Effective date of filing and total number of units (1000 shares per unit)	December 19, 2018 3,000 units	
Issue (Processing) Date	2019/8/15	2019/11/5
Issue unit (1000 shares per unit)	1,586 units	320 units
Number of units still available for issuance (1000 shares per unit)	1,094 units	
Ratio of subscribable shares to total issued shares (%) (Note 1)	0.50	0.10
Subscription period	Warrants may be exercised two years after the grant date of the employee stock warrants.	
Exercise method	Delivery of newly issued shares	
Period and ratio in which subscription is restricted (%)	Two years from the issue date: 50%; three years from the issue date: 100%	
Number of shares that have been obtained through exercise of subscription rights	635,000	0
NT dollar amount of the shares subscribed	10,477,500	0
the number of unsubscribed shares	115.5 units	0 units
Subscription price per share of the unsubscribed shares	NT\$16.5	NT\$0
Ratio of the number of unsubscribed shares to the number of issued and outstanding shares (%)	0.04	0.00
Effect on shareholders' equity	The Company is committed to attracting and retaining talent, as well as encouraging and motivating its employees for the benefit of both the Company and the shareholders, all of which will have a positive effect on shareholder interests.	

Note 1: As of the date of publication of the Prospectus, there were 317,399,107 shares outstanding.

Note 2: Number of shares lapsed 1,155,500 (employees resigned).

- (2) Names and acquisition status of managerial officers who have acquired new restricted employee shares and of employees who rank among the top ten in the number of new restricted employee shares acquired, cumulative to the date of publication of the annual report.

May 7, 2025; Unit: thousand shares, %, NTD thousand

Title		Name	Number of options acquired	Ratio of acquired options to total issued shares	Exercised				Not exercised			
					Number of subscribed shares	Subscribed price	Amount of subscription	Ratio of subscribed shares to total issued shares	Number of subscribed shares	Subscribed price	Subscription Amount	Ratio of subscribed shares to total issued shares
Managerial officer	Vice President	Chou Chia-Chu	1,433	0.45	430.5	16.5~24.8	7,967	0.14	80	16.5	1,320	0.03
	Vice President	Lin Yen-Lan										
	Former CEO (Note)	Man-Chin Ku										
	Former President (Note)	Chen Yung-Fa										
	Former QA Vice President (Note)	Shih Yu-Nan										
	Former President (Note)	Pan Shih-Hsien										
	Former Vice President (Note)	Ming-Fa Lin										
	Former Assistant Vice President (Note)	Bang-Liang Liu										
	Former Assistant Vice President (Note)	Su Wei-Wen										
	Former Assistant Vice President (Note)	Liu Yen										
	Former Assistant Vice President (Note)	Liu Chia-Wen										
	Former Assistant Vice President (Note)	Emma Wang										
	Former Vice President (Note)	Kuo Lung-Huang										
	Former Assistant Vice President (Note)	Lo Yu-Wen										
Staff	Senior Manager (Note)	Hu Yu-Cen	770	0.24	213	16.5~24.8	4,791	0.07	0	0	0	0
	Manager (Note)	Hsueh He-Sheng										
	Manager (Note)	Chang Sheng-Chi										
	Former Senior Manager (Note)	Lin Yu-Nung										
	Former Senior Manager (Note)	Chen Wen-Ren										
	Former Senior Manager (Note)	Chen Cheng-Te										
	Former Manager (Note)	Chu Hsueh-Wen										
	Former Manager (Note)	Chang Yuan-Kang										
	Former Manager (Note)	Wang Chiu-Kuei										
	Former Manager (Note)	Jeffrey Wang										

Note: The manager and employee have resigned.

VI. Restricted Stock Award (RSA): None.

VII. Issuance of new shares in connection with mergers or acquisitions of, or succession to shares of other companies: None.

VIII. Implementation of Capital Utilization Plan

(1) Contents of the plan: For the quarter preceding the date of publication of the annual report, the Company had no uncompleted public issue or private placement of securities, or completed such issuance and placement in the most recent three fiscal years but the issue or placement has not yet fully yielded the planned benefits.

(2) Implementation status: Not applicable.

Four. Business Overview

I. Business Activities

1. Scope of business

The Company is specialized in the development, production and sale of sterile APIs (Active Pharmaceutical Ingredients, also known as APIs, which are the therapeutic components of the medicines) and injectables.

(1) Main content of the business operated

- A. Basic Chemical Industry.
- B. Precision Chemical Materials Manufacturing.
- C. Manufacture of Drugs and Medicines
- D. Biotechnology Services.
- E. Wholesale of Western Pharmaceutical.
- F. Retail Sale of Western Pharmaceutical.
- G. International Trade.

"The product lines which the Company researches, develops, produces and sells are as follows:

- 1. Carbapenem generics
- 2. Injection generics
- 3. controlled-release generics
- 4. Development of new dosage forms
- 5. Development of new drugs
- 6. APIs, excipients, intermediates and dosage forms for the above-mentioned products
- 7. Medicine manufacture technology and service.
- 8. Import and export trade related to the aforementioned products.]

(2)Weight of business

Unit: NTD thousand, %				
Item \ Year	2023		2024	
	Amount	Operating revenue percentage (%)	Amount	Operating revenue percentage (%)
Antibiotics	880,860	83.87%	1,136,666	93.37%
Others	169,417	16.13%	80,661	6.63%
Total	1,050,277	100.100%	1,217,327	100.00%

(3) Present product items of the Company

Our current products are the broad spectrum antibiotics Meropenem and Ertapenem which are new broad spectrum β -lactam antibiotics containing Carbapenem and which have the broadest antibacterial spectrum and the strongest antibacterial activity to date, playing an important role as the last defense in the fight against severe clinical infections.

(4) New products planned for development

- A.API and injections for new Carbapenem antibiotics

Ertapenem has a broader spectrum of antibacterial activity than Meropenem in fighting a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria. This product has been in mass production since Q4 2017 and Ertapenem injection was granted license for sale by the US FDA at the end of Q1 2019.

In addition to Ertapenem, the Company has also started a collaboration with an international pharmaceutical research and development company to develop the new penem type antibiotics known as SLC-017 and SLC-029. The new drug is now in the registration and batch manufacturing stages, and the Company will become a new drug manufacturing company when the new drug has been successfully developed and granted a marketing license in the future.

B. Small molecule API and injections

The new product selected by Savior Lifetec is SLC-033: a drug for treating constipation with a market size of approximately USD 80 million.

C. APIs for sterile peptides and nanomedicines and injections

(A) Market for Peptide Drugs

Peptide drugs are drugs consisting of fewer than 50 amino acids and are classified as biotechnological drugs. Peptide drugs are highly effective with specificity. Their molecular structure is larger than that of small molecule drugs and they have a partial granular structure, so they bind strongly to the target organ and are generally more effective than small molecule drugs; they are also less likely to have non-specific effects with other non-target organs and therefore have fewer side effects than small molecule drugs. In addition, according to an analysis of the global drug market estimates provided by IMS, the global market for peptides has reached USD 14 billion and is estimated to be growing rapidly around 9% annually.

Therefore, based on global drug market sales, original drug analysis, and design around and manufacturing technology analysis, Savior Lifetec Corporation has selected a few drug products as candidates and decided to move up from API manufacturing to high margin and high technology injection manufacturing and sales, in order to reduce exploitation by middle agents and pharmaceutical fillers and to maximize profit.

Savior Lifetec's initial selection of new product candidates is supported by a detailed technical analysis in a proposal analysis report; each product is listed below with niche product characteristics.

(a) SLC-028: A drug to treat infertility; current US market size is approximately US\$70 million

(b) SLC-030: A drug to treat infertility; current US market size is approximately US\$50 million.

SLC-033: A drug for treating chronic idiopathic constipation in adults; the current US market size is approximately USD 0.8 billion.

(B) The Nanotechnology Drug Market

Most conventional drugs are “immediate release drugs”, which are rapidly absorbed by the body after administration, resulting in high drug levels in the blood; due to metabolic effects, the drug only remains in effective concentration for a short period of time, so patients need to increase the dosage frequently and may suffer from toxic side effects caused by high drug concentration in the blood. In recent years, with the development of nanotechnology, “controlled release technology” has been rapidly developed to enhance the efficacy of drugs, reduce the toxicity and side effects of drugs, and decrease the frequency of drug administration so that patients' suffering can be minimized.

The long-acting nano-controlled release injection takes an important place in treating mental illness because patients with mental illness require long-term and frequent medication, but their compliance with medical advice is relatively poor; their primary caregivers need to make a lot of effort to confirm whether the patient is taking medication or not, which often results in increased tangible and intangible costs to society. The long-acting nano-controlled release injection drug can last for more than a month, which not only achieves better drug efficacy control, but also significantly reduces the social cost; as a result, major pharmaceutical companies in Europe and the United States are actively developing relevant dosage forms, and the drugs we expect to develop are all nano-controlled release injections with the highest market share for schizophrenia.

The new product selected by Savior Lifetec is SLC-021: a drug for schizophrenia with a market size of approximately USD 2.1 billion.

The economic scale of these drugs is very large; in addition, the patent for the original pharmaceutical products will expire from 2016 to 2025, which is the best time for us to enter the market and obtain maximum profit. Since 2014, we have been working on the process of patent avoidance and development, trial production, applying for plant use license, making process amplification and trial runs, confirming the efficacy and applying for registration. The whole process takes about 5~7 years, so Savior Lifetec can quickly take over the market of the original drug after the expiry of the original patent to obtain the highest profit to gain a position in the generic drug market of this drug.

2. Industry Overview (For mass production items)


(1) Industry Overview and Development

A generic drug is a drug with the same chemical composition that is manufactured by a qualified pharmaceutical company after the patent of the original drug has expired, based on the information disclosed in the patent application of the original drug, which should be identical or biosimilar in terms of use, dosage form, safety, efficacy and administration route, quality and efficacy characteristics; furthermore, the price of a generic drug is usually lower than that of a patented drug.

Although the global market for generic drugs is limited by patent and quality regulation risks, generic drugs have the advantage of lower prices so that when there are two or more generic drugs competing with the same patent drug, the price of the drug will drop rapidly. Government policies also play an important role as the FDA's strict review of new drugs has led to a stagnation in the quantity of new drugs produced in recent years, resulting in increasing costs of new drug development for international pharmaceutical companies. As the world's population ages, countries are spending more on health care than ever before, so they are actively pursuing health care reform and encouraging the use of generic drugs to reduce health care costs.


Our current products are the broad spectrum antibiotics Meropenem and Ertapenem which are new broad spectrum β -lactam antibiotics containing carbapenem, and which have the broadest antibacterial spectrum and the strongest antibacterial activity to date. These antibiotics play an important role as the last defense in the fight against severe clinical infections. According to IMS global statistics (2024 Q1 MAT), the global market for Meropenem is estimated at a compound annual growth rate of approximately 2.98% from 2021 to 2024, based on the sales volume of Meropenem. Based on the sale volume of Ertapenem, the global market for Ertapenem is estimated at a compound annual growth rate of approximately 3.39% from 2021 to 2024.

The global market scale for Meropenem is approximately USD 1,344 million in 2024.




Source: New Port, 2024 Q1 MAT

The global market scale for Ertapenem is approximately USD 295 million in 2024.



(2) Correlation among upstream, midstream and downstream in the industry



Source: ITRI IEK (2006/2)

The upstream raw materials of the pharmaceutical industry are mainly general chemicals; the midstream is mainly the API (including intermediates); and the downstream is the processing of raw materials and excipients into easy-to-use preparations. The following is a summary of the upstream, midstream and downstream of the pharmaceutical industry:

A. Upstream

The upstream of the pharmaceutical industry is raw material for the preparation of pharmaceuticals, which consists of natural plants, animals and general chemicals, mainly from synthetic chemicals or other intermediates; other APIs may also be obtained from minerals, animal organs and microbial strains and related tissue cells. In recent years, thanks to advances in biotechnology, the use of gene transfer, tissue culture or direct cultivation of plants or animals for the production of drugs is a major breakthrough in upstream production technology.

B. Midstream

The majority of pharmaceutical industries are organic chemical industries, the mainstay of which is chemical synthesis, which is convenient, fast and inexpensive.

Meanwhile, there are different production methods available depending on the source of raw materials. For those obtained from natural substances, apart from the preparation of raw materials such as fermentation and cultivation, the main process techniques are extraction, hydrogenation by separation, alcoholysis, esterification, saponification, alkylation and purification (e.g., distillation, extraction, crystallization, etc.). The production process for APIs is very complex, and the synthesis technology is the most sophisticated, among which the production technology of APIs and intermediates is the most crucial for production.

C. Downstream

The downstream sector is the pharmaceutical industry, which mainly processes APIs and pharmaceutical excipients such as excipients, disintegrants, adhesives, lubricants, emulsifiers and so on, into easy-to-take dosage forms.

Savior Lifetec Pharma has integrated upstream, midstream and downstream into a full-service pharmaceutical company. This double-A strategy (API to ANDA) will ensure a stable supply and competitive market advantage for the Company.

(3) Development trends of products

Antibiotics have been available for more than 80 years. In the past, when medicine was not well developed, many countries and pharmaceutical companies invested heavily in research and development to produce a wide range of antibiotics. However, in the past decade, many pharmaceutical companies and research units in Europe, the United States and Japan have shifted their research focus to other areas such as cardiovascular and psychotropic drugs, resulting in very few new antibiotics being introduced in the past decade. In addition, as most antibiotics are fermented products, which generate pollution during the production process, and due to concerns about the cost of production, the main production of antibiotics has shifted to Asian countries such as China and India in the last decade. The few new products have made it difficult for small pharmaceutical companies to survive, resulting in a situation where big antibiotic manufacturers are getting bigger and bigger. Today, most of the world's fermentable antibiotics are concentrated in a few large factories in mainland China (previously, they were all government-owned companies).

Carbapenem is a synthetic antibiotic; European, US, and Japanese regulations require that Carbapenem must be completely separated from existing antibiotic production lines to avoid cross-contamination; therefore, these Chinese antibiotic manufacturers cannot compete with Carbapenem API manufacturers with their existing advantages because these Chinese manufacturers alternately manufacture Penicillin, Cephalosporin, and other antibiotics resulting in cross-contamination, and it is not easy to pass inspection from regulatory countries.

Based on past experience with cephalosporins and other medicines, once the patents of the original medicines have expired, relatively low-priced generic drugs are introduced into the market and the demand for them grows considerably as a result of

the decrease in the price for drugs that were previously expensive, so countries or hospitals that previously could not afford these drugs can now benefit from the introduction of generic drugs. In addition, Carbapenem is a backline antibiotic that is not easily replaced by other antibiotics in treating infections and therefore has great potential for market demand.

Ertapenem, the latest generation of Ertapenem, has been growing in global sales. The patent for Ertapenem in the US Orange Book expired at the end of 2017, the Company obtained US FDA marketing authorization for Ertapenem injection at the end of the first quarter of 2019, and the generic Ertapenem has gradually replaced the market share of the original drug. In addition, as the standard of drug use has improved in recent years, the healthcare system has begun to pay attention to the use of broad-spectrum antibiotics such as carbapenem. In order to improve the effectiveness of antibiotics in fighting disease and to avoid the occurrence of drug resistance in bacteria, the use of antibiotics has been divided into those for minor or community-origin infections and those for major infections in hospitals. Ertapenem is recommended for infections of community origin or for less severe cases, while Meropenem, Imipenem/Cilastatin or Doripenem are recommended for severe cases at high risk of infection with drug-resistant strains. As a result, the relationship between products may appear to be competitive, but they do not actually compete with each other.

(4) Competition

The global pharmaceutical market can be roughly divided into a Regulated Market and a Semi-regulated Market. Regulated markets are usually referred to in countries in Europe, the United States and Japan, where regulations are more stringent in terms of complexity, enforcement and penalties.

There are currently only a very small number of qualified manufacturers in the regulated market and the main suppliers of APIs are listed below:

Product	Regulated Market
Meropenem	*ACS Dobfar SPA (Italy, OEM of the original pharmaceutical manufacturer) *Shenzhen Haibin Pharmaceutical Co., Ltd. (China) *Aurobindo (India)
Ertapenem	*Merck (the original pharmaceutical manufacturer, USA) *ACS Dobfar SPA (Italy) *Aurobindo (India) *Savior Lifetec Corporation (Taiwan)

Source of information: the Company

The Carbapenems produced by the Company are exclusive for dedicated factories. The factory engaged in production of the API for Ertapenem has passed the factory inspections and successfully obtained the cGMP approval in the USA and Europe. With Savior Lifetec's high quality products, global registrations and

partnerships with customers, Savior Lifetec is well positioned in the global antibiotics market.

3. Technology and Research and Development Overview

(1) Research and development costs

Unit: NT\$ thousand, %

Item	2024	For the current year ending in Q1 of 2025
R&D expenses (A)	75,112	16,672
Operating revenue (B)	1,217,327	263,861
Ratio (A)/(B)	6.17	7.00

(2) Skill level and research development of the company's business

Our product manufacturing process is a fully organic synthesis with complex manufacturing process, all process technology including the development for synthesis pathway, process technology, column purification technology, RO concentration technology, crystallization research, crystallization purification technology, freeze-drying technology, peptide solid phase synthesis, biofermentation, nanoparticle preparation, long-lasting slow release dosage form, process scaling parameters research, aseptic manufacturing technology, solvent recovery process, cGMP trial and mass production, etc. These processes are all self-developed by our R&D team with over 300 million in R&D funds over five years. There are currently about 24 R&D staff who are continuously improving relevant process technology as well as developing new products in the research phase.


The six core technologies currently in the control of the Company are as follows:

- A. Aseptic Manufacturing Technology: The Company develops its own (a) design of aseptic production equipment which is suitable for the production of aseptic APIs, (b) sterilization technology, and (c) aseptic surveillance technology and standard operating procedures to ensure the sterility of the product.
- B. Aseptic operation: Through long-term testing, review and training, we have a team of highly qualified and experienced operators and have established standard operating procedures and an international standard microbiology laboratory for aseptic testing in compliance with regulations and validation to ensure product stability and consistency. Our aseptic operation has a nearly 100% successful production rate.
- C. Process Amplification Technology: Chromatography can be used to purify products; we have successfully amplified this technology to a mass-production scale, effectively improving the quality and yield and reducing overall production costs.

- D. Low temperature dehydration technology: The products produced are not stable during the production process and therefore need to be kept at a low temperature at all times. The challenge is how to cure the products that are dissolved in large amounts of water at low temperatures while maintaining product quality, efficiency and productivity. Through our own research and development, we have the technology to not only meet the requirements, but also to significantly reduce production times.
- E. Synthesis technology: There are many patent traps for this type of product. We have been able to innovate our synthesis technology and break through the limits of the patents to shorten production time, increase yield and improve operational stability. We have applied for patents for critical raw materials processes and new crystal forms.
- F. Patent matters: As there are hundreds of patents for these antibiotic products and processes, we need to dedicate a considerable amount of professional staff to search, analyze and break through patent restrictions and work with the patent office.

In addition, we have established a cGMP system that complies with European, American and Japanese regulations to standardize our aseptic production procedures. This allows us to differentiate ourselves from mainland or Indian pharmaceutical companies that are unable to obtain certification from European, American and Japanese manufacturers; thus, we are able to more effectively remove our competitors from the market.

In summary, the key technologies that the Company has in place are as follows:



Source of information: the Company

(3) Technology and products developed successfully in the last five year:

A summary of successful products developed by the Company in the last five years

is as follows:

2019	SLC-017 technology was successfully transferred and registered for batch production. Synthetic pathway of SLC-021 in laboratory was successfully constructed and trial scale-up production was successful. Synthetic pathway of SLC-028 in laboratory was successfully constructed and trial scale-up production was successful. Synthetic pathway of SLC-030 in laboratory was successfully constructed.
2020	SLC-021 was successfully registered for batch production. SLC-028 was successfully registered for batch production. Trial scale-up production of SLC-030 was successful.
2021	SLC-029 lozenge process technology was transferred. SLC-030 was successfully registered for batch production. Synthetic pathway of SLC-033 in laboratory was successfully constructed and trial scale-up production was successful.
2022	SLC-029 technology was transferred and registered for batch production. Contract manufacturing of SLC-033 lozenge process was completed.
2023	SLC-026 technology transfer and process optimization has entered trial batch/registration batch planning.
2024	SLC-026 technology transfer and process optimization has completed the trial batch/put into production. We will continue to work with customers to plan future production plans.

4. Long-term and Short-term Business Development Plan:

(1) Short-term: Increasing the global market share for Ertapenem

Since Q4 of 2017, Savior Lifetec has been manufacturing Ertapenem in commercial production and selling APIs and injections; both the Company and its customers have been obtaining sales licenses in Europe and South America. In January 2018, the Company also signed a sales agreement with a leading international pharmaceutical company for the sale of ertapenem in the USA and obtained US FDA sales license at the end of the first quarter of 2019. The ertapenem products have been rolled out in the US and its market share has been growing. Ertapenem injectable is a generic drug whose patent has just expired. Its unit price and profitability are higher than those of other generic drugs in the penem category; as the market continues to grow and the Company continues to obtain drug licenses, Ertapenem will bring more room for future sales and profit growth for Savior Lifetec.

(2) Mid-term: Partnership Development for the New Penem Drugs

Carbapenem is a fully synthetic antibiotic; European, American and Japanese regulations require Carbapenem to be exclusively manufactured in its own plant to

avoid cross-contamination. Savior Lifetec is one of the few companies in the world that can manufacture Meropenem injection products that meet US regulations, making Savior Lifetec a major target for cooperation with biotechnology companies in Europe and the USA. In 2018, the Company signed a product research services contract with a European and US pharmaceutical company to perform pre-production process validation services for new antibiotic products. The Company also signed a contract with another European and US new drug development company to invest USD 7 million in a plant for oral tablets. There will be further research and development collaboration for new drugs, and the Company will be responsible for the production of oral tablets once the new drugs are available on the market. The construction of the plant has been completed. The product has also entered the pre-production process validation stage. In the future, Savior Lifetec will have the opportunity to enter the new drug manufacturer industry, bringing another opportunity for the Company to grow and profit.

(3) Long Term: Highly profitable specialty and niche generic drugs launch.

Based on global drug market sales, original drug analysis, design around and manufacturing technology analysis, the Company has selected drug products as candidates and decided to move up from API manufacturing to high-margin and high-technology manufacturing and sales, in order to maximize profits.

At the same time, we will work together with our business partners to participate in R&D, production and sales. This is another new opportunity for Savior Lifetec Corporation.

II. Market and Production/Sales Overview

1. Market Analysis

(1) Sales region of the Company's main production

About 90% of our products are sold overseas, including Europe, the Middle East, America and Asia.

Unit: %

Sales region	2023	2024
Europe	14	7
America	51	63
Asia	35	24
Others	0	6
Total	100	100

(2) Market share

We are currently one of the top three suppliers of Penem products in the United States.

(3) Market future supply and demand status and growth

So far, the patents for Meropenem and Ertapenem, the Company's main products, have both expired. Based on past experience with the growth of other antibiotics, demand for Meropenem and Ertapenem is expected to grow rapidly after the patents

on these products expire. The Company's Meropenem and Ertapenem API and injection filling plants have been inspected by the US FDA and the EU and have obtained the drug licenses, which will help the Company's market share in the US and European regulated markets to continue to grow. The Company has also been actively negotiating with a number of pharmaceutical companies for the supply of APIs and injections to increase the Company's global market share.

(4) Competitive niche

We are the only manufacturer in Taiwan with the capability to produce sterile APIs; we are the pioneer in the manufacture of sterile APIs (for injections) in Taiwan, and we are also one of the few manufacturers in the world with the capability to produce sterile APIs, making our products the world's leading generic pharmaceuticals, not only replacing the original manufacturers' sales, but also exporting to Europe, the United States and Japan and other leading countries.

Unlike other APIs for injection, Penem's API must be produced as a powder by aseptic crystallisation in a dust-free, sterile and isolated environment. The sterile powder is used as the API and then filled into glass bottles by the pharmaceutical manufacturer. Therefore, the company has vertically integrated not only the production of this sterile API, but also expanded the injection filling plant to produce injection products. Other general API manufacturers are not equipped with a dust-free and sterile manufacturing quality control system, so vertical integration is a challenge. Since the completion of our Tainan injection plant, we have passed GMP inspections in Taiwan, Europe and the Americas since 2013 and are now shipping products to Europe, Asia and the Americas.

We have accumulated a lot of experience in cGMP for aseptic and dust-free operation through the development of a Meropenem and Ertapenem aseptic raw materials plant, which has been approved by Taiwan (2008), Japan Ministry of Health and Welfare (2009), Korea KFDA (2011), France Afssaps (2011), UK MHRA (2011) and US FDA (2012). The remaining major competition niches are described below:

A. Relevant technologies are leading the way.

- (a) aseptic processing technology, (b) chromatography technology, (c) low temperature dehydration technology, (d) synthesis technology,
- (e) aseptic freeze-drying technology

B. We have a stable source of customers, and our cGMP system is compliant with European, American and Japanese regulations.

C. All certification documents for the production line are available.

D. We have injection plants that are vertically integrated to provide better service to our customers.

E. The new synthesis technology provides a process cost advantage.

F. The demand for generic drugs is high while the production capacity for APIs is low. The increase in production capacity cannot meet the increase in demand in the short term.

G. In the short term, there are only a few specialized injection manufacturers qualified to supply the European and US markets.

H. We have a complete sales channel, selling to non-regulated markets such as Asia, the Middle East, Central and South America, as well as regulated markets such as Europe, the USA and Japan.

Through this dust-free and sterile manufacturing quality system platform, we are also planning to develop highly effective, difficult and patent-challenged long-acting injection products that are not based on Penem.

In addition, our product is a specialized Penem drug. There are very few reputable pharmaceutical companies in the world that can compete for this type of product; besides the stringent plant requirements, the production technology is particularly difficult, including complex chemical synthesis, harsh conditions and difficult control, special chemical equipment, difficult chemical technology and difficult aseptic technology. We have invested a great deal of money and manpower over the years and have integrated many difficult technologies to produce products that meet international pharmacopoeial specifications, so we are proud to say that our technology is as good as the original manufacturer's and that our technical specifications lead the way.

- (5) The Company's competitive advantages and positive and negative factors in future development and the company's response strategies

A. Positive factors

(a) Patented drugs expired

Carbapenem is in high demand worldwide and has a high unit price. The price of the brand drugs is still high while the market is dominated by European and American countries where people have higher incomes, resulting in demand being expected to multiply in the future as the price decreases due to generic drugs entering the market with lower prices.

(b) Carbapenems are less drug resistant.

Since the existing first and second line antibiotics are highly resistant, the Carbapenem group of antibiotics is the least highly drug resistant and has a broad spectrum of activity against over 80% of bacteria, so hospitals have started to use them for immediate effect.

(c) Fewer suppliers worldwide

Due to the high technical threshold, there are only a limited number of pharmaceutical companies that can be subject to inspection by national pharmaceutical authorities, so the market is characterized by moderate competition.

(d) Population structure is aging and the population with chronic diseases is increasing

With the population structure aged, the demand for various related drugs is expected to increase, leading to an increasing market for APIs.

(e) Government's Medical Policy

The increase in the number of deaths caused by heart disease, cerebrovascular disease, cancer and respiratory disease has led to more countries actively

promoting healthcare, adopting policies or legislation to control drug prices and medical expenditure, and improving the overall quality of healthcare; this will lead international pharmaceutical companies to look for lower cost manufacturers with quality systems that meet international quality standards, which will benefit future development of Company sales.

(f) Government Incentives and Counselling

The government has made the API industry a key development project. In addition to investing in research and development on industrial technology, the government has also provided various incentives to manufacturers in terms of rent, tax and financing, such as the “Regulations for Providing Assistance in the Development of New Leading Products”, the “Statute for Upgrading Industry” and the “Action Plan for Biotechnology Industry” These are all favorable factors for domestic API manufacturers to explore opportunities in the global market. It is also beneficial to the Company's development in the international API market.

B. Negative factors and responsive strategy

(a) Increasing competition in the API industry

Chinese and Indian pharmaceutical companies have low-cost labor and raw materials, but the quality of their products and regulations is questionable. However, due to the low cost, they often compete with low-grade products and disrupt the market in non-regulated markets. In addition, both China and India are currently looking to expand their facilities and production capacity, which is expected to lead to increased competition in the API industry.

Response Strategy:

The manufacture of Carbapenem is difficult because of high technical hurdles, chemical technical difficulties, dedicated plants, special chemical equipment, special drug classes, chemical engineering difficulties, many raw material combinations, long manufacturing processes and key technologies in process amplification, so there are not many API manufacturers in the world capable of providing APIs that meet international pharmacopeial specifications. In addition, the quality of our pharmaceutical products has been certified by many countries in Europe, the United States, Japan and Korea. Therefore, through vertical integration, we have established consistent production operations from APIs to injections and cooperated with major international manufacturers, which will effectively differentiate our products from the low-price competition in China and enable us to quickly introduce our products into the international market.

(b) Over-concentrated product line

Our main products include Meropenem and Ertapenem, which are APIs for antibiotics.

Response Strategy:

The patent for our new product, Ertapenem, expired in 2017. Litigation between the original manufacturer and the Company over the process patent (which expires in 2020) has been withdrawn. The Company commenced

commercial production of Ertapenem API in late 2017 and will continue to enhance its manufacturing processes to improve its product competitiveness. The Company has also submitted applications for drug licenses in several countries and has successfully obtained licenses in the United Kingdom and the United States; we expect to continue to obtain additional licenses in other countries to expand our sales market.

In addition, the Company is actively developing peptide products and will use its existing sterile technology platform to develop SLC-021 injections and niche generics with high technology and high unit cost. In the development of peptide products, we have utilized our existing technologies, including synthetic pathway development, process technology, column purification technology, RO concentration technology, crystalline form research, crystalline purification technology, freeze-drying technology, peptide solid phase synthesis, process amplification parameters research, aseptic manufacturing technology, solvent recovery process development, cGMP trial production and mass production and so on. In addition to the development of the peptide synthesis technology platform, we have also developed an advanced technology platform and applied for a patent to protect the intellectual property rights for Savior Lifetec. In addition to self-development, we also collaborate with other companies in the industry to conduct multi-product research and development in order to increase our product range and enhance our market value and operational flexibility.

2. Key purpose and manufacturing process of main products


(1) Key purpose of main products:

Main products	Main purpose
Meropenem (Meropenem)	Used to treat pneumonia, skin infections, urinary tract infections, gynecological infections, sepsis, meningitis, and so on.
Ertapenem (Ertapenem)	For complicated intra-abdominal infections, complicated skin and skin tissue infections, diabetic foot infections without osteomyelitis, infectious pneumonia, complicated urinary tract infections including pyelonephritis, acute pelvic infections including postpartum endometritis, septic abortion and post-surgical gynecological infections, etc.

(2) Manufacturing process for main products

The Company's production process is now vertically integrated in a one-stop solution.

One-stop solution for niche drugs




Production process for Ertapenem injection

Technical niche – Vertically integrated aseptic freeze-drying technology platform

From synthetic APIs, sterile APIs to sterile injection products

GMP "Grade A" dust-free and aseptic operation



3. Primary raw materials supply status

Primary raw material	Primary supplier	Supply status
03M-9, 05-M11, Catalyst	1002090, 1001001 1002116, 1002084	Normal

4. Name of customers a for more than 10% of total purchase (sales) amount of the company in the last two years or in any year and the purchase (sales) amount and ratio thereof

Information of main customers of sales of the Company in the last two years

Unit: NTD thousand

	2023				2024				For the current year ending in Q1 of 2025			
Item	Name	Amount	Annual net sales percentage (%)	Relationship with the issuer	Name	Amount	Annual net sales percentage (%)	Relationship with the issuer	Name	Amount	Proportion to the net sales amount of the current year up to the previous quarter (%)	Relationship with the issuer
1	A02C001	298,865	28.46	None	A02C001	527,197	43.31	None	A02C001	58,311	22.10	None
2	A01C005	99,613	9.48	None	C01C004	155,077	12.74	None	A01T001	36,096	13.68	None
3				None	A01C005	130,712	10.74	None	C01C004	25,771	9.77	None
4	Others	651,799	62.06	None	Others	404,341	33.21	None	Others	143,683	54.45	None
	Net sales amount	1,050,277	100.00		Net sales amount	1,217,327	100.00		Net sales amount	263,861	100.00	

Note: The financial statements for the year ended March 30, 2025 have been audited by CPAs as of the publication date of this annual report.

A02C001, A01C005 and C12C002 remained one of the top three major customers in 2023 and 2024. No significant changes occurred.

Information about main suppliers of the Company in the last two years

Unit: NTD thousand

	112 years				113 years				For the current year ending in Q1 of 2025			
Item	Name	Amount	Annual net purchase percentage (%)	Relationship with the issuer	Name	Amount	Annual net purchase percentage (%)	Relationship with the issuer	Name	Amount	Proportion to net purchase amount of the current year up to the previous quarter (%)	Relationship with the issuer
1	1002090	35,422	21.27	None	1002090	40,503	20.07	None	1002090	25,340	33.19	None
2	1001001	30,089	18.06	None	1002104	28,488	14.12	None	1002116	13,919	18.23	None
3	1002085	26,468	15.89	None	1002116	27,041	13.40	None	1002104	7,639	10.00	None
4	1002116	26,433	15.87	None	1002084	26,964	13.36	None	1002085	6,009	7.87	None
5	Others	48,163	28.91	None	Others	78,789	39.05	None	Others	23,447	30.71	None
	Net purchase amount	166,575	100.00		Net purchase amount	166,575	100.00		Net purchase amount	76,355	100.00	

Note: The financial statements for the year ended March 30, 2025 have been audited by CPAs as of the publication date of this annual report.

1002090 is a supplier of specialized intermediate raw materials, as one of the top 3 suppliers from 2023 to 2024. Therefore no significant change has occurred.

1001001 is a supplier of catalyst palladium. The demand decreased in 2024, so the purchase amount was relatively small.

1002104 is the supplier of purchased finished products. Due to the business adjustment, the Company transformed from self-making to outsourcing. Therefore, the demand increased in 2024.

III. Number of workers, average length of service, average age and educational profile of the employees in service for the last two years and up to the date of printing of the annual report

Data date: May 7, 2025 Units: persons; %

Year		2023	2024	2025 until May 7
Number of Employees (person)	Marketing management personnel	43	38	36
	R&D personnel	17	20	21
	Technical personnel	252	227	216
	Total	312	285	273
Average age (age)		38.55	36.74	39.25
Average service years (year)		6.19	5.5	5.64
Educational background distribution ratio (%) (%)	PhD	0.32	0.35	0.73
	Masters	22.76	23.86	27.11
	College	72.11	70.18	67.4
	Senior High School	4.49	5.61	4.76
	Under Senior High School	0.32	0	0

IV. Information on Environmental Protection Expense

1. The amount of losses and penalties that the Company suffered as a result of environmental pollution for the year 2024 up to the date of publication of the annual report: None.
2. Future responses (including improvement measures) to major environmental capital expenditure:
 - (1) Air pollution prevention: The cost of equipment maintenance and consumables replacement was approximately NT\$245 thousand.
 - (2) Wastewater pollution prevention: The cost of equipment maintenance, consumables replacement and the treatment of wastewater in the Science Park was approximately NT\$1,710 thousand.
 - (3) Waste disposal: The cost of waste disposal was approximately NT\$13,662 thousand.

The total amount was approximately NT\$15,617 thousand.

V. Labor-management relationship

1. Please list the Company's various staff welfare measures, education, training and retirement systems and implementation status, as well as labor-management agreements and measures to protect the rights and interests of employees:
 - (1) Employee welfare plan

Based on the good faith principle and to protect the rights and interests of our employees, our management procedures and work rules are formulated in accordance

with the principles of the Labor Standards Act in order to provide our employees with good remuneration and a safe working environment.

In addition to national health insurance and labor insurance, the Company provides group insurance for all employees and annual health check-ups in accordance with various laws and regulations. A Employee Welfare Committee has been established and relevant welfare funds have been allocated to increase employee welfare funding for the purpose of implementing the various welfare initiatives and activities that have been planned.

(2) Employee education and Training

In order to improve the professional skills of our staff and enhance their research and development capabilities, we encourage our staff to attend diverse education and training courses, including new recruit training, on-the-job training courses, professional courses, workplace safety courses and seminars, as well as various job-related training courses, in order to help employees to develop professional skills.

(3) Retirement system and implementation status

The Company has employee retirement management measures. On the date of arrival, employees should contribute 6% of the monthly pension according to the “Monthly Contribution of Labor Pension” published by the Bureau of Labor Insurance and deposit with the Bureau of Labor Insurance. Labor pension individual accounts. Employees may also voluntarily contribute up to 6% of their monthly wages to their pension plans.

Employees' retirement benefits are paid either on a monthly or lump sum basis, depending on the amount of the employee's individual pension account and accumulated earnings.

(4) Labor-management agreements and various employee benefit protection measures status:

The Company is governed by the Labor Standards Act. We value labor-management relations and conduct all operations in accordance with the Labor Standards Act. In addition, the Company has established a labor-management council in July 2009 to hold regular meetings in order to provide a good communication platform between employers and employees and to maintain harmonious labor-management relations.

The Company has established various rules and regulations to ensure that the rights and interests of employees are well protected in accordance with the law, and the opinions expressed in regular labor-management meetings are actively adopted and improved in order to satisfy and appreciate employee feelings.

2. For the most recent year and up to the date of publication of the annual report, any current loss due to labor-management disputes and possible future loss estimated amount and responsive measures:

Date of punishment	Reference number of the penalty document	Illegal laws and regulations	Contents of violation	Amount of Fines and Ballots
--------------------	--	------------------------------	-----------------------	-----------------------------

2022/04/20	Nan-Huan-Zhi-No. 1110011752	Labor Standards Act Article 38-4	The regular item of salary for the settlement of untaken special leave for underpaid workers.	20,000
2022/05/19	Nan-Huan-Zhi-No. 1110015138	Labor Standards Act Article 43	Inconsistencies in the content of wage calculations resulted in underpayment of workers' leave of absence.	20,000
2022/06/06	Zhu-Huan-Zhi-No. 1110017967	Labor Standards Act Article 22-2	The wages of the remaining months are calculated based on the actual number of working days. As a result, the wages of the month that the employees leave the company are not paid in full amount directly.	20,000
2022/07/13	Zhu-Huan-Zhi-No. 1110022886	Labor Standards Act Article 38-4	The regular item of salary for the settlement of untaken special leave for underpaid workers.	20,000

The above fines have been paid in full, and corrections have been made in accordance with the laws and regulations.

VI. Information and communication security management

1. State the information and communication security risk management framework, the information and communication security policy, the specific management plan and the resources invested in the information and communication security management.
 - (1) Information security risk management framework: The Company's unit dedicated to information and communication security is the Information Department.
 - (2) Information and communication security policy: To reinforce our information security management, monitor and improve information security protection and effectively reduce the risk of theft, improper use, leakage, tampering or destruction of information assets caused by human negligence or intentional or natural disasters, we have formulated the Information System Security Control Regulations.
 - (3) Specific management plan:
 - A. Computer system security protection:
The computer network is protected by a double-layer firewall to prevent our network from being intruded. Antivirus software is installed on personal computers to prevent virus attacks. Spam gateway system that automatically filters viruses and spam to prevent accidental opening of emails containing virus. Account passwords should be replaced mandatorily every 90 days The data backup is under the framework of two-machine offsite crossover and offline backup to prevent cyber kidnapping.
 - B. Access control:
Access to data in application systems and file servers requires an application for permission, and those without permission cannot access the data.
 - C. Portable storage device:
The Company has completely prohibited the use of USB storage devices, and taken advantage of the information security rules to directly prohibit USB devices to prevent data leakage and infection of virus.
 - D. Physical and security environment management:
The computer room is equipped with access control, and visitors should leave records of entry and exit. The air conditioning system in the computer room operates by two machines in rotation. The room is equipped with fire extinguishers and alarms and an uninterruptible power supply system for emergency power generation.
 - E. Personnel management:
Personnel need to apply for permission to use the computer system and all accounts and access authorities should be disabled when they resign.

F. System development and contracted management:

At present, we manage the systems on our own, and small-scale system development is conducted in the existing operating environment.

- (4) Information and communication security resources invested by the Company: firewall, anti-virus software, data backup, account and password management, privilege management, uninterruptible power supply system, air-conditioning equipment, access control management, and fire extinguishers.

2. Specify the losses or potential impact of significant information and communication security incidents in the most recent year and up to the publication date of this annual report as well as countermeasures. If it is impossible to estimate them reasonably, the fact that they cannot be reasonably estimated shall be specified: None.

VII. Important Contracts

Nature of contract	Related parties	Commencement and Expiry of the contract	Content	Covenants
Land lease	Southern Taiwan Science Park Bureau	2024.01.01 2033.12.31	Land Lease within the Park – Southern Taiwan Science Park Plant No. 1	The term of the lease shall not exceed twenty years, subject to a new contract being made at the expiration of the term.
Land lease	Southern Taiwan Science Park Bureau	2010.11.01 2030.10.31	Land Lease within the Park – Southern Taiwan Science Park Plant No. 2	The term of the lease shall not exceed twenty years, subject to a new contract being made at the expiration of the term.
Plant Lease Agreement	Southern Taiwan Science Park Bureau	2025.01.01 2025.12.31	Standard Lease Agreement for Plant (for Injection plant,3F, 4F, 5F, No. 12 Chuangye Road, 3F, 4F, No. 16, Chuangye Road, and 4F, No. 8 Chuangye Road)	A new contract shall be made upon expiry of the term.
Process Development and Research Services Contracts	S Company	2018.11.28~Performance of contract is completed.	New drug (SLC-029) product design service for the new oral tablet production line	The contract shall commence on the date of execution and expire upon completion of the contract.

Five. Review and Analysis of Financial Position and Financial Performance and Risk Matters

I. Financial Status

Unit: NTD thousand

Item \ Year	2023	2024	Increase (decrease) ratio	
			Amount	%
Current assets	2,546,210	3,249,209	702,999	27.61
Property, plant and equipment	860,365	728,057	(132,308)	(15.38)
Intangible assets	2,599	1,455	(1,144)	(44.02)
Other assets	413,497	397,399	(16,098)	(3.89)
Total assets	3,822,671	4,376,120	553,449	14.48
Current liabilities	200,918	690,439	489,521	243.64
Non-current Liabilities	257,039	169,584	(87,455)	(34.02)
Total liabilities	457,957	860,023	402,066	87.80
Capital stock	3,173,991	3,173,991	-	-
Capital surplus	135,127	135,127	-	-
Retained earnings	43,624	198,977	155,353	356.12
Non-controlling interests	11,972	8,002	(3,970)	(33.16)
Total shareholders' equity	3,364,714	3,516,097	151,383	4.50

Description of significant change: (Change of 20% or more and change of NT\$10 million or more)

1. The increase in current assets: Due to the increase in bank time deposits of more than 3 months and the sale of Zhunan Plant stated as the non-current assets held for sale .
2. Increase in current liabilities: Due to the sale of Zhunan Plant stated as liabilities directly related to the non-current assets held for sale.
2. Decrease in non-current liabilities: Due to the sale of the Zhunan Plant and deduction of the public utilities rent by Southern Taiwan Science Park Bureau, resulting in the derecognition of lease liabilities.

II. Financial performance

1. Comparative analysis of financial performance

Unit: NTD thousand

Item \ Year	2023	2024	Increase (decrease) ratio	
			Amount	%
Net operating revenue	1,050,277	1,217,327	167,050	15.91
Operating costs	829,328	870,571	41,243	4.97
Gross operating profit (loss)	220,949	346,756	125,807	56.94
Operating expenses	223,369	227,856	4,487	2.01
Operating profits (losses)	(2,420)	118,900	121,320	(5,013.23)
Non-operating income and expense	29,959	60,501	30,542	101.95
Net profit (loss) before tax	27,539	179,401	151,862	551.44
Current net income (loss)	27,497	178,410	150,913	548.83
Actuarial loss on defined benefit plan	0	0	0	0
Current total comprehensive income	27,497	178,410	150,913	548.83

Description of significant change: (Change of 20% or more and change of NT\$10 million or more)

<div>Item \ Year</div>	Year	2023	2024	Increase (decrease) ratio	
				Amount	%
1. Increase in gross profit and operating income: Mainly because the Company adjusts its operating strategy and increases the sales of niche products, thereby resulting in an increase in operating revenue, gross profit and operating income in 2024.					
2. Increase in non-operating revenue: Due to the impact posed by the fluctuations in the exchange rate of the USD, resulting in the increase in non-operating revenue in 2024.					

2. Expected sales volume and its basis, possible impact on the Company's future finance and business and response plan: The Company has been pro-actively promoting the global deployment of Ertapenem products in recent years and achieved outstanding results. Following the successful completion of the deployment in the United States, the largest market in the world, the Company has successfully expanded into China, the second largest market in the world, to further consolidate its international presence and enhance its competitiveness. Immediately afterwards, Savior Lifetec executed the cooperation agreements with marketing partners from Europe, South America, South Africa, New Zealand, Australia and Southeast Asia to pro-actively launch the registration of Ertapenem products. Meanwhile, the registrations which Savior Lifetec completed with various partners around the world have been approved successively. Savior Lifetec generated remarkable results therefor. At present, Ertapenem products have been successfully launched in more than 20 countries in the world, which still continue to expand the market domain. It is expected that the products will enter more countries in the future, provide better quality medical options for patients worldwide and continue to deepen its international influence.

III. Cash flow

1. Analysis of changes in cash flows for the most recent year

Unit: NTD thousand

Item \ Year	Year	2023	2024	Increase (decrease) ratio	
				Amount	%
Net cash inflow (outflow) from operating activities		387,952	518,378	130,426	33.62
Net cash inflow (outflow) from investing activities		181,190	(203,494)	(384,684)	(212.31)
Net cash outflow from financing activities		(572,216)	(39,740)	532,476	(93.06)
Description of major variations of reported items: (where the percentage of change is more than 20%)					
1. Increase in net cash outflow from operating activities: Mainly due to the increase in earnings in 2024, resulting in net cash inflow from operating activities.					
2. Increase in net cash outflow from investing activities: Due to the increase in bank time deposits of more than 3 months, the expansion of new production lines and equipment expenditures, etc. , resulting in an increase in net cash outflow from investing activities.					
3. Decrease in net cash outflow from financing activities: Mainly due to the					

convertible corporate bond issued in 2020 was repaid in May 2023, but no such bond repaid this year, thereby resulting in the decrease in net cash outflow from financing activities.

2. Improvement plan for insufficient liquidity.

The Company's capital has been covered by the own fund generated from its operations. Besides, the Company always maintains fair relationship with its correspondent banks; therefore, no shortage of fund occurs to the Company.

3. Cash liquidity analysis for the next year

Unit: NTD thousand

Opening cash balance (A)	Estimated annual flow from operating activities (B)	Estimated annual flow from investing activities (C)	Estimated annual flow from investing activities (D)	Projected cash surplus (Insufficient) Amount (E) = (A) + (B) + (C) + (D)	Projected corrective measures against insufficient cash position	
					Investment plan	Financial management plan
1,358,063	412,262	404,719	(181,142)	1,993,902	N/A	N/A
1. Analysis of cash flow change for next year: B. Operating activities: mainly from the cash inflow from operations. C. Investing activities: mainly due to the expenditure in the expansion of new production lines and the replacement and update of the old equipment. D. Fund-raising activities: Mainly due to distribution of cash dividends, remuneration to directors and employees, etc. 2. Analysis on the projected corrective measures against insufficient cash position and liquidity: Not applicable.						

IV. Significant capital expenditures in recent years: The Company's significant capital expenditures are mainly fixed expenditures in the expansion of new production lines and the replacement and update of the old equipment, which have no significant impact on the Company's financial operations.

V. The investment policy, main reasons for profit or loss, improvement plans, and investment plans for the next year in the recent year: The Company established its subsidiary, SLC BioPharm Co., Ltd., in February 2022. In addition to continuing with original niche-type product development and technology transfer cooperation, the subsidiary also spans the health care product market and develops the products under its own brand, which have been offered for sale in pharmacies, drug stores and e-commerce platforms throughout Taiwan. SLC reinvested in Ruize Biotechnology at the end of 2022, primarily engaged in the management of sales channels of health food and Taiwan-made medicines. SLC established a subsidiary, Peng Rui Construction Co., Ltd., in 2023 to engage in the real estate appraisal and investment.

The Group's entire investment policy adopts the diversification to increase the Company's income from diversified sources.

VI. Risks factors

- (1) Impact of interest rate, exchange rate fluctuation and inflation condition on the profit/loss of the company and future countermeasures

- (1) Interest rate change

The Company's interest income and interest expense for 2024 were NT\$43,879 thousand and NT\$7,477 thousand, respectively, representing 3.60% and 0.61% of net operating income, respectively; fluctuation in interest rates had little impact on the Company's overall profitability. However, as the Company's operations expand and its capital requirements increase, the Company will continue to monitor interest rate fluctuations in the future and maintain good relationships with banks in order to obtain lower cost capital to reduce the risk of interest rate fluctuations.

- (2) Exchange rate change

The Company's exchange gains for 2024 was NT\$60,263 thousand, which represents a ratio of (4.95%) to net operating revenue. The Company's imports and exports are mainly in US dollars. In order to reduce the impact of exchange rate fluctuations on the Company's profit and loss, the Company manages foreign currency funds by appropriately retaining the portion generated from sales in foreign currencies to repay accounts payable in foreign currencies for natural hedging purposes. In addition, the Company's finance department actively collects information on exchange rates, pays attention to the major currency changes in the international exchange market to keep track of exchange rate trends, and maintains good relationships with banks in order to obtain more favorable exchange rate offers so as to reduce the impact of exchange rate fluctuations on the Company's profit and loss.

- (3) Inflation

The Company has not yet experienced a significant impact on profit or loss due to inflation. However, the Company will continue to monitor the price of raw materials and adjust the sales price and negotiate with suppliers in order to reduce the impact of inflation.

- (2) Policies on engaging in high risk, high leverage investments, loaning funds to others, endorsement and guarantee as well as derivative transactions, main causes of profit and loss as well as future countermeasures

- (1) The policy of engaging in high-risk, high-leverage investments, the main reasons for profits or losses and the measures to be taken in the future:

The Company focuses on the operation of its own business and does not

engage in high risk, high leverage investments based on the conservatism principle.

- (2) Policies on engaging in loaning funds to others, endorsement and guarantee as well as derivative transactions, main causes of profit and loss as well as future countermeasures:

In the most recent year and up to the date of publication of the annual report, the Company made loans only to subsidiaries over which it has controlling power, but did not engage in endorsement/guarantees and derivative trading. The Company has established the “Procedures for Lending Funds to Others,” “Procedures for Endorsement and Guarantee” and “Procedures for Engaging in Derivative Transactions” for future implementation as necessary to ensure the best interests of the Company.

- (3) Future R&D plan and expected investment in R&D budget

The Company has set up a Research and Development Centre to meet the needs of the Company's technology development and to upgrade the R & D Centre's position in the Company's organization, to integrate the Company's technology and related fields, to strengthen the original product development capabilities, to develop new product, and to focus on long-term R & D layout and patent applications, in order to improve the quality of the Company's products.

The Company will continue to actively invest in manpower, funds and technology in the R&D Centre in the future. The ratio of R&D expenses to net operating revenue from 2022 to 2024 was 9.4%, 10.56% and 6.17%, respectively. The Company expects to spend approximately NT\$80 million on research and development in 2025. The Company is actively developing peptide products and will use its existing sterile technology platform to develop SLC-021 injections and niche generics with high technology and high unit cost. In the development of peptide products, we have utilized our existing technologies, including synthetic pathway development, process technology, column purification technology, RO concentration technology, crystalline form research, crystalline purification technology, freeze-drying technology, peptide solid phase synthesis, process amplification parameters research, aseptic manufacturing technology, solvent recovery process development, cGMP trial production and mass production, and so on. In addition to the development of the peptide synthesis technology platform, we have also developed an advanced technology platform and applied for a patent to protect the intellectual property rights for Savior Lifetec. In addition to self-development, we also collaborate with other companies in the industry to conduct multi-product research and development in order to increase our product range and enhance our market value and operational flexibility.

- (4) Impacts of domestic/foreign important policies and law changes on the financial business of the company and responsive measures

The Company keeps track of important domestic and international policy and regulatory changes, and immediately considers responsive measures to update operating strategies in response to changes in market conditions; there have been no material events affecting the Company's financial operations in the most recent year and up to the date of printing of the annual report due to major domestic and foreign policies and changes of laws.

- (5) The impact of technological transformation (including information and communication security risks) and industrial changes on the Company's financial business and countermeasures

The Company keeps a close watch on developments in the pharmaceutical industry and sets up evaluation teams to study the impact on the future development and financial operations and strategies to address the situation if necessary. Up to the date of printing of the annual report, there have been no significant changes in technology that have had a material impact on the financial operations of the Company.

- (6) Impacts of change of corporate image on corporate crisis management and countermeasures

The Company operates its business in the spirit of sustainable management. As at the date of printing of the annual report, there has been no incident affecting the corporate image of the Company.

- (7) Expected Benefits, Possible Risks and Responses to Mergers and Acquisitions

Up to the date of printing of the annual report, the Company does not have any merger and acquisition plan. However, if there is any merger and acquisition plan in the future, the Company will carefully assess whether the merger can bring the Company substantial comprehensive effect in order to protect the interests of the Company and shareholders' rights.

- (8) Expected benefits, possible risks and responses to factory expansion: None.
(9) Risks faced during material incoming or sales concentration and responsive measures

- (1) Risk of supplier concentration

The main raw materials purchased by the Company are 03M-9, 05-M11 and catalysts. In the recent year until the date of publication of the annual report, the purchase of raw materials from various suppliers is less than 25%. Therefore, no concentration on any single supplier exists. Further, in order to ensure the stability, reliability and safety of the quality of raw materials, the Company has to prioritize the purchase of raw materials to meet its requirements, which has led to the selection of cooperation with this supplier. In addition, the Company maintains a good relationship with its largest supplier who provides a stable delivery schedule for the Company's products. In order to effectively diversify the risk of supplier concentration, the Company keeps at least two suppliers to avoid shortage or interruption

of supply.

(2) Risk of sales concentration

The sales to the largest customer in 2023 and 2024 accounted for 28.46% and 43.31% of the Company's net sales, respectively. Except, due to the strong market demand for Ertapenem in the USA, its sales value accounted for more than 20%, there was no sales concentration. This will also help to reduce the risk of sales concentration as the Company continues to develop new products along with its sales units actively expanding the market.

(10) Effect upon and risk to the Company if a major quantity of shares belonging to a director, supervisor or shareholder holding greater than a 10 percent shareholding has been transferred or replaced and measures to be taken in response: None.

(11) Impacts, risks, and countermeasures of change in management rights: None.

(12) The Company and directors, President, substantial responsible person, major shareholder with shareholding exceeding 10% of the Company and affiliates that are involved in major lawsuits with affirmative judgment or is pending in the court proceeding, non-litigation or administrative dispute cases with results capable of causing material impacts on the interests of shareholders or stock price, the dispute fact, claim amount, litigation starting date, primary litigation parties and handling status up to the printing date of the annual report shall be disclosed: None.

(13) Other significant risks and measure to be taken to response: None.

VII. Other Important Matters: None.

Six. Special Items

I. Information on Affiliates

Please refer to the Market Observation Post System (MOPS) (Single Company Electronic document Download > Affiliated Enterprises Disclosure Section) for further details.

II. Private placement of securities during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report: None.

III. Other matters that require additional description: None.

IV. If any of the situations listed in Article 36, paragraph 3, subparagraph 2 of the Securities and Exchange Act, which might materially affect shareholders' equity or the price of the company's securities, has occurred during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report, such situations shall be listed one by one: None.

Savior Lifetec Corporation

Chairman: Concord Consulting Inc.

Representative: Rebecca Lee